|
|
|
|
|
St.Vincent Hospital Renews Multi-Year, System-wide Contract for Masimo SET® Pulse
Oximetry Technology
Indianapolis-Based Health Provider Adds Six More Years to its Masimo SET
Pulse Oximetry Standardization Contract
Irvine, California – December 30, 2009 – Masimo
(NASDAQ: MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion
and Low Perfusion pulse oximetry, announced today that St.Vincent Indianapolis
Hospital has renewed its campus-wide contract for Masimo SET pulse oximetry
technology. A Masimo customer since 2000, St.Vincent cites advanced monitoring
technology, an upgradable platform, and innovative new capabilities as key
reasons for the six-year system-wide renewal of their technology standardization
contract, which will continue to support the oximetry needs of the quaternary
facility.
"All pulse oximetry technologies are not created equal," stated Kathy Gatons,
BA, RRT, Director of Clinical Support at St.Vincent Hospital. "Masimo offers the
best, most advanced oximetry technologies available. We know the measurements
can be trusted and the alarms are valid when a Masimo pulse oximeter is on the
patient. That's why we chose to standardize on Masimo SET 10 years ago and why
we continue to leverage Masimo as our pulse oximetry platform for the future.
Patient safety is a huge initiative that we support by placing Masimo technology
at every patient bedside."
Continuing their standardization on Masimo SET pulse oximetry technology
allows St.Vincent Hospital to leverage the unique breakthrough noninvasive blood
constituent monitoring capabilities of Masimo Rainbow SET Pulse CO-Oximetry.
Masimo Rainbow SET is the first-and-only technology platform capable of
continuously and noninvasively measuring multiple blood constituents and
parameters that previously required invasive procedures, including: total
hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), PVI® for fluid responsiveness, and acoustic respiration
rate (RRa™), in addition to oxyhemoglobin (SpO2), pulse rate
(PR), and perfusion index (PI). The ability to immediately detect and treat
potentially life-threatening conditions without having to draw blood and wait
for the results facilitates earlier and better clinical decisions that may help
St.Vincent clinicians to save lives and improve patient outcomes.
According to Rex McKinney, MBA, RRT, CHP, FACHE, Executive Director, Clinical
Support Services at St.Vincent Hospital, "Masimo has excelled at providing
leading technology that we need to support our patient safety initiatives.
St.Vincent places the highest priority on providing healthcare that is safe. The
Masimo technology platform provides our clinicians with the tools to monitor
patients effectively and provide the safest clinical setting possible."
Masimo Founder and CEO, Joe E. Kiani, stated, "As an early adopter of Masimo
SET technology, St.Vincent was one of the first hospitals to see the clinical
value and patient impact of Masimo technology. Today, their unwavering
commitment to delivering the best possible patient outcomes and remaining on the
front line of medical advances is as strong as ever. And, we are happy that they
have chosen to bring the latest noninvasive technologies to the patients they
serve with Masimo Rainbow SET—helping provide faster, more accurate diagnosis,
treatment, and recovery to those in need."
St.Vincent Hospitals and Health Services
Driven by the
faith of four Daughters of Charity who arrived in Indianapolis in 1881 with
$34.77 in their pockets, the St.Vincent Hospital mission is to treat the poor
and sick by following our Core Values of Service of the Poor, Reverence,
Integrity, Wisdom, Creativity and Dedication. Our healthcare ministry has grown
to include seven Centers of Excellence: Women's, Children's, Orthopedics,
Cardiovascular, Neuroscience, Cancer Care and Bariatrics. The ageless mission of
St.Vincent remains unchanged: to minister to the minds, bodies and spirits of
those in need.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), PVI®, and acoustic respiration rate (RRa), in addition
to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion
index (PI), allowing early detection and treatment of potentially
life-threatening conditions. Founded in 1989, Masimo has the mission of
"Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive
Monitoring to New Sites and Applications." Additional information about Masimo
and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the repeatability of
clinical results, risks related to our belief that Masimo SET and Masimo Rainbow
SET will provide sufficient sensitivity and specificity to detect physiological
abnormalities in real-time—enabling clinicians to detect and identify
potentially life-threatening conditions earlier and make better clinical and
treatment decisions that may help save lives and improve outcomes for their
patients, risks related to our assumption that the system-wide renewal of St.
Vincent Health Care will serve to substantially increase revenues, and risks
related to our assumptions regarding the future of the St. Vincent Health Care
system-wide pulse oximetry renewal contract, as well as other factors discussed
in the "Risk Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be
obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the applicable
securities laws.
Media Contacts:
Dana Banks
Masimo
Corporation
(949) 297-7348
dbanks@masimo.com
Johnny Smith
St.Vincent Health
(317) 583-3961
jasmith1@stvincent.org
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo Rainbow SET® SpHb™ Measurement Receives New CPT Code and Medicare Pricing
Irvine, California – December 29, 2009 – Masimo, the
inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low-Perfusion
pulse oximetry, announced today that the American Medical Association has
granted a new Current Procedural Terminology (CPT) code, 88738, for Masimo's
noninvasive hemoglobin (SpHb) measurement. Medicare has priced the CPT code at
$7.19 on the 2010 Medicare Clinical Laboratory Fee Schedule, effective January
1, 2010. The new CPT code and pricing will allow healthcare providers to bill
and receive payment when testing eligible patients.
1 2010 Medical Clinical Laboratory Fee Schedule.
Available at http://www.cms.hhs.gov
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), PVI®, and acoustic respiration rate (RRa™) in addition
to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion
index (PI), allowing early detection and treatment of potentially
life-threatening conditions. Founded in 1989, Masimo has the mission of
"Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive
Monitoring to New Sites and Applications." Additional information about Masimo
and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our belief that the establishment of CPT codes
for Masimo SpHb will increase the application and broaden the use of Masimo
Rainbow SET Pulse CO-Oximetry technology or serve to provide substantially
increased revenues for the company, and risks related to our assumptions that
SpHb will deliver a sufficient level of clinical improvement over alternative
measurement capabilities to allow for rapid adoption of the technology, risks
related to our assumptions regarding the repeatability of clinical results,
risks related to our assumptions that Masimo SpHb is an accurate, reliable and
acceptable clinical alternative to invasive blood tests, as well as other
factors discussed in the "Risk Factors" section of our most recent reports filed
with the Securities and Exchange Commission ("SEC"), which may
be obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the applicable
securities laws.
Media Contacts:
Dana Banks
Masimo Corporation
+1
(949) 297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo Expands its Irvine, California Corporate Headquarters to Accommodate Growth Projections
December 24th Open House Showcases the Addition of a New Building to the
Corporate Campus and New Health Care & Wellness Plan For Masimo
Employees
Irvine, California – December 24, 2009 – Masimo
(NASDAQ: MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion
and Low Perfusion pulse oximetry, today announced the expansion of its Irvine,
California headquarters with the addition of an adjacent 32,000 sq. ft.
building—the company's third building at its corporate campus. Expanding its
corporate headquarters is a natural progression for Masimo, which continues to
post double-digit growth increases. The company hosted an open house on
Thursday, December 24th, from 11 a.m. to 2 p.m., to celebrate the new building
and the launch of the Masimo Health Care and Wellness Program.
The expansion is further proof that, despite a slumping U.S. economy, Masimo
continues to buck national economic trends, reporting product revenue growth of
17% during the first nine months of 2009 compared to the first nine months of
2008. The new building is expected to house more than 200 employees, many of
which the company anticipates adding to its engineering, sales, and
administrative functions in 2010 to accommodate the growing demand for its
breakthrough medical technologies, including the expansion of its Masimo Rainbow
SET Pulse CO-Oximetry and new Acoustic Monitoring business.
Today, Masimo SET, the "Gold Standard" in pulse oximetry, is at work in the
world's most demanding hospitals, with more than half of the top U.S.
hospitals—including four of the top five, as listed on the US News &
World Report Honor Roll—adopting Masimo SET as their primary pulse oximetry
platform. This year alone, more than 150 hospitals throughout the world have
converted to Masimo's advanced pulse oximetry technology.
In addition to celebrating the expansion of its corporate campus, Masimo
employees also celebrated the unveiling of a new 2010 Masimo Wellness Plan—an
employee-controlled healthcare solution designed to promote wellness and
incentivize employees to lead healthy lifestyles. The plan provides the umbrella
protection and safety net of a traditional PPO health insurance plan with 100%
coverage for preventative care—making it easier and more cost-effective for
employees to get routine physicals, annual exams, wellness check-ups and
immunizations to stay healthy.
"Over the last year, U.S. healthcare reform has taken center stage. And, as a
medical technology innovator on the forefront of improving care and safety for
patients, we at Masimo understand just how crucial it is for our nation to get
healthcare right," explained Masimo Founder and CEO Joe Kiani. "We know that
millions of Americans are depending on it, and billions of people around the
world are watching us! That's why we have been an active member in both
local/community and national discussions concerning healthcare reform in
America. We felt a duty to represent the 'patient care' side of the healthcare
story and doing so allowed us to learn best practices from the nation's most
forward-thinking organizations."
Kiani explained that what struck Masimo about what these forward-thinking
organizations were doing was that they were building insurance plans that put
more control and responsibility in the hands of their employees.
"They allowed their employees to navigate and chart their own course to
better health—leading the charge for healthcare reform within their own
organizations while lowering its costs," Kiani added. "This inspired us to 'do
what is best for patient care,' starting with our own employees!"
Masimo believes that these efforts will pay off by helping to improve the
health of its employees and by reducing the immediate and long-term costs for
the company and its employees. For example, the total cost of our U.S. group
insurance benefits in 2009 was in excess of $6 million, and was expected to rise
further in 2010. According to Kiani, the decision to implement a comprehensive
Wellness Plan will allow Masimo to keep its costs flat for 2010 and will likely
reduce costs for future years.
The company is so convinced that healthier people mean a healthier company
that it is planning on putting money on it with a new Wellness Rewards Program
slated to begin in 2011. Under the program, employees will earn cash rewards for
reaching optimal health goals, like maintaining a healthy body mass index (BMI),
keeping blood pressure and cholesterol levels in normal ranges, even smoking
cessation. The company believes that incentivizing employees to "shape up and
save" will not only lead to healthier bodies and lifestyles, but healthier minds
and savings too.
"We're excited to be in a position to spread this sort of holiday cheer this
year. For many businesses, the prospect of growth within the current economy is
a far stretch," Kiani concluded. "Yet, thankfully for us, our unique technology
and product offerings allow us to benefit from market demand and expansion
opportunities that make growth a reality that we are actively planning for
despite the many obstacles. I am grateful that we are able to provide the
lifesaving and life-changing medical technologies that clinicians and patients
all over the world depend on, and the job growth and employment opportunities
that our economy needs."
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), PVI®, and acoustic respiration rate (RRa™), in addition
to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion
index (PI), allowing early detection and treatment of potentially
life-threatening conditions. Founded in 1989, Masimo has the mission of
"Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive
Monitoring to New Sites and Applications." Additional information about Masimo
and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: the certainty of future growth and market opportunities,
expectations for future business expansion, and job growth and employment
opportunities facilitated by business growth and/or the addition of the building
located at 60 Parker, as well as other factors discussed in the "Risk Factors"
section of our most recent reports filed with the Securities and Exchange
Commission ("SEC"), which may be obtained for free at the SEC's
website at www.sec.gov. Although we believe
that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of today's date. We do not undertake any obligation to update,
amend or clarify these forward-looking statements or the "Risk Factors"
contained in our most recent reports filed with the SEC, whether as a result of
new information, future events or otherwise, except as may be required under the
applicable securities laws.
Contact:
Dana Banks
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo to Present at the 28th Annual J.P. Morgan Healthcare Conference
IRVINE, Calif., December 23, 2009 – Masimo Corporation
(NASDAQ: MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion
and Low Perfusion pulse oximetry, today announced that its management is
scheduled to present at the 28th Annual J.P. Morgan Healthcare Conference at the
Westin St. Francis Hotel in San Francisco on Monday, January 11, 2010, at 2:00
p.m. Pacific Time. A live audiocast of the presentation will be available on the
Masimo website at www.masimo.com. A replay
of the audiocast will be available following the live presentation.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care-helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET®
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), PVI® and acoustic respiration rate (RRa), in addition to
oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index
(PI), allowing early detection and treatment of potentially life-threatening
conditions. Founded in 1989, Masimo has the mission of "Improving Patient
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications." Additional information about Masimo and its products may be
found at www.masimo.com.
Masimo Corporation
Investor Contact:
Sheree
Aronson
Vice President, Investor Relations
Masimo Corporation
(949)
297-7043
saronson@masimo.com
Media Contact:
Dana Banks
Manager, Public
Relations
Masimo Corporation
(949) 297-7348
dbanks@masimo.com
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Happy Holidays from Masimo!
Irvine, California—December 22, 2009—This has been another
exciting year for us here at Masimo, as we commemorated the 20th anniversary of
our founding, and continued to see clinicians use our technologies to improve
patient safety and enhance the quality of patient care in around the world. It
was a year in which we celebrated the commercial launch of the world's first
noninvasive and continuous hemoglobin monitoring technology and the debut of the
world's first acoustic respiration rate monitoring technology. It is at this
very special time of year that we look to share our blessings by making a
special donation on your behalf to a charitable organization that needs our help
the most.
As we look to the future, we are encouraged by the successes of the past and
driven by the desire to continue working with the clinical community to
facilitate even greater advancements in patient care in the years to come. It is
with great appreciation for our customers, partners, shareholders and employees
that we close out this year by making a donation of $10 to the charity of your
choice. We will make this donation in the name of each person who is an official
member of Livewire as of today and who responds to this Livewire with his or her
charity choice from the list below:
- Amnesty International
- CARE
- Doctors Without Borders
- Huntington's DSA
- Make-a-Wish Foundation
- March of Dimes
- Opportunity International
- SOS Children's Villages
- Swan Foundation
- UNICEF
- United Way
- World Vision
Please send us an e-mail specifying your selection to: charity@masimo.com. Only requests by e-mail
to this address will be processed. We also encourage you to include any comments
or suggestions you might have that will help us to better fulfill our mission
and adhere to our guiding principles.
Masimo Mission Statement
Improving patient outcomes and reducing cost of care by taking noninvasive
monitoring to new sites and applications.
Masimo Guiding Principles
- Remain faithful to your promises and responsibilities.
- Thrive on fascination and accomplishment and not on greed and power.
- Make each day as fun as possible.
- Strive to make each year better than the year before, both personally and
for the Team.
- Do what is best for patient care.
We thank each of you for your support in helping us to make life better for
the clinicians and patients we diligently serve, and look forward to a new year
full of great possibilities.
With sincere gratitude and warmest regards,
Masimo
|
|
|
|
|
|
Masimo Announces Transition of Chief Technical Officer to Full-Time Chief Engineer
Irvine, California – December 18, 2009 – Masimo (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low
Perfusion pulse oximetry, announced today that Ammar Al-Ali, the Company's Chief
Technical Officer, will be transitioning from his current position to the full
time position of Engineer Fellow, Chief Engineer of the Company. The transition
will remove day-to-day management responsibility for the CTO office and allow
Mr. Al-Ali to focus his efforts exclusively on the creation and development of
new technologies and products for the Company.
Joe Kiani, Founder & CEO of Masimo, stated: "On behalf of the entire
company, I thank Ammar for his years of service as Masimo's Chief Technical
Officer and the major contributions he has made during his tenure in this role.
I am delighted that he will be moving into a new full-time role with the Company
that will allow him to continue to help us meet our continuing mission of
improving patient outcomes and reducing the cost of care by taking noninvasive
monitoring to new sites and applications. Based on Ammar's contributions to
Masimo over the past 15 years, including his most recent role as CTO, we are
very excited about the prospects that this new role presents for both Ammar and
us."
The transition is expected to occur on or about December 31, 2009. After
December 31, 2009, Joe Kiani will serve as Masimo's acting CTO while Masimo
continues its search for a new Chief Technology Officer, which has already
begun.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), PVI®, and acoustic respiration rate (RRa), in addition
to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion
index (PI), allowing early detection and treatment of potentially
life-threatening conditions. Founded in 1989, Masimo has the mission of
"Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive
Monitoring to New Sites and Applications." Additional information about Masimo
and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including those
discussed in the "Risk Factors" section of our most recent reports filed with
the Securities and Exchange Commission ("SEC"), which may be
obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the applicable
securities laws.
Media Contacts:
Dana Banks
Masimo Corporation
+1
(949) 297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
New Clinical Study Finds Masimo Perfusion Index (PI) Predicts Low Systemic
Blood Flow in Preterm Infants
Masimo PI May Provide an Easy, Noninvasive Method for Early Intervention
and Treatment of Cardiovascular Compromise
Irvine, California – December 17, 2009 – Masimo
(NASDAQ: MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion
and Low Perfusion pulse oximetry, today announced that new research findings,
published in the November 2009 issue of the Journal of Perinatology,
show that Masimo perfusion index (PI) accurately predicts low superior vena cava
flow (SVC) in preterm, very-low-birth-weight infants—representing a promising
method for continuous and noninvasive monitoring of systemic blood flow.1
SVC flow, a measure of blood flow returning to the heart from the upper body,
is useful information in the cardiovascular management of neonates because it
helps determine risk for intraventricular hemorrhage, developmental impairments,
morbidity, and mortality.2-4 However, detecting
low SVC flow is challenging because current measurement methods are complicated,
operator dependent, or can be inaccurate in certain neonatal conditions.5-6 Masimo PI provides a reliable continuous,
noninvasive measure of the ratio of pulsatile blood flow to the non-pulsatile or
static blood in peripheral tissue, which provides a rapid, reliable, and
cost-effective method to help clinicians assess perfusion and circulatory
status.
In the study, Dr. Takahashi and colleagues at the National Center for Child
Health and Development in Tokyo, Japan, used the Masimo Radical pulse oximeter
and Masimo LNOP NeoPt-L sensor to monitor PI in 24 preterm infants during the
first 72-hours following birth. When comparing PI to echocardiography to
directly measure SVC, they found that a PI of <0.44 detected low SVC flow
(defined as <40ml kg-1 min-1) with good sensitivity (88%) and specificity (86%).
A total of eight out of 24 infants were confirmed to have low SVC flow, and PI
positively detecting seven—leading researchers to conclude that Masimo PI is a
"useful index for detecting low SVC flow in very low birth weight infants born
before 32 weeks of gestation" and that "the PI should be evaluated in the
cardiovascular management of preterm infants."
Masimo Executive Vice President of Medical Affairs Dr. Michael O'Reilly,
stated, "The current study provides additional evidence supporting the clinical
utility of Masimo PI, a reliable noninvasive measure of perfusion. Previous work
demonstrated the value of Masimo PI as an early indicator of clinical
deterioration in neonates and life-threatening congenital heart disease. Masimo
PI has also been shown highly effective in assessing the response to painful
stimuli and the proper placement of epidural and regional anesthesia. These
results reinforce the value of Masimo PI to routinely assess circulatory
disorders and improve detection and treatment of life-threatening
conditions."
1 S Takahashi, S Kakiuchi, Y Nanba, K Tsukamoto, T
Nakamura, Y Ito. "The Perfusion Index Derived from a Pulse Oximeter for
Predicting Low Superior Vena Cava Flow in Very Low Birth Weight Infants."
Journal of Perinatology (12 November 2009) doi:10.1038/jp.2009.159.
Available online at: http://www.nature.com/jp/journal/vaop/ncurrent/full/jp2009159a.html
2 Kluckow M, Evans N. "Low Superior Vena Cava Flow and
Intraventricular Haemorrhage in Preterm Infants." Arch Dis Child Fetal
Neonatal Ed 2000; 82: F188–F194.
3 Osborn DA, Evans N,
Kluckow M. "Hemodynamic and Antecedent Risk Factors of Early and Late
Periventricular/Intraventricular Hemorrhage in Premature Infants."
Pediatrics 2003; 112: 33–39.
4 Miletin J, Dempsey EM.
"Low Superior Vena Cava Flow on Day 1 and Adverse Outcome in the Very Low
Birthweight Infant." Arch Dis Child Fetal Neonatal Ed 2008; 93:
F368–F371.
5 Kluckow M, Evans N. "Superior Vena Cava Flow in
Newborn Infants: A Novel Marker of Systemic Blood Flow." Arch Dis Child
Fetal Neonatal Ed 2000; 82: F182–F187.
6 Osborn DA, Evans N,
Kluckow M. "Clinical Detection of Low Upper Body Blood Flow in Very Premature
Infants Using Blood Pressure, Capillary Refill Time, and Central-Peripheral
Temperature Difference." Arch Dis Child Fetal Neonatal Ed 2004;
89:F168–F173.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), PVI®, and acoustic respiration rate (RRa™), in addition
to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion
index (PI), allowing early detection and treatment of potentially
life-threatening conditions. Founded in 1989, Masimo has the mission of
"Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive
Monitoring to New Sites and Applications." Additional information about Masimo
and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the repeatability of
clinical results, risks related to our belief that Masimo PI provides unique
clinical advantages as an automatic noninvasive measurement of low SVC and
intraventricular hemorrhage in very low birth weight, preterm infants, risks
related to our assumptions that Masimo PI is a useful noninvasive indicator of
perfusion, an early predictor of high illness severity in neonates, and an early
detection tool for left heart obstruction, and risks related to our assumptions
that Masimo PI represents a more rapid, reliable and cost-effective clinical
alternative for assessing perfusion and circulatory status, as well as other
factors discussed in the "Risk Factors" section of our most recent reports filed
with the Securities and Exchange Commission ("SEC"), which may
be obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the applicable
securities laws.
Contact:
Dana Banks
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award
Masimo Lauded for "An Unprecedented Ability in Understanding Customer
Requirements, Developing New Technologies, Delivering Relevant Products" and
"Integrity in Conducting Businessand Truthfulness in Advertising"
Irvine, California – December 15, 2009 – Masimo
(NASDAQ: MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion
and Low Perfusion pulse oximetry, today announced that Masimo Chairman and CEO
Joe Kiani has been awarded the 2009 Frost & Sullivan CEO of the Year Award
in the North American Patient Monitoring market. According to Frost &
Sullivan, the award is presented in recognition of Mr. Kiani's "unprecedented
ability in understanding customer requirements, developing new technologies,
delivering relevant products, and thereby exploiting new market opportunities.
In leading Masimo, he has not only made technology innovation the core of the
company's philosophy but also equally emphasized protection of that innovation
through patent licensing and OEM contracts with established patient monitoring
manufacturing companies such as GE Medical, Philips, Zoll, Atom, Draeger, and
Medtronic. While accomplishing all of these things, Masimo and Mr. Kiani have
also been recognized for their integrity in conducting business and truthfulness
in advertising."
In its summary outlining the reasons they chose to honor Kiani with the CEO
of the Year award, Frost & Sullivan referenced his significant contributions
to the industry, starting with the development of Masimo SET pulse oximetry.
With the assistance of his friend and fellow engineer Mohamed Diab, Frost &
Sullivan noted, "Kiani embarked on achieving the impossible goal of developing a
pulse oximetry technology that provides precise, reliable measurements during
low peripheral profusion and patient motion. The outcome of this endeavor was
the invention of a breakthrough technology in pulse oximetry, Masimo SET, which
considerably reduced false alarms and increased the instrument's capability of
detecting critical conditions."
"This revolutionary discovery marked the beginning of Masimo's legacy as
pulse oximetry technology innovator developing and manufacturing advanced,
unique equipment each year. Under Mr. Kiani's leadership, in 2005 Masimo
unveiled its second ground-breaking innovation, Masimo Rainbow SET Pulse
CO-Oximetry with the advanced ability to measure several blood constituents that
traditionally necessitated invasive methods," Frost & Sullivan continued.
"Considerable enhancements were made in this product line with the capacity to
measure carboxyhemoglobin (SpCO®) in 2005, methemoglobin (SpMet®) in 2006, and
pleth variability index (PVI™) in 2007. The latest Rainbow innovation from
Masimo launched in 2008 is the noninvasive total hemoglobin (SpHb™).
Additionally, this novel equipment also measures pulse rate, perfusion index,
and oxyhemoglobin and plays a critical role in early detection and treatment of
life-threatening conditions."
Frost & Sullivan added that the key to Mr. Kiani's success as the CEO of
Masimo "lies in directing his technological inventions to strategically address
the unmet needs of the market" and that under his leadership, Masimo's
innovations have "redefined patient monitoring systems." The award summary goes
on to cite "the strategies adopted by Mr. Kiani as the CEO of Masimo have
persistently created new industry standards. The novel product portfolio of
Masimo has added a new dimension to noninvasive patient monitoring equipment
that has considerably facilitated early detection of challenging patient
conditions."
"As a dynamic entrepreneur, he has accepted technological and business
challenges successfully, resolved them, and created new industry benchmarks
during this process. In this context, it is relevant to mention that in 2006,
Mr. Kiani's relentless efforts enabled Masimo to attain a historic victory
against Nellcor division of Tyco Healthcare in one of the biggest patent
infringement violation lawsuits. Despite Tyco Healthcare's stature and market
dominance, Mr. Kiani won his company more than $300 million in damages setting a
dramatic precedent that has changed the very face of the healthcare industry,"
the award summary states. "In addition, his testimony before the U.S. Senate in
2002 led to Group Purchasing Organization (GPO) reforms that help ensure
clinicians have access to the best technology and that every company making
effective products, competitively priced, is given a chance to compete and sell
to hospitals through a GPO, not just the dominant suppliers."
In addition, Frost & Sullivan said that Mr. Kiani's "technology licensing
strategy has successfully demonstrated the infallibility of patenting as a
critical growth propeller for emerging medical device companies. Masimo's
victory against Tyco Healthcare buttresses the importance of patenting in
guarding the innovations of the emerging companies against established market
participants. Furthermore, this victory also indicates the capability of
emerging companies to compete with the market leaders that control the
market."
Frost & Sullivan continued: "While leading innovation and industry
change, Masimo and Mr. Kiani have also been guided by the highest principles and
ethics, resulting in recognition by customers and partners alike for their
integrity in conducting business. Masimo has also received high rankings by
industry publications and professional societies for truthfulness in
advertising."
"In successfully augmenting his scientific acumen, his formal university
training, his business foresight, and the highest integrity, Mr. Kiani has
demonstrated the characteristic virtues of a true entrepreneur. As the CEO, he
has constantly assisted Masimo in taking confident, progressive strides in the
highly monopolized patient monitoring equipment market," the award summary
concludes. "In strategically balancing product innovation, manufacturing,
licensing, and marketing, Mr. Kiani has carefully delineated the cardinal
elements of an effective business model. Fostering healthy competition and
transforming challenges to drivers, Mr. Kiani has emerged as the ideal choice
for the 2009 Frost & Sullivan CEO of the Year Award in the North American
Patient Monitoring market."
"On behalf of the entire Masimo team around the world, I am humbled to accept
this award," Mr. Kiani said. "This award truly reflects the hard work and
dedication of a large group of dedicated men and women at Masimo who come to
work each day to solve the unsolvable, and as a result make a real difference in
the lives of patients."
A complete description of this award and the multiple other awards Masimo has
received is available at: http://www.masimo.com/awards/index.htm
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), PVI®, and acoustic respiration rate (RRa™), in addition
to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion
index (PI), allowing early detection and treatment of potentially
life-threatening conditions. Founded in 1989, Masimo has the mission of
"Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive
Monitoring to New Sites and Applications." Additional information about Masimo
and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: whether Mr. Kian's receipt of the Frost & Sullivan award as
CEO or the Year will have any material affect on our business, as well as other
factors discussed in the "Risk Factors" section of our most recent reports filed
with the Securities and Exchange Commission ("SEC"), which may
be obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the applicable
securities laws.
Contact:
Dana Banks
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress
Masimo Rainbow SET® Acoustic Respiration Rate Monitoring Generates
Significant Interest
Irvine, California – December 9, 2009 – Masimo (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low
Perfusion pulse oximetry, announced today that it has received the prestigious
Zenith Award for equipment and service excellence from the American Association
of Respiratory Care (AARC) at their 55th Annual AARC International Congress in
San Antonio, Texas. Masimo Rainbow SET Acoustic Monitoring was also featured in
live demonstrations at the Masimo commercial exhibit and received very favorable
reviews from respiratory therapists.
For the second year in a row, Masimo has achieved AARC's top industry
recognition honoring respiratory care equipment and pharmaceutical manufacturers
for quality and service excellence. More than 400 companies were eligible for
one of five Zenith Award honors. Award winners are chosen by the association's
membership—more than 44,000 respiratory care professionals—based upon the
quality of equipment and/or supplies, accessibility and helpfulness of sales
personnel, as well as the company's responsiveness, service record, truth in
advertising, and overall support of the respiratory care profession.
In addition, hundreds of respiratory care professionals from all over the
world were among the first to see live demonstrations of Masimo Rainbow SET
Acoustic Monitoring—providing noninvasive and continuous respiration rate (RRa™)
that is accurate, easy-to-use, and enhances patient compliance. Masimo Rainbow
SET Acoustic Monitoring may enable earlier detection of respiratory compromise
and patient distress—offering a breakthrough in patient safety for post-surgical
patients on the general floor. Comments received from respiratory therapists at
the AARC Congress included the following:
David Gibson, RRT, Supervisor, Medical City Dallas Hospital in Dallas, Texas,
stated: "As a caregiver, I appreciate Masimo's commitment to innovation—they
have done it again with their new Acoustic Respiration Rate Monitoring
technology. Finally, there is a reliable, easy, comfortable, and cost-effective
way to monitor breathing sounds on my patients on the general floor."
Jenni Raake, MBA, RRT, Respiratory Care Coordinator, Cincinnati Children's
Hospital Medical Center, stated: "I see so many uses for Masimo's Rainbow
Acoustic Monitoring, across so many care areas. With the wireless Masimo Rad-87
monitor, I believe it will be a great technology for patients needing
ambulation. It should also be perfect for conscious sedation procedures."
Abbie Rosenberg, RRT, RCP in Santa Cruz, California, added: "I believe that
Masimo Acoustic Respiration Rate will help hospitals effectively monitor and
avoid sentinel events in post-surgical patients using patient controlled
analgesic pumps."
Joe Kiani, Founder & CEO of Masimo, stated: "We are honored to receive
the Zenith Award. This recognition is especially gratifying because it comes
from the clinicians who use our products every day. It's also exciting to see
the reactions and hear the positive reviews from respiratory therapists who saw
first-hand demonstrations of Rainbow Acoustic Monitoring."
Michael O'Reilly, MD, Masimo's EVP of Medical Affairs, stated: "Respiratory
care professionals attending the AARC Congress were truly excited by the
introduction of Rainbow SET Acoustic Monitoring with its ability to monitor the
breathing status of patients, 24/7. Respiratory care professionals are not alone
in their excitement, as all clinicians who care for patients receiving
patient-controlled analgesia for pain management know that sedation can slow
breathing and place patients at considerable risk. For these patients, early
intervention and appropriate treatment could mean the difference between life
and death."
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), PVI®, and acoustic respiration rate (RRa), in addition
to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion
index (PI), allowing early detection and treatment of potentially
life-threatening conditions. Founded in 1989, Masimo has the mission of
"Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive
Monitoring to New Sites and Applications." Additional information about Masimo
and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our belief that the breakthrough respiration
rate monitoring capabilities of Masimo Rainbow SET Acoustic Monitoring
technology will allow clinicians to detect and treat respiratory compromise and
patient distress earlier, risks related to our belief that Masimo Rainbow SET
Acoustic Monitoring technology will provide sufficient sensitivity and
specificity to measure respiratory rate in a variety of patients and monitoring
conditions, risks related to our assumptions regarding the commercial timing and
availability of the technology, as well as other factors discussed in the "Risk
Factors" section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at
the SEC's website at www.sec.gov. Although we
believe that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of today's date. We do not undertake any obligation to update,
amend or clarify these forward-looking statements or the "Risk Factors"
contained in our most recent reports filed with the SEC, whether as a result of
new information, future events or otherwise, except as may be required under the
applicable securities laws.
Media Contacts:
Dana Banks
Masimo Corporation
+1
(949) 297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Brookdale University Hospital and Medical Center Completes System-wide Conversion
to Masimo SET® Pulse Oximetry and Adds Noninvasive Hemoglobin to Select
Care Areas
Standardization Makes Large Teaching Hospital in Brooklyn First in New
York to Leverage Noninvasive and Continuous Hemoglobin for Bloodless Hemoglobin
Monitoring
Irvine, California – December 7, 2009 – Masimo (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low
Perfusion pulse oximetry, announced today that Brookdale University Hospital and
Medical Center in Brooklyn, New York, has completed its system-wide conversion
to Masimo SET pulse oximetry technology. As part of its system-wide technology
standardization, Brookdale has also installed first-ever continuous and
noninvasive hemoglobin monitoring (SpHb™) technology in select care
settings—allowing clinicians to detect and treat chronic or acute anemia
earlier, identify internal bleeding sooner, and more effectively manage blood
transfusions for their patients.
By converting to Masimo SET, Brookdale clinicians gain all the
Measure-Through Motion and Low Perfusion benefits of Masimo SET pulse oximetry,
along with the breakthrough noninvasive blood constituent monitoring
capabilities of Masimo Rainbow SET Pulse CO-Oximetry. Masimo Rainbow SET is the
first-and-only technology platform capable of continuously and noninvasively
measuring multiple blood constituents that previously required invasive
procedures, including: total hemoglobin (SpHb™), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI®, in addition to
oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index
(PI). The ability to immediately detect and treat potentially life-threatening
conditions—without having to draw blood and wait for the results—enables earlier
and better clinical decisions that may help save lives and improve patient
outcomes.
According to Thomas Crimi, M.D., Director of the Blood Conservation Program
at Brookdale, Masimo SpHb is helping to improve blood management and
conservation at Brookdale. "SpHb provides us with the unique ability to
proactively identify and address patient's requiring blood transfusions much
earlier, while avoiding unnecessary transfusions and other invasive tests. This
certainly contributes to better quality care, patient safety, and improved
clinical outcomes."
Masimo Founder and CEO, Joe E. Kiani, stated, "Brookdale's history of
implementing sophisticated diagnostics and treatment technologies makes it the
ideal care setting to pioneer Masimo SpHb for Brooklyn-area residents. We
applaud their use of advanced medical technologies to help improve blood
conservation efforts, patient care and clinical outcomes within their
community."
The Brookdale University Hospital and Medical Center is one of Brooklyn's
largest voluntary nonprofit teaching hospitals with 530 inpatient beds. With an
extensive ambulatory care network, and an Emergency Department and Level I
Trauma Center that is among the busiest in the region, Brookdale is also a New
York State DOH designated Stroke Center.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI®, and acoustic respiration rate (RRa), in
addition to oxyhemoglobin (SpO2), pulse rate (PR), and
perfusion index (PI), allowing early detection and treatment of potentially
life-threatening conditions. Founded in 1989, Masimo has the mission of
"Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive
Monitoring to New Sites and Applications." Additional information about Masimo
and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the repeatability of
clinical results, risks related to our belief that Masimo SET and Masimo Rainbow
SET will provide sufficient sensitivity and specificity to detect physiological
abnormalities in real-time, enabling clinicians to detect and identify
potentially life-threatening conditions earlier and make better clinical and
treatment decisions for their patients, risks related to our assumption that
Masimo SET and Masimo Rainbow SET will deliver a sufficient level of clinical
improvement over alternative pulse oximetry and noninvasive patient monitoring
technologies to allow for further adoption of the technology at other hospitals,
and risks related to our assumption that the conversion of Brookdale University
Medical Center will serve to substantially increase revenues, as well as other
factors discussed in the "Risk Factors" section of our most recent reports filed
with the Securities and Exchange Commission ("SEC"), which may
be obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the applicable
securities laws.
Media Contacts:
Dana Banks
Masimo
Corporation
(949) 297-7348
dbanks@masimo.com
Ruth Richman
Brookdale University Hospital
(718) 240-5345
rrichman@brookdale.edu
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo Receives FDA Clearance for Masimo Rainbow SET® Acoustic Respiration Rate
Monitoring
The First Acoustic Respiration Rate Monitoring Technology will Debut at
the Annual American Association of Respiratory Care Conference
Irvine, California – December 1, 2009 – Masimo (NASDAQ: MASI), the inventor of Pulse
CO-Oximetry™ and Measure-Through Motion and Low Perfusion pulse oximetry, today
announced FDA clearance of its latest innovation—Masimo Rainbow SET Acoustic
Monitoring™—providing noninvasive and continuous respiration rate (RRa™) that is
accurate, easy-to-use, and enhances patient compliance. Masimo Rainbow SET
Acoustic Monitoring may enable earlier detection of respiratory compromise and
patient distress – offering a breakthrough in patient safety for post-surgical
patients on the general floor. The limited market release, which will begin in
December, will allow select hospitals to be the first to benefit from the new
technology.
 |
| Masimo Rainbow SET Acoustic Monitoring noninvasively and continuously
measures respiration rate using an innovative adhesive sensor with an integrated
acoustic transducer that is easily and comfortably applied to the patient's neck
to detect upper airway acoustic vibrations on the surface of the skin during the
respiratory cycle. |
Respiration rate is defined as the number of breaths per minute and is
considered a critical vital sign in assessing the physiological status of
hospitalized patients. Continuous monitoring of respiration rate is especially
important for post-surgical patients receiving patient-controlled analgesia
(PCA) for pain management as sedation can induce respiratory depression and
place patients at considerable risk of serious injury or death.1-4 Although the Anesthesia Patient Safety Foundation
(APSF) recommends continuous oxygenation and ventilation monitoring in all
patients receiving opioids,5,6 current methods
for respiration rate monitoring are limited by accuracy and patient compliance.
Masimo Rainbow SET Acoustic Monitoring features an innovative adhesive sensor
with an integrated acoustic transducer that is easily and comfortably applied to
the patient's neck to detect upper airway acoustic vibrations on the surface of
the skin during the respiratory cycle. Using patented acoustic signal
processing that leverages Masimo's revolutionary Signal Extraction Technology
(SET), the respiratory signal is separated and processed to display continuous
respiration rate.
When Masimo Rainbow SET Acoustic Monitoring is used in conjunction with Masimo Rainbow SET Pulse
CO-Oximetry and the Masimo Patient
SafetyNet™ Remote Monitoring and Clinician Notification System, clinicians
can follow key indicators of oxygenation with Masimo gold standard SpO2, ventilation with the breakthrough RRa, circulation with Masimo
measure through motion pulse rate (PR), and bleeding with Masimo noninvasive and continuous
hemoglobin (SpHb™) – enabling them to monitor more patients, more safely,
than ever before.
According to Michael Ramsay, M.D., Chief of the Department of Anesthesiology
and Pain Management at Baylor University Medical Center in Dallas, Texas,
"Breathing adequately is what matters most. Masimo acoustic respiration rate
provides clinicians with the ability to automatically and continuously monitor
the breathing status of post-surgical patients in general care or
post-anesthesia settings—alerting them to the first sign of an abnormal or
compromised breathing pattern that may be indicative of airway obstruction or
respiratory distress." After using the new technology, Dr. Ramsay also stated
"The Masimo Acoustic Sensor is virtually unnoticeable when worn – making it
extremely patient-friendly."
Masimo Founder and CEO, Joe E. Kiani, stated, "Solving 'unsolvable' problems
that have plagued patient monitoring is key to advancing medicine and improving
patient care. Masimo Rainbow SET Acoustic Monitoring addresses a longstanding
and growing need to accurately and easily monitor patient breathing, which is
expected to improve patient safety and decrease the cost of care in hospitals.
It also adds another compelling reason for hospitals to choose the Masimo
Rainbow SET upgradeable platform for pulse oximetry, Pulse CO-Oximetry, and
now—Acoustic Monitoring."
Live demonstrations of Masimo Rainbow SET Acoustic Monitoring will be
featured at the Masimo exhibit at the American Association
of Respiratory Care December 5-7, 2009 in San Antonio, Texas.
1 Joint Commission on Accreditation of Healthcare Organizations.
Sentinel Event Alert: Patient controlled analgesia by proxy. Chicago: JCAHO,
2004
2 Institute for Safe Medication Practice. Safety issues with
patient-controlled analgesia: Part 1-How errors occur. Huntingdon Valley: ISMP,
2003
3 Institute for Safe Medication Practices. Safety issues with
patient-controlled analgesia: Part II – How to prevent errors Huntingdon: ISMP,
2003
4 Bird M. Acute pain management: a new area of liability for
anesthesiologists ASA Newsletter. Park Ridge: American Society of
Anesthesiologists, 2007
5 Weinger MB. Dangers of Postoperative Opioids: APSF
Workshop and White paper address prevention of postoperative respiratory
complications. APSF Newsletter, 2006;21:61–7. http://www.apsf.org/assets/Documents/winter2007.pdf
6 Stoelting RK, Weinger MB. Dangers of Postoperative Opioids—Is There a
Cure? APSF Newsletter, 2009;24:25-26. http://www.apsf.org/assets/Documents/summer2009.pdf
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), PVI™, and acoustic respiration rate (RRa), in addition
to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion
index (PI), allowing early detection and treatment of potentially
life-threatening conditions. Founded in 1989, Masimo has the mission of
"Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive
Monitoring to New Sites and Applications." Additional information about Masimo
and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the repeatability of
clinical results and performance of Masimo Rainbow SET Acoustic Monitoring,
risks related to our belief that the breakthrough respiration rate monitoring
capabilities of Masimo Rainbow SET Acoustic Monitoring technology will allow
clinicians to detect and treat respiratory compromise and patient distress
earlier, risks related to our belief that Masimo Rainbow SET Acoustic Monitoring
technology will provide sufficient sensitivity and specificity to measure
respiratory rate in a variety of patients and monitoring conditions, risks
related to our assumptions regarding the commercial timing and availability of
the technology, as well as other factors discussed in the "Risk Factors" section
of our most recent reports filed with the Securities and Exchange Commission
("SEC"), which may be obtained for free at the SEC's website at
www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the applicable
securities laws.
Media Contacts:
Dana Banks
Masimo
Corporation
+1 (949) 297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, RRa, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Advocate Health Care Renews Multi-Year, System-wide Contract for Masimo SET® Pulse Oximetry Technology
Irvine, California – November 23, 2009 – Masimo (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and
Low-Perfusion pulse oximetry, announced today that Advocate Health
Care—Illinois' largest health care provider—has renewed its multi-year,
system-wide contract for Masimo SET pulse oximetry technology. A Masimo customer
since 2001, Advocate Health Care's renewal of its Masimo SET technology
standardization contract means Masimo will continue to support the pulse
oximetry needs of more than 200 Advocate sites of care across metropolitan
Chicago.
Masimo SET pulse oximetry technology allows hospitals and other care sites to
leverage the superior Measure-Through Motion and Low-Perfusion benefits of
Masimo SET pulse oximetry, along with the unique breakthrough noninvasive blood
constituent monitoring capabilities of Masimo Rainbow SET Pulse CO-Oximetry.
Masimo Rainbow SET is the first-and-only technology platform capable of
continuously and noninvasively measuring multiple blood constituents that
previously required invasive procedures, including: total hemoglobin (SpHb™),
oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and
PVI®, in addition to oxyhemoglobin (SpO2), pulse rate (PR),
and perfusion index (PI). The ability to immediately detect and treat
potentially life-threatening conditions—without having to draw blood and wait
for the results—enables earlier and better clinical decisions that may help save
lives and improve patient outcomes.
"Advocate Health Care's healing mission calls us to work with partners that
share our commitment to our patients' health and safety," said Paul Hoffmann,
R.R.T., chairman of the Advocate Health Care respiratory care council. "We are
very satisfied with the features and functionality of the Masimo pulse oximetry
technology, and we are pleased to continue our relationship with Masimo."
Masimo Founder and CEO, Joe E. Kiani, stated, "Advocate Health is one of the
premier health care institutions in the US. We are proud to have earned
Advocate's trust over the last eight years and that they have decided to place
their trust, business, and pulse oximetry needs in our hands for many more
years."
Advocate Health Care, one of the nation's top 10 health systems based on
clinical performance, is the largest health care provider in Illinois. As a
not-for-profit, mission-based health system, Advocate operates more than 200
sites of care across metropolitan Chicago, including nine acute care hospitals,
two children's hospitals, four Level I trauma centers (the state's highest
designation in trauma care), a home health care company and one of the region's
largest medical groups.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the repeatability of
clinical results, risks related to our belief that Masimo SET and Masimo Rainbow
SET will provide sufficient sensitivity and specificity to detect physiological
abnormalities in real-time, enabling clinicians to detect and identify
potentially life-threatening conditions earlier and make better clinical and
treatment decisions that may help save lives and improve outcomes for their
patients, risks related to our assumption that Masimo SET and Masimo Rainbow SET
will deliver a sufficient level of clinical improvement over alternative pulse
oximetry and noninvasive patient monitoring technologies to allow for further
adoption of the technology at other hospitals, risks related to our assumption
that the system-wide renewal of Advocate Health Care will serve to substantially
increase revenues, and risks related to our assumptions regarding the future of
the Advocate Health Care system-wide pulse oximetry renewal contract, as well as
other factors discussed in the "Risk Factors" section of our most recent reports
filed with the Securities and Exchange Commission ("SEC"),
which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the applicable
securities laws.
Media Contacts:
Dana Banks
Masimo
Corporation
(949) 297-7348
dbanks@masimo.com
Kelly Jo Golson
Adovate Health Care
(630) 990-5615
kellyjo.golson@advocatehealth.com
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo to Present at the 21st Annual Piper Jaffray Health Care Conference
IRVINE, Calif., November 20, 2009 – Masimo Corporation
(NASDAQ: MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion
and Low-Perfusion pulse oximetry, today announced that its management is
scheduled to present at the 21st Annual Piper Jaffray Health Care Conference at
the New York Palace Hotel in New York on Tuesday, December 1, 2009, at 12:00
p.m. ET. A live audiocast of the presentation will be available on the Masimo
website at www.masimo.com. A replay of the
audiocast will be available following the live presentation.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care-helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET®
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI®, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at http://www.masimo.com.
Masimo Corporation
Investor
Contact:
Mark P. de Raad
Executive Vice President and Chief
Financial Officer
Masimo Corporation
(949) 297-7080
mderaad@masimo.com
Media Contact:
Dana Banks
Manager, Public
Relations
Masimo Corporation
(949) 297-7348
dbanks@masimo.com
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Uni.H.A. in France Signs Purchasing Agreement for Masimo SET® Pulse Oximetry Products
Network of 53 Hospitals Gain Access to Masimo SET Pulse
Oximeters
Irvine, California – November 18, 2009 – Masimo (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and
Low-Perfusion pulse oximetry, announced today that Lyon, France-based Uni.H.A.,
one of the largest healthcare Group Purchasing Organizations (GPO) in France,
has signed a multi-year purchasing agreement for "gold standard" Masimo SET®
pulse oximeters. The agreement offers preferred contract pricing to Uni.H.A.'s
53 member hospitals and provides for more than 1,000 Masimo SET bedside pulse
oximeters and 650 handheld pulse oximeters to be purchased within
four-years.
Masimo pulse oximeters feature the most advanced pulse oximetry technology
available to deliver accurate, reliable measurements and meaningful alarms that
reflect a patient's true oxygenation status. The superior fidelity of Masimo SET
pulse oximetry technology—clinically-proven in more than 100 independent and
objective studies to provide the most trustworthy SpO2 and
pulse rate measurements, even under the most difficult clinical conditions of
patient motion and low peripheral perfusion—allows clinicians to maximize their
efficiency by concentrating on caring for their patients, rather than chasing
false alarms.
In addition, the agreement provides Uni.H.A.-member hospitals with an upgrade
path to the breakthrough noninvasive blood constituent monitoring capabilities
available only as part of the Masimo Rainbow SET Pulse CO-Oximetry technology
platform. These unique noninvasive measurements—including total hemoglobin
(SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), and PVI™ for fluid responsiveness—can be field-installed on Masimo
Rainbow-ready devices through a simple software upgrade, allowing hospitals to
easily purchase and add them when they are ready. Masimo Rainbow SET
measurements enable earlier detection of potentially life-threatening conditions
to help increase patient safety, improve the quality of care, and reduce the
cost of care.
Jon Coleman, President of Masimo International, stated: "This agreement with
Uni.H.A. provides many of Europe's most demanding hospitals with direct and open
access to Masimo pulse oximetry and noninvasive blood constituent monitoring
solutions that facilitate faster, easier and safer health decisions. We are
happy to partner with Uni.H.A. in providing their member hospitals with the
industry-leading medical technology solutions they need to advance patient care
and outcomes."
Uni.H.A. members include 32 Hospital University Centers and 21 major
hospitals across Europe that represent 45% of French state hospital
expenditures. Today, Masimo SET pulse oximetry technology is at work in more
than 100 top-ranked hospitals throughout France, including the largest public
hospital system in Europe—Assistance Publique Hopitaux de Paris (AP-HP).
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the repeatability of
clinical results, risks related to our assumptions that a sole-supplier
agreement with UNI.H.A. will expand European market access to Masimo SET pulse
oximeters, risks related to our belief that Masimo SET will deliver sufficient
sensitivity and specificity to deliver the most accurate and reliable
measurements under all conditions of patient motion and low peripheral
perfusion, and risks related to our assumption that this multi-year supplier
agreement will serve to broaden the use of Masimo SET pulse oximetry or will
serve to provide substantially increased revenues for the company, as well as
other factors discussed in the "Risk Factors" section of our most recent reports
filed with the Securities and Exchange Commission ("SEC"),
which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the applicable
securities laws.
Media Contacts:
Dana Banks
Masimo Corporation
+1
(949) 297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET® Pulse CO-Oximetry™
CareFusion plans to Integrate Breakthrough Noninvasive Blood Constituent
Monitoring Capabilities into Future Infusion and Respiratory Products
Irvine, California – November 12, 2009 – Masimo (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and
Low-Perfusion pulse oximetry, and CareFusion (NYSE: CFN), a leading global
medical device company, today announced a multi-year technology licensing
agreement establishing the breakthrough noninvasive blood constituent monitoring
capabilities of Masimo Rainbow SET Pulse CO-Oximetry technology to be used in
CareFusion infusion and respiratory products under development*.
Incorporating Masimo Rainbow SET Pulse CO-Oximetry technology will enable
CareFusion's future infusion and respiratory products (under development*) to
noninvasively and continuously measure multiple blood constituents to more
accurately assess dyshemoglobins affecting oxygenation, predict fluid
responsiveness, and provide earlier identification of respiratory compromise.
The ability to automatically assess total hemoglobin (SpHb™), oxygen content
(SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI® for fluid
responsiveness, in addition to oxyhemoglobin (SpO2),
perfusion index (PI), and pulse rate directly from CareFusion's ventilators and
infusion pumps may facilitate earlier detection, diagnosis and treatment of
potentially life-threatening conditions.
Currently, CareFusion uses Masimo technology in the Alaris® SpO2 module to help safeguard PCA delivery through the Alaris®
System. The Alaris® PCA module together with the Alaris® SpO2 module—featuring Masimo SET® pulse oximetry technology for
accurate and trustworthy measure-through motion and low-perfusion SpO2, pulse rate, and perfusion index measurements—provides an
additional safety net for risk factors not covered by programming safety and bar
coding, such as previously undiagnosed clinical conditions and PCA by proxy. The
system offers the clinician the unique ability to automatically pause PCA
infusion if a patient falls below hospital-defined respiratory monitoring
limits.
"Masimo is a great partner with excellent technology," said Gordon LaFortune,
senior vice president and general manager of Infusion Systems for CareFusion.
"We're happy to be working with them to incorporate their technology in our
products."
Masimo President of OEM Business, Rick Fishel stated, "We look forward to a
growing technology partnership with CareFusion and the possibilities created by
the integration of Masimo Rainbow SET into CareFusion's infusion and respiratory
products."
*Future vision: As of the date of the communication, the products under
development have not been cleared for commercial sale by the FDA. The products
under development may not be cleared for commercial sale by the FDA. The company
may not make the products under development available for commercial sale.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to the timing, commercial availability, and
regulatory clearance of CareFusion infusion and respiratory products under
development that may or may not incorporate Masimo Rainbow SET, risks related to
our assumptions regarding the repeatability of clinical results, risks related
to our belief that the noninvasive blood constituent monitoring capabilities of
Masimo Rainbow SET may facilitate earlier detection, diagnosis, and treatment of
potentially life-threatening conditions to increase patient safety, improve the
quality of care, and reduce the cost of care, risks related to our belief that
Masimo SET will deliver sufficient sensitivity and specificity to deliver the
most accurate and reliable measurements under all conditions of patient motion
and low peripheral perfusion, and risks related to our assumption that Masimo
SET will help improve the regulation and delivery of oxygen therapy to neonates,
as well as other factors discussed in the "Risk Factors" section of our most
recent reports filed with the Securities and Exchange Commission
("SEC"), which may be obtained for free at the SEC's website at
www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the applicable
securities laws.
Media Contacts:
Dana Banks
Masimo Corporation
+1
(949) 297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
IRVINE, Calif., November 10, 2009 – Masimo Corporation
(NASDAQ: MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion
and Low-Perfusion pulse oximetry, today announced that its management is
scheduled to present at the Lazard Capital Markets 6th Annual Healthcare
Conference at The St. Regis Hotel in New York on Tuesday, November 17, 2009, at
10:25 a.m. ET. A live audiocast of the presentation will be available on the
Masimo website at www.masimo.com. A replay
of the audiocast will be available following the live presentation.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care-helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET®
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI®, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at http://www.masimo.com.
Masimo Corporation
Investor Contact:
Mark P.
de Raad
Executive Vice President and Chief Financial Officer
Masimo
Corporation
(949) 297-7080
mderaad@masimo.com
Media Contact:
Dana Banks
Manager, Public
Relations
Masimo Corporation
(949) 297-7348
dbanks@masimo.com
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
New Published Study Shows Masimo Rainbow SET® Pulse CO-Oximetry™ Reliably
Determines Carbon Monoxide Levels in the Blood
Researchers Highlight the Unique Advantages of Masimo SpCO® to Facilitate
Early Diagnosis of Carbon Monoxide Poisoning On-the-Scene
Irvine, California – November 5, 2009 – Masimo (NASDAQ: MASI), the inventor of Pulse
CO-Oximetry™ and Measure-Through Motion and Low-Perfusion pulse oximetry,
announced today that a new peer-reviewed clinical study published in this
month's Inhalation
Toxicology demonstrates that Masimo Rainbow SET® Pulse
CO-Oximetry (SpCO) provides reliable measurements of carbon monoxide (CO) in
the blood that facilitate fast, accurate diagnosis of CO poisoning in pre-hospital emergency
and rescue environments.1
Carbon monoxide – often called the silent killer - is a colorless, odorless,
tasteless, and deadly gas that is extremely difficult to detect. Prior to Masimo
Rainbow SET Pulse CO-Oximetry, an invasive blood draw followed by laboratory
blood gas analysis was the only reliable method for diagnosing CO poisoning.
Without immediate access to complex and costly laboratory blood analyzers to
measure CO in the blood (COHb), emergency first responders were at a critical
disadvantage—unable to confirm the diagnosis of CO poisoning necessary to
initiate appropriate, often lifesaving treatment. Today, the portable, handheld
Masimo Rad-57 Pulse
CO-Oximeter provides an accurate and noninvasive way to detect elevated CO levels in the
bloodstream in just seconds—allowing emergency first responders to quickly
and easily diagnose CO poisoning on-the-scene and initiate prompt, possibly
lifesaving treatment.
Dr.
Piatkowski and colleagues at the University Hospital Aachen (Germany) used
the Masimo Rad-57 Pulse CO-Oximeter to measure SpCO in 20 patients suspected of
CO poisoning who were admitted to the burn center and in five healthy volunteers
(used as a control group). Comparing SpCO measurements to COHb measurements
obtained hourly via invasive blood samples processed using three different
laboratory analyzers, researchers found that the mean error of the three
different blood gas analyzers was just 1% lower than noninvasive Pulse
CO-Oximetry. The SpCO measurements from Pulse CO-Oximetry resulted in a mean
error of approximately 3.15% over a COHb range of 1% to 38%, while the invasive
COHb measurements from three different blood analyzers resulted in a mean error
of 2.4%. Researchers concluded that Pulse CO-Oximetry "represents a reliable
measurement technique that is easy to handle and could facilitate the early
diagnosis of CO intoxication in pre-hospital rescue conditions."
Masimo Executive Vice President of Medical Affairs, Dr. Michael O'Reilly,
stated, "This study adds to the compelling evidence base showing that Masimo
Pulse CO-Oximetry SpCO provides accurate and reliable measurements that enable
clinicians and first responders to make earlier and better decisions. This study
is also the first to show that the differences in COHb measurement from
different laboratory analyzers are similar to the differences between laboratory
analyzer measurement and noninvasive Pulse CO-Oximetry measurement."
1 A. Piatkowski, D. Ulrich, G. Grieb, N. Pallua. "A
New Tool for the Early Diagnosis of Carbon Monoxide Intoxication."
Inhalation Toxicology, November 2009; 21(3):1144-1147.
*Editor's
Note: The study is available online at: http://informahealthcare.com/doi/abs/10.3109/08958370902839754
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the repeatability of
clinical results, risks related to our belief that Masimo Rainbow SET will
provide sufficient sensitivity and specificity to deliver the most accurate and
reliable SpCO measurements under all emergency and rescue conditions, and risks
related to our belief that the Rad-57 enables fast, reliable, accurate diagnosis
of carbon monoxide poisoning, as well as other factors discussed in the "Risk
Factors" section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at
the SEC's website at www.sec.gov. Although we
believe that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of today's date. We do not undertake any obligation to update,
amend or clarify these forward-looking statements or the "Risk Factors"
contained in our most recent reports filed with the SEC, whether as a result of
new information, future events or otherwise, except as may be required under the
applicable securities laws.
Media Contact:
Dana Banks,
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo Reports Third Quarter 2009 Financial Results
Q3 2009 Highlights:
- Product revenues increased 14% to $75.1 million from $66.1 million in prior
year
- Rainbow revenues increased approximately 100% to $6.0 million from $3.0
million in prior year
- Shipped 26,200 Masimo SET and Masimo Rainbow SET pulse oximetry units
Livewire – Irvine, California, November 3, 2009 – Masimo
Corporation (NASDAQ: MASI), the inventor of Pulse CO-Oximetry™ and
Measure-Through Motion and Low-Perfusion pulse oximetry, today announced its
financial results for the third quarter of 2009.
For the third quarter of 2009, Masimo reported product revenues of $75.1
million representing a 14% increase over $66.1 million for the third quarter of
2008. Including royalty revenues, Masimo reported total 2009 third quarter
revenues of $87.4 million compared to $78.1 million for the third quarter of
2008. For the third quarter of 2009, Masimo reported earnings per share of $0.22
compared to $0.22 per share for the third quarter of 2008.
Masimo reported that it shipped 26,200 Masimo SET and Masimo Rainbow SET
pulse oximetry units, excluding handheld units, during the third quarter of
2009, resulting in over 600,000 Masimo SET and Masimo Rainbow SET pulse
oximeters in use worldwide. In the third quarter of 2009, revenues from Masimo
Rainbow SET products increased to $6.0 million from $3.0 million in the same
prior year quarter.
For the first nine months of 2009, Masimo reported product revenues of $219.7
million representing a 17% increase over $188.0 million for the first nine
months of 2008. Including royalty revenues, Masimo reported total 2009 year to
date revenues of $256.5 million compared to $224.0 million for the prior year
period. For the first nine months of 2009, Masimo reported earnings per share of
$0.65, up 20% from $0.54 per share for the first nine months of 2008.
Joe E. Kiani, Chairman and Chief Executive Officer of Masimo, said, "We are
encouraged by the continuing growth of our business, especially during a period
of historical economic turmoil. We are seeing great enthusiasm combined with
solid growth for our latest innovation, Masimo Rainbow SET technology, which has
ushered in new noninvasive measurements, including hemoglobin and carbon
monoxide."
Masimo also reported that as of October 3, 2009, cash and cash equivalents
totaled $174.7 million, up from $146.9 million at January 3, 2009.
Conference Call
Masimo will hold a conference call today
at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. The dial-in numbers are
(888) 520-7182 for domestic callers and +1 (706) 679-9937 for international
callers. The reservation number for both dial-in numbers is 35275093. A live web
cast of the conference call will be available online from the "Investor
Relations" page of the Company's corporate website at www.masimo.com. After the live web cast, the
call will remain available on Masimo's website through December 3, 2009. In
addition, a telephonic replay of the call will be available until November 17,
2009. The replay dial-in numbers are (800) 642-1687 for domestic callers and +1
(706) 645-9291 for international callers. Please use reservation code 35275093.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care-helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Rainbow SET continuously and noninvasively measures total
hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI®, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com. Information on the company's
website does not form part of this press release.
Forward-Looking Statements
All statements other than
statements of historical facts included in this press release that address
activities, events or developments that we expect, believe or anticipate will or
may occur in the future are forward-looking statements including, in particular,
the statements about: our financial condition, results of operations, prospects
and business generally; and expectations regarding our ability to design and
deliver innovative new noninvasive technologies. These forward-looking
statements are based on management's current expectations and beliefs and are
subject to uncertainties and factors, all of which are difficult to predict and
many of which are beyond our control and could cause actual results to differ
materially and adversely from those described in the forward-looking statements.
These risks include, but are not limited to, those related to: our dependence on
Masimo SET and Masimo Rainbow SET products and technologies for substantially
all of our revenue; any failure in protecting our intellectual property exposure
to competitors' assertions of intellectual property claims; the highly
competitive nature of the markets in which we sell our products and
technologies; any failure to continue developing innovative products and
technologies; the lack of acceptance of any new products and technologies of
ours; obtaining regulatory approval of our current and future products and
technologies, including the recently announced total hemoglobin measurement; the
risk that the implementation of our international realignment, will not produce
the anticipated operational and financial benefits, including a continued lower
effective tax rate; the loss of our customers the failure to retain and recruit
senior management; product liability claims exposure; a failure to obtain
expected returns from the amount of intangible assets we have recorded; the
maintenance of our brand; the impact of the decline in the worldwide credit
markets on us and our customers; the amount and type of equity awards that we
may grant to employees and service providers in the future; and other factors
discussed in the "Risk Factors" section of our most recent periodic reports
filed with the Securities and Exchange Commission ("SEC"),
which you may obtain for free on the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. You are cautioned not to
place undue reliance on these forward-looking statements, which speak only as of
the date hereof, even if subsequently made available by us on our website or
otherwise. We do not undertake any obligation to update, amend or clarify these
forward-looking statements, whether as a result of new information, future
events or otherwise, except as may be required under applicable securities laws.
Masimo Corporation
Investor Contact:
Mark P. de Raad
Executive Vice President and Chief Financial
Officer
Masimo Corporation
(949) 297-7080
mderaad@masimo.com
Media Contact:
Dana Banks
Manager, Public Relations
Masimo Corporation
(949) 297-7348
dbanks@masimo.com
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpCO, SpMet, PVI, Pulse CO-Oximetry and Pulse
CO-Oximeter are trademarks or registered trademarks of Masimo
Corporation.
|
|
|
|
|
|
Federal Court of Appeals Upholds Antitrust Liability Verdict Against Tyco HealthCare
Affirms 2006 District Court ruling that found Tyco unlawfully maintained
monopoly power and utilized unlawful restraints of trade and exclusionary
dealing arrangements in the pulse oximetry market
Irvine, California – November 2, 2009 – Masimo (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low
Perfusion pulse oximetry, announced today that the Ninth Circuit Court of
Appeals has affirmed the 2006 Federal District Court decision that Tyco
Healthcare, now Covidien, violated the antitrust laws through anticompetitive
business practices related to the sale of its Nellcor pulse oximetry products.
The 2006 decision found that Tyco had unlawfully maintained monopoly power in
violation of Section 2 of the Sherman Act, and that Tyco's sole-source
agreements and market-share based compliance pricing contracts were unlawful
restraints of trade in violation of Section 1 of the Sherman Act and unlawful
exclusionary dealing arrangements in violation of Section 3 of the Clayton Act.
The Ninth Circuit also held that above-cost bundling discounts when combined
with sole-source or market-share-based pricing can be anticompetitive when such
practices involve a significant portion of the market. The suit was originally
filed by Masimo in 2002.
Joe E. Kiani, Founder and CEO of Masimo, stated: "We hope that the results
that we have fought for will help improve patient care and reduce the cost of
care by improving caregivers' access to cost-effective, innovative products.
Medical products, from drugs and implantable devices to pulse oximeters, should
be judged on their own merits and not based on artificial restraints on hospital
purchasing placed by large manufacturers. America is struggling with rising
health care costs. The best medicine for this challenge is innovation and
competition. Since Masimo began our travails in the Senate and the courts to
restore competition, American hospitals and care givers have begun to have more
choice. That choice in pulse oximetry has not only caused pulse oximetry pricing
to decrease by over 30%, but many people's lives were either saved or improved
as a direct result of their access to Masimo pulse oximeters. We hope this
ruling will improve the accessibility of all life-saving products for the best
care at lowest price possible for patients."
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the repeatability of
clinical results, risks related to our belief that Masimo Rainbow SET and Masimo
PVI provide unique clinical advantages that facilitate earlier intervention and
prevention of adverse patient outcomes, risks related to our assumptions that
Masimo SpHb is an accurate, reliable and acceptable clinical alternative to
invasive blood tests for hospitalized patients and healthy patients in
outpatient settings, and risks related to our assumptions that Masimo PVI is an
accurate, reliable and acceptable clinical alternative to invasive methods of
predicting fluid responsiveness, as well as other factors discussed in the "Risk
Factors" section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at
the SEC's website at www.sec.gov. Although we
believe that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of today's date. We do not undertake any obligation to update,
amend or clarify these forward-looking statements or the "Risk Factors"
contained in our most recent reports filed with the SEC, whether as a result of
new information, future events or otherwise, except as may be required under the
applicable securities laws.
Media Contacts:
Mark de Raad
Masimo Corporation
(949) 297-7041
mderaad@masimo.com
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo® Inaugurates International Operations Center in Switzerland
New International Headquarters Part of Masimo's Commitment to Support and
Serve the Global Medical Community
Livewire (Internal Only) - Irvine, California – October 27, 2009 –
Masimo (NASDAQ: MASI), the inventor of Pulse CO-Oximetry and
Measure-Through Motion and Low-Perfusion pulse oximetry, announced today the
inauguration of its international operations center in Neuchatel, Switzerland.
Masimo International SARL was initially established in December 2008 to serve as
Masimo's international headquarters. Today's formal inauguration ceremony at the
Neuchatel facility underscores the company's commitment to growing and expanding
its operations to better serve the international medical community.
Masimo Founder and CEO, Joe E. Kiani, stated, "Neuchatel is a growing,
thriving center for medical technology companies that offers the best of
Switzerland—from its excellent infrastructure and direct access to the European
markets to its favorable business climate. This affords us the opportunity to
build a world class international team and business structure to continue to
grow our business."
"Masimo is an important addition that will not only add to the creation of
jobs and economic investment, but will also further enhance Neuchatel's position
as a growing center for medical technology," stated Frederic Hainard, State
Counselor in charge of the Department of the Economy for the Canton of
Neuchatel, Switzerland. "This reinforces the attractiveness of the Canton of
Neuchatel and its international influence as a favorable residence for growing
corporations. We are pleased to welcome Masimo and look forward to their
continued growth and success in the Canton of Neuchatel."
Masimo—a global developer and manufacturer of innovative noninvasive patient
monitoring technologies that significantly improve patient care—will centralize
its international sales management, marketing, planning, logistics, customer
service, technical support, finance and administrative activities at the
Neuchatel facility to better and more responsively serve international
customers. As the company continues to expand to meet the growing global demand
for its breakthrough medical technologies and products, its international
operations will enable direct sales and service channels for Masimo medical
technologies and products in international markets, facilitate direct support
and expand interaction between the company and clinicians throughout Europe,
Asia Pacific, Africa, the Middle East, Canada, and Latin America.
According to Jon Coleman, President of International Business for Masimo,
"Growing international demand for Masimo's advanced medical technologies and
solutions is the driving force behind the establishment of our new international
operations. Staffed with dedicated resources in key business areas—all focused
exclusively on servicing our growing international customer base—the Neuchatel
facility will be the nerve center of our international operations. Ultimately,
this will ensure that we are more proactively and aggressively working to meet
the needs of medical providers in international markets."
Masimo's new international operations center is expected to contribute new
technical and professional jobs and investment in local infrastructure projects
and subcontract activities to the local economic profile of the region. Today's
inauguration was hosted by Neuchatel's Economic Promotion Office and was
attended by Neuchatel's State Counselor Monsieur Frederic Hainard, key Masimo
executives, and European customers.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions that the new International
operations in Neuchatal will contribute or create new jobs, subcontract
activities, new opportunities for R&D collaboration, and synergistic
relationships between medical technology and biotechnology, and risks related to
our belief that the new headquarters will operations enable the company to
better and more responsively serve international customers, as well as other
factors discussed in the "Risk Factors" section of our most recent reports
filed with the Securities and Exchange Commission ("SEC"),
which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the applicable
securities laws.
Media Contacts:
Dana Banks
Masimo Corporation
+1
(949) 297-7348
Federic Hainard
Department of the Economy – Canton of Neuchatel
+ 41 32
889 68 00
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous
Hemoglobin Monitoring Technology
Irvine, California – October 21, 2009 – Masimo (NASDAQ: MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and
Low Perfusion pulse oximetry, announced today that new clinical studies
presented this week at the American Society of Anesthesiology
(ASA) Annual Meeting in New Orleans, Louisiana, show Masimo noninvasive and continuous
hemoglobin (SpHb™) technology is reliable and accurate compared to invasive
blood tests for both healthy subjects and hospitalized patients. Another study
presented found Masimo PVI to be an
accurate, reliable automatic noninvasive indicator of a patient's ability to
respond to fluid.
Clinical Study Highlights
Accuracy
of Noninvasive Hemoglobin Measurements by Pulse CO-Oximetry in Hemodilution
Subjects (A184)1, a clinical
study led by Dr. Martin W. Allard at Loma Linda
University in Loma Linda, California, compared SpHb measurements to
165 invasive laboratory measurements in 20 healthy adult patients undergoing
hemodilution. All 20 patients had one unit of blood drawn through an arterial
line while isolyte intravenous fluid was given (to compensate for the decrease
in intravascular volume) until they reached a 30% reduction in hemoglobin or a
maximum of 30 ml/kg of fluid. Blood samples were drawn after each 500 ml of
fluid administered and analyzed for total hemoglobin by laboratory CO-Oximeter.
Masimo SpHb had a bias of 0.15 g/dL and precision of 0.92 g/dL, leading
researchers to conclude that SpHb "measurement accuracy was unaffected by
perfusion index levels" and offers an "acceptable alternative to invasive
hemoglobin tests in many clinical scenarios."
Validation
of a New Noninvasive Hemoglobin Algorithm in Patients Undergoing Liver
Transplantation (A751)2, a clinical
study led by Dr. Klaus D. Torp at the Mayo Clinic in Jacksonville,
Florida, compared SpHb measurements to 55 invasive laboratory measurements
in five patients undergoing liver transplantation and found significant
agreement between the two methods. The study showed that SpHb—using the new Masimo ReSposable™ Sensor
that helps to reduce medical waste and costs——had a bias of 0.2 g/dL and
precision of 0.8 g/dL. Researchers concluded that "the accuracy of noninvasive
SpHb measurements obtained by the Pulse CO-Oximeter with new ReSposable sensors
was high."
Additionally, two studies presented at the ASA highlight the importance of
understanding the variation in invasive arterial and venous hemoglobin
measurements. A study
(A937) of 471 paired invasive hemoglobin measurements from 33 patients on
two different invasive laboratory devices (Beckman Coulter® hematology analyzer
and Nova Biomedical® CO-Oximeter) showed a bias of -0.97 g/dL and a precision of
0.58 g/dL. The authors noted that "different devices using different principles
of operation can produce consistent differences in the absolute value of
measurement".3 Another study
(A1294) comparing hemoglobin measurements in 107 subjects from time-matched
arterial and venous blood samples on the same invasive laboratory device found
average differences as high as 0.5 g/dL and noted that "arterial and venous
hemoglobin values from the same individual are not interchangeable."4
Influence
of Site of Measurement to Predict Automatically and Noninvasively Fluid
Responsiveness (A477)5, a clinical
study led by Dr. Olivier Desebbe at the Hospices Civils de Lyon in Lyon, France,
studied the finger, forehead, and ear as measurement sites for PVI and found that all three sites allowed
discrimination between fluid responders and non-responders. Researchers measured
hemodynamic data in 12 patients under general anesthesia using pulmonary artery
catheter and Masimo PVI (obtained via noninvasive sensors attached to the
forehead using a Masimo TF-I, ear using a Masimo TC-I, and finger using a Masimo
LNOP Adt) before and after volume expansion of 500 ml of hetastarch 6%. Fluid
responders were defined as patients presenting >15% increase in cardiac index
(CI) following VE. Study results showed that a PVI >17% for the forehead and
ear, and a PVI >13% for the finger before volume expansion "allowed
discrimination between responders and non-responders with a sensitivity and
specificity of 100 and 83% for the forehead, 83 and 100% for the ear, and 100
and 67% for the finger"—demonstrating that PVI is an accurate and reliable
automatic noninvasive indicator of a patient's ability to respond to fluid and
that clinicians should take site measurement into account when utilizing PVI to
predict fluid responsiveness.
Dr. Michael O'Reilly, Executive Vice President of Medical Affairs for Masimo,
stated: "We appreciate the work of these clinical researchers for not only
validating the value of SpHb and PVI, but for also showing that invasive
hemoglobin spot check measurements—considered to be the gold standard—have
similar bias and precision as our noninvasive, continuous hemoglobin
measurements. These new Masimo Rainbow SET studies reinforce the importance of
monitoring changes in hemoglobin—facilitated by Masimo's continuous SpHb
monitoring technology as opposed to a single measurement of hemoglobin—when
caring for patients at risk for significant blood loss."
1 Allard, M., Macknet, M., Kherzi, S., Rook, J.
"Accuracy of Noninvasive Hemoglobin Measurements by Pulse CO-Oximetry in
Hemodilution Subjects." ASA 2009 Annual Meeting: A184. Anesthesiology, Loma
Linda University, Loma Linda, California.
2 Torp, K., Aniskevich,
S., Shine, T., Shapiro, D., Peiris, P. "Validation of a New Noninvasive
Hemoglobin Algorithm in Patients Undergoing Liver Transplantation." ASA 2009
Annual Meeting: A751. Anesthesiology, Mayo Clinic Florida, Jacksonville,
Florida.
3 Torp, K., Shine, T., Aniskevich, S., Peiris, P.,
Shapiro, D. "Comparison of Coulter Counter and Co-Oximeter (pHOx) Measurements
for Hemoglobin." ASA 2009 Annual Meeting: A937. Anesthesiology, Mayo Clinic
Florida, Jacksonville, Florida.
4 Rook, J., Khezri, S.,
Bertolizio, G., Allard, M. "Arterio-Venous Hemoglobin Differences in Healthy
Subjects During Rapid Volume Expansion." ASA 2009 Annual Meeting: A1294.
Department of Anesthesiology, Loma Linda University Medical Center, Loma Linda,
California.
5 Desebbe, O., Robin, J., Lehot, J., Cannesson, M.
"Influence of Site of Measurement to Predict Automatically and Noninvasively
Fluid Responsiveness." ASA 2009 Annual Meeting: A477. Anesthesiology and
Intensive Care, Hospices Civils de Lyon, Lyon Bron, France.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the repeatability of
clinical results, risks related to our belief that Masimo Rainbow SET and Masimo
PVI provide unique clinical advantages that facilitate earlier intervention and
prevention of adverse patient outcomes, risks related to our assumptions that
Masimo SpHb is an accurate, reliable and acceptable clinical alternative to
invasive blood tests for hospitalized patients and healthy patients in
outpatient settings, and risks related to our assumptions that Masimo PVI is an
accurate, reliable and acceptable clinical alternative to invasive methods of
predicting fluid responsiveness, as well as other factors discussed in the "Risk
Factors" section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at
the SEC's website at www.sec.gov. Although we
believe that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of today's date. We do not undertake any obligation to update,
amend or clarify these forward-looking statements or the "Risk Factors"
contained in our most recent reports filed with the SEC, whether as a result of
new information, future events or otherwise, except as may be required under the
applicable securities laws.
Media Contacts:
Dana Banks
Masimo Corporation
(949) 297-7348
dbanks@masimo.com
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo to Report Third Quarter 2009 Financial Results on November 3, 2009
Conference call and webcast to begin after markets close at 1:30 p.m. PT
(4:30 p.m. ET)
IRVINE, Calif., October 20, 2009—Masimo Corporation (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and
Low-Perfusion pulse oximetry, today announced it will release third quarter 2009
financial results for the period ended October 3, 2009, after the market closes
on Tuesday, November 3, 2009.
A conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m.
ET) and will be hosted by Joe E. Kiani, Chairman and Chief Executive Officer,
and Mark P. de Raad, Executive Vice President and Chief Financial Officer.
A live webcast of the conference call will be available online from the
investor relations page of the Company's corporate web site at www.masimo.com. The dial-in numbers are (888)
520-7182 for domestic callers and +1 (706) 679-9937 for international callers.
The reservation number for both dial-in numbers is 35275093. After the live
webcast, the call will remain available on Masimo's website through December 3,
2009. In addition, a telephonic replay of the call will be available through
November 17, 2009. The replay dial-in numbers are (800) 642-1687 for domestic
callers and +1 (706) 645-9291 for international callers. Please use reservation
code 35275093.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care-helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Rainbow SET continuously and noninvasively measures total
hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI®, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at http://www.masimo.com.
Masimo Corporation
Investor Contact:
Mark P.
de Raad
Executive Vice President and Chief Financial Officer
Masimo
Corporation
(949) 297-7080
mderaad@masimo.com
Media Contact:
Dana Banks
Manager, Public
Relations
Masimo Corporation
(949) 297-7348
dbanks@masimo.com
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
University Medical Center Mainz Completes Installation of Masimo Noninvasive and Continuous Hemoglobin Throughout their Operating Rooms, Intensive Care Units and Emergency Department
SpHb™ Technology Now Advancing Patient Care at One of Largest Hospitals
in Germany
Irvine, California – September 22, 2009 – Masimo (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and
Low-Perfusion pulse oximetry, announced today that the University
Medical Center of the Johannes Gutenberg University in Mainz, Germany has
completed its clinical installation of Masimo noninvasive and
continuous hemoglobin (SpHb) technology in their ORs, ICUs and EDs, as part
of their efforts to improve patient care.
According to clinicians at the University Medical Center Mainz, their 57
Masimo Radical-7® Pulse CO-Oximeters with continuous and noninvasive hemoglobin
are already providing significant clinical advantages and patient care benefits
by allowing them to more effectively manage blood transfusions, identify
internal bleeding sooner, and detect and treat chronic or acute anemia earlier—all of
which may help save lives and improve patient outcomes.
Christian Werner, M.D., Chair of the Department of Anesthesiology at the
University Medical Center Mainz, stated, "Masimo noninvasive hemoglobin is an
exciting novel technology with wide clinical applications, which may ultimately
improve peri-operative outcome. Furthermore, noninvasive SpHb monitoring could
also reduce overall treatment costs."
By choosing Masimo
Radical-7 Pulse CO-Oximeters, Mainz clinicians have also gained all the
benefits of Masimo SET Measure-Through Motion and Low-Perfusion pulse oximetry,
proven superior in over 100 independent and objective clinical studies. Masimo
Rainbow SET is the first and only technology platform capable of continuously
and noninvasively measuring multiple blood constituents that previously required
invasive procedures, including: hemoglobin (SpHb™), oxygen content (SpOC™)
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI™ for fluid
responsiveness, in addition to oxyhemoglobin (SpO2),
perfusion index (PI) and pulse rate.
Masimo Founder and CEO, Joe E. Kiani, stated, "This multi-department
installation at a leading German hospital is a good example of the growing
recognition and adoption of Masimo SpHb, which gives hospitals and clinicians
the opportunity to advance clinical practice in a way that has the potential to
transform healthcare delivery. We applaud University Medical Center Mainz for
recognizing the value of SpHb and for leading the advancement of patient care
with the deployment of Masimo rainbow SET across their ORs, ICUs and EDs."
The University Medical Center Mainz is a healthcare facility, as well as a
research and teaching hospital that leverages state-of-the-art diagnostic and
therapeutic procedures to optimize patient care. It consists of more than 50
specialist clinics, institutes and departments, as well as two central
health-care facilities, a pharmacy and a transfusion center. The hospital has
over 1,600 beds and treats approximately 61,000 in-patients and 217,000
out-patients every year.
About University Medical Center of the Johannes Gutenberg University
Mainz
The 'University Medical Center Mainz' consists of more than 50
specialist clinics, institutes and departments as well as two central
health-care facilities, a pharmacy and a transfusion center. All of these
clinics and institutes work together on an interdisciplinary basis. The hospital
has over 1600 beds and treats more than 61,000 in-patients every year. It also
serves an additional 217,000 people per year on an out-patient basis.
We define ourselves as the patients' best source for optimum patient care. In
our work, we use state-of-the-art diagnostic and therapeutic procedures based on
recent medical research. It is our goal to serve as optimally as possible by
integrating our knowledge and experience into the excellent services we provide.
We offer nearly every kind of clinical facility you might need. The University
Medical Center offers health care to the highest university standard. In
addition, we are not only a health-care center; but also a research and teaching
hospital. These three pillars of medicine – clinical health care, medical
education and research – are inseparable aspects of integrated health care. For
more information, please visit: www.klinik.uni-mainz.de
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the repeatability of
clinical results, risks related to our belief that the breakthrough blood
constituent monitoring capabilities of Masimo Rainbow SET will allow clinicians
to detect and treat life-threatening conditions earlier, risks related to our
belief that Masimo noninvasive and continuous hemoglobin (SpHb) will provide
sufficient sensitivity and specificity to instantaneously measure hemoglobin
blood levels noninvasively and continuously to enable earlier identification of
necessary blood transfusions, reduction in unnecessary transfusions and invasive
tests, increased patient safety, and improved clinical outcomes, as well as
other factors discussed in the "Risk Factors" section of our most recent reports
filed with the Securities and Exchange Commission ("SEC"),
which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the applicable
securities laws.
Media Contacts:
Dana Banks
Masimo Corporation
+1
(949) 297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
PHYSIO-CONTROL RECEIVES MARKET APPROVAL FROM HEALTH CANADA FOR LIFEPAK® 15 MONITOR/DEFIBRILLATOR
LIFEPAK 15 is the First Monitor/Defibrillator to Integrate Masimo Rainbow
SET® Pulse CO-Oximetry™ Technology for the Noninvasive Detection of
Carboxyhemoglobin and Methemoglobin
REDMOND, WASH. – Sept. 22, 2009 – Physio-Control, Inc., a
wholly owned subsidiary of Medtronic, Inc., (NYSE: MDT) announced today it
received approval by Health Canada to market the LIFEPAK 15
monitor/defibrillator within Canada. Official license notification was received
on Sept. 1, 2009.
Physio-Control was granted CE mark in January 2009, certifying compliance
with the European Union Medical Device Directive and began its U.S. market
release of the LIFEPAK 15 monitor/defibrillator in March 2009.
The LIFEPAK 15 monitor/defibrillator builds on a 54-year Physio-Control
heritage of providing innovative, reliable equipment to lifesaving teams around
the world. With an all-new product platform, it delivers best-in-class clinical
and operational innovations and raises the bar on the legendary LIFEPAK®
standard for durability.
Clinically innovative, the LIFEPAK 15 provides the widest range of energy
dosing up to 360 joules, and the broadest selection of monitoring options
available. It continues Physio-Control's legacy of industry firsts as the first
monitor/defibrillator to integrate Masimo Rainbow SET® Pulse CO-Oximetry™
technology for the noninvasive detection of carboxyhemoglobin (carbon monoxide
in the blood; the leading cause of poisoning death in industrialized
countries1) and methemoglobin in the blood (which
may result from exposure to certain chemicals and drugs).
The design focuses on several key operational innovations which include the
largest color screen on the market, with a one-touch button that flips the
screen to high-contrast SunVue™ mode for easy viewing in sunlight; along with 10
times the processing speed and three times the battery life of its predecessor.
Needed for the harshest rescue environments, Physio-Control developed the
LIFEPAK 15 to be tougher than any other monitor/defibrillator on the market. For
current LIFEPAK customers, this model reduces transition costs, with a user
interface that complements the market-leading LIFEPAK 12 defibrillator/monitor.
Emergency care providers are able to work with a mixed fleet of LIFEPAK
monitors, and transition their equipment when budgets allow—enabling them to
save on critical operational costs and minimize their overall training
resources.
"Physio-Control has been developing and refining monitoring and
defibrillation technology for more than 50 years. With the latest approval for
distribution by Health Canada the LIFEPAK 15 continues to build momentum in the
marketplace and is setting the new standard for emergency care products," said
Brian Webster, president of Physio‐Control. "The '15' has already been put into
use by multiple leading EMS systems around the world."
Masimo Founder and CEO, Joe E. Kiani, stated, "The LIFEPAK 15 monitor with
Masimo Rainbow SET Pulse CO-Oximetry technology represents a significant
advancement for emergency first responders who provide lifesaving care and
treatment to combat a range of silent killers. The combination of a
defibrillator with noninvasive carboxyhemoglobin (SpCO) and methemoglobin
(SpMet) monitoring capabilities means that more cases of potentially
life-threatening conditions may be detected and treated earlier to improve
patient safety, outcomes and recoveries."
About Physio-Control
Physio-Control, a wholly-owned
subsidiary of Medtronic, is located in Redmond, Wash. Physio-Control pioneered
defibrillation technology more than 54 years ago. With nearly 800,000 LIFEPAK®
defibrillators distributed worldwide, the company is the world's leading
provider of external defibrillation and monitoring technology for the treatment
of sudden cardiac arrest and other cardio-respiratory emergencies. To find out
more about Physio-Control, go to www.physio-control.com or call
1-800-442-1142.
About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in
Minneapolis, is the global leader in medical technology – alleviating pain,
restoring health, and extending life for millions of people around the
world.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com. PR Contact: Dana Banks, Masimo
Corporation, 949-297-7348.
Any forward-looking statements are subject to risks and uncertainties
such as those described in Medtronic's Annual Report on Form 10-K for the year
ended April 24, 2009. Actual results may differ materially from anticipated
results.
1 Omaye ST. (Nov 2002). "Metabolic modulation of
carbon monoxide toxicity". Toxicology 180 (2): 139–50.
Contact:
Jeff Warren
Investor
Relations
763-505-2696
Jennifer Roth
Media Relations
425-867-4393
|
|
|
|
|
|
Masimo Launches Enhanced Masimo Patient SafetyNet™ System to Help Hospitals Reduce
Preventable Deaths on the General Floor
New Features Expand Monitoring Capabilities, Simplify Operation and
Extend Capabilities to Cover Up to 80 Patients Per Server on Up to Four
Floors
Irvine, California – September 15, 2009 – Masimo (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and
Low-Perfusion pulse oximetry, today introduced a new enhanced version of the
Masimo Patient SafetyNet system designed to help hospitals avoid preventable
patient deaths and injuries associated with failure to rescue—one of today's
most common medical errors.1 New features such as
an intuitive touch-screen interface and the ability to monitor up to 80 patients
simultaneously on four separate floors allow hospitals to noninvasively and
remotely monitor more patients, in more care areas, more efficiently, and in
more clinical detail—enabling an enhanced level of patient safety when a
clinician can't be at the bedside.
The Masimo Patient SafetyNet remote monitoring and clinician notification
system combines the gold standard performance of Masimo SET® pulse oximetry with
optional Oridion Microstream® end tidal CO2-based
respiration rate monitoring at the point of care and wireless clinician
notification via pager to provide an unmatched level of patient safety on
general care floors. The system uses IEEE industry standards for
connectivity—allowing for more efficient sharing of data across a hospital's IT
platforms and the option of full integration into a hospital's existing IT
infrastructure, providing a lower overall cost of ownership and improved
financial benefits.
One of the most common dangers in hospitals today is the risk of death or
serious injury caused by medications designed to relieve pain and help keep
patients comfortable. Growing concerns over the use of patient-controlled
analgesia (PCA) in the post-operative period have caused leading patient safety
organizations to institute new recommendations and guidelines to combat the
"unexpected and potentially harmful opioid-induced respiratory depression that
continues to occur." According to the latest direction from the Anesthesia
Patient Safety Foundation (APSF), these dangers exist because "in most cases,
there is inadequate monitoring of oxygenation and/or ventilation." The APSF
further warns hospital clinicians that "intermittent subjective assessments of
ventilation or level of consciousness are unreliable predictors of future
respiratory depression, even over short time frames" and continuous monitoring
of oxygenation via pulse oximetry must be "the routine and not the
exception."2
The new Patient SafetyNet system is already having a big impact on both
nurses and post-surgical patients for two hospitals involved in limited market
release testing. Marilyn Nemerever, R.N., director of Acute Care at Swedish
Medical Center in Seattle, where the new system is being used to monitor
patients in three separate post-surgical units at three different hospitals from
a single central monitoring station, stated "We love it. ICU beds are in high
demand these days and Patient SafetyNet allows us to more closely monitor
post-surgical patients in our med-surg units, so we can use our ICU resources
more appropriately. Our nurses now have the piece of mind that comes with
knowing that Patient SafetyNet is helping watch over their patients if and when
they cannot. And our patients are having better outcomes because we can see, as
well as respond to changes earlier."
Clinicians at Dartmouth-Hitchcock Medical Center, who found that Patient
SafetyNet reduced rescue activations by 65% and ICU transfers by 48%—while in
some patients where ICU transfer was avoided, length of stay was also reduced
from 5.8 to 3.6 days with an associated cost of care reduction of 30%, have also
embraced the capabilities of the new Patient SafetyNet system. George T. Blike,
M.D., Medical Director of Patient Safety at Dartmouth-Hitchcock Medical Center
in Lebanon, New Hampshire, stated; "The new system enhancements allow us to see
real-time numerics for each patient at a glance, while the ability to monitor
more patients on a single server will enable us to deploy the system across more
care areas than before to reduce overall costs of implementation."
Another significant risk that post-surgical patients face is undetected
internal bleeding. The Patient SafetyNet system can also be easily upgraded to
Masimo Rainbow SET Pulse CO-Oximetry technology through a simple software
upgrade—allowing hospitals to measure a patient's hemoglobin noninvasively and
continuously, which may improve patient safety by providing an earlier
indication of undetected internal bleeding and enabling immediate intervention.
Masimo Executive Vice President of Medical Affairs, Michael O'Reilly, MD,
stated, "Each year healthy patients admitted for routine procedures become
failure to rescue statistics because an adverse event was not recognized in time
to save them. The new capabilities in Masimo Patient SafetyNet significantly
expand the functionality of a system that has already been proven to help
clinicians improve patient outcomes and decrease costs—two things every hospital
wants and needs."
1 "The Sixth Annual HealthGrades Patient Safety in American
Hospitals Study" April 2009. http://www.healthgrades.com/media/DMS/pdf/PatientSafetyInAmericanHospitalsStudy2009.pdf
2 "Dangers of Postoperative Opioids—Is there a Cure?" APSF
Newsletter: The Official Journal of the Anesthesia Patient Safety
Foundation. Summer 2009; Volume 24, No. 2, 25-32. http://www.healthgrades.com/media/DMS/pdf/PatientSafetyInAmericanHospitalsStudy2009.pdf
3 Dartmouth-Hitchcock Medical Center Clinical Abstract Presented at the
Society for Technology in Anesthesia (STA) Annual Meeting in San Antonio, Texas
on January 15, 2009.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our belief that Masimo Patient SafetyNet will
provide an effective early warning system of a patient's deteriorating
physiological condition to enable timely rescue, risks related to our belief
that Masimo Rainbow SET Pulse CO-Oximetry measurements and Masimo Desat Index 3D
Alarms will provide sufficient sensitivity and specificity to detect
physiological abnormalities and potentially life-threatening conditions in
real-time for all patients, risks related to our assumptions regarding the
repeatability of Swedish Medical Center and/or Dartmouth-Hitchcock Medical
Center clinical results, and risks related to our assumptions regarding the
systems' ability to deliver clinical improvement over alternative patient
monitoring and assessment methods to increase patient safety and allow for
further adoption of the technology, as well as other factors discussed in the
"Risk Factors" section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at
the SEC's website at www.sec.gov. Although we
believe that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of today's date. We do not undertake any obligation to update,
amend or clarify these forward-looking statements or the "Risk Factors"
contained in our most recent reports filed with the SEC, whether as a result of
new information, future events or otherwise, except as may be required under the
applicable securities laws.
Media Contact:
Dana Banks,
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
FDNY Makes Largest First Responder Purchase of Masimo Rad-57 Pulse CO-Oximeters
to Improve Survival of Firefighters and Victims of Carbon Monoxide Poisoning
Nation's Largest Fire & EMS Provider Leads First Responder
Deployments of Rad-57s Worldwide
Irvine, California – September 8, 2009 – Masimo (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and
Low-Perfusion pulse oximetry, today announced that the Fire Department of New
York City (FDNY) has purchased 86 Masimo Rad-57 Pulse CO-Oximeters as part of
their strategic initiative to "improve the survivability of firefighters and
victims suffering from carbon monoxide (CO) toxicity." The purchase is the
single largest first responder deployment of Rad-57s, making FDNY the largest
department to implement a department-wide program for noninvasive carbon
monoxide monitoring in the U.S.
The Masimo Rad-57 Pulse CO-Oximeter enables EMS and fire department first
responders to quickly, accurately, and noninvasively detect carbon monoxide
poisoning on the scene. FDNY will put its 86 new Rad-57s to work throughout the
5 boroughs of New York City on all 35 of its HazTac and rescue ambulances,
Supervisor units, and Major Emergency Response Vehicles—allowing for prompt and
possibly life-saving treatment for both victims and firefighters alike.
According to John Peruggia, Chief of EMS for the Fire Department City of New
York, the Masimo Rad-57 Pulse CO-Oximeter has become a key component in FDNY
fire and emergency medical response operations "because it allows our EMTs and
Paramedics to accurately evaluate a patient's blood chemistry, determine
toxicity levels, and commence initial treatment of patients found to be poisoned
by CO—all within seconds. The Rad-57 has also become an integral part of
firefighter rehab, with all fire personnel being evaluated for CO after
operating at large fire incidents, to insure responder health and safety.
Expanding our utilization of the Rad-57 with this purchase is a natural
progression of the success we have achieved, both in terms of lives saved and
hazards averted."
Masimo Founder and CEO, Joe E. Kiani, stated, "We commend FDNY for their
leadership, dedication, and vigilance in the battle against the unsuspected,
deadly hazards of carbon monoxide poisoning. We are particularly proud that they
have chosen the Rad-57 to help ensure the public health and safety of all New
York City residents, visitors, and first responders."
About FDNY
The Fire Department City of New York
(FDNY) is the largest combined Fire and EMS provider in the
United States. With more than 11,000 firefighters and 3,000 EMTs and paramedics,
FDNY provides the fire protection and inspection, emergency medical, technical
rescue, and biological, chemical and radioactive hazard first response services
for more than 8 million citizens in an area of more than 320 square miles.
Annually, FDNY responds to over 990,000 fire calls, more than 1.3 million EMS
calls.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our belief that Masimo Rad-57 will provide
sufficient sensitivity and specificity to detect elevated levels of
carboxyhemoglobin and potentially life-threatening carbon monoxide poisoning
within seconds for all patients and will provide an effective early warning
system to enable timely rescue, as well as other factors discussed in the "Risk
Factors" section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at
the SEC's website at www.sec.gov. Although we
believe that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of today's date. We do not undertake any obligation to update,
amend or clarify these forward-looking statements or the "Risk Factors"
contained in our most recent reports filed with the SEC, whether as a result of
new information, future events or otherwise, except as may be required under the
applicable securities laws.
Media Contacts:
Dana Banks
Masimo Corporation
+1
(949) 297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo Radical-7® and Rad-57® Pulse CO-Oximeters™ Awarded Airworthiness Release Certification by the United States Army
Airworthiness Designation Green Lights Masimo Pulse CO-Oximeters for
Military Flight Operations
Irvine, California – September 3, 2009 – Masimo (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and
Low-Perfusion pulse oximetry, today announced that its Radical-7 and Rad-57
Pulse CO-Oximeters have achieved Airworthiness Release (AWR) Certification from
the United States Army. AWR certification is a fundamental milestone that allows
the U.S. military to use Masimo's multi-function, advanced noninvasive patient
monitoring devices during flight operations aboard rotary aircraft.
 |
 |
| Masimo Radical-7® Pulse
CO-Oximeter™ |
Masimo Rad-57® Pulse
CO-Oximeter™ |
The U.S. Army Aeromedical Research Laboratory (USAARL) completed extensive
aeromedical testing and evaluation on the Radical-7 and Rad-57—including
electromagnetic interference and compatibility, environmental, vibration/motion,
and human factors testing—to certify that both devices meet stringent
requirements to operate onboard U.S. military aircraft in flight. Meeting the
Army's airworthiness testing requirements and standards affirms the durability,
reliability and superior performance of both the Radical-7 and Rad-57, which are
designed to excel in a wide range of demanding environments, including those
faced by emergency medical services, fire, law enforcement, military field
medical operations and medevac units.
Joe E. Kiani, Founder and CEO of Masimo, stated, "We are proud of our
long-standing presence in military hospitals. Now, with the Radical-7 and Rad-57
both receiving airworthiness certification, U.S. troops can benefit from
definitive, lifesaving physiological monitoring from the moment they need it on
the ground and during transport to a medical center. Masimo is committed to
supporting the military through the entire care continuum, from the battlefield
to the bedside."
The Masimo Radical-7 Pulse CO-Oximeter features first-ever noninvasive and
continuous hemoglobin (SpHb™) monitoring technology, which may allow combat
medics to quickly and easily detect and assess the severity of internal bleeding
and provide the most appropriate frontline trauma care on the battlefield.
During surgery, the Radical-7 may help guide more effective transfusions and
enable better blood management strategies. Radical-7 also noninvasively and
continuously measures oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), PVI™ for fluid responsiveness, oxyhemoglobin (SpO2), perfusion index (PI), and pulse rate to quickly detect and
treat potentially life-threatening conditions earlier. The Masimo Rad-57
portable, handheld Pulse CO-Oximeter accurately and noninvasively measures
carboxyhemoglobin (SpCO) and methemoglobin (SpMet) levels in the blood in
seconds, along with SpO2 and pulse rate to facilitate rapid,
reliable treatment decisions in military settings where carbon monoxide
poisoning or methemoglobinemia may be encountered.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET
Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding repeatability of the
performance and results for the Radical-7 and Rad-57 Pulse CO-Oximeters during
laboratory and flight operations, as well as other factors discussed in the
"Risk Factors" section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at
the SEC's website at www.sec.gov. Although we
believe that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of today's date. We do not undertake any obligation to update,
amend or clarify these forward-looking statements or the "Risk Factors"
contained in our most recent reports filed with the SEC, whether as a result of
new information, future events or otherwise, except as may be required under the
applicable securities laws.
Contact:
Dana Banks
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Children's Hospital Oakland Standardizes to Masimo Rainbow SET® Pulse CO-Oximetry™
Technology
Pioneering Noninvasive and Continuous Hemoglobin Hospital-wide,
Children's Hospital Oakland Leverages State-of-the-Art Masimo Rainbow Platform
to Advance Pediatric Care
Irvine, California – September 1, 2009 – Masimo (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and
Low-Perfusion pulse oximetry, announced today that Children's Hospital &
Research Center Oakland has completed its system-wide conversions to Masimo
Rainbow SET Pulse CO-Oximetry technology. Standardizing to Masimo Rainbow SET
makes Children's Hospital Oakland the first children's hospital to pioneer new
continuous noninvasive blood monitoring capabilities hospital-wide—allowing
earlier and better clinical decisions without the intermittent pain and wait
associated with drawing blood.
By converting to Masimo Rainbow SET, Children's Hospital Oakland clinicians
will gain all the benefits and Measure-Through Motion capabilities of Masimo SET
pulse oximetry, along with the breakthrough innovation of the first-ever
continuous and noninvasive hemoglobin monitoring (SpHb™) technology. Noninvasive
hemoglobin will allow clinicians at Children's to detect and treat chronic or
acute anemia earlier, identify internal bleeding sooner, and more effectively
manage blood transfusions for their patients. The ability to immediately detect
and treat potentially life-threatening conditions earlier may help save lives
and improve patient outcomes.
Katie Sabato, MS, RRT, director of Respiratory Care, Pulmonary Function &
Sleep Labs at Children's Hospital Oakland, stated, "All of our efforts are
focused on helping kids get better, which requires a very special level of care
and some of the world's most sophisticated technology. Masimo Rainbow SET will
allow us to measure critical components of a child's blood quickly and easily,
without the pain of a needle stick and the discomfort of having blood drawn.
It's also a great example of how we leverage advanced technology and innovative
care solutions to improve comfort and care and speed-up a child's recovery."
Masimo Founder and CEO, Joe E. Kiani, stated, "We are proud of our
relationship with Children's Hospital Oakland. Children's was one of the first
children's hospitals to convert to Masimo SET years ago and, with a history of
leadership in the practice of neonatal and pediatric care, they are continuing
to lead new efforts to transform pediatric patient care with their conversion to
Masimo Rainbow SET Pulse CO-Oximetry. We are delighted that they have chosen to
significantly impact the care and treatment of children and advance the practice
of medicine using our noninvasive and continuous Rainbow platform."
Masimo Rainbow SpHb is transforming the way patients are managed in the
operating room, intensive care unit and emergency department, where clinicians
are reporting earlier identification of necessary blood transfusions, reduction
in unnecessary transfusions and invasive tests, increased patient safety, and
improved clinical outcomes.
Amit Gupta, M.D., pediatric anesthesiologist at Children's Hospital &
Research Center Oakland, stated, "Preserving safe hemoglobin levels are always a
particular concern for pediatric patients who already have very little
hemoglobin to spare. With Masimo Rainbow SET in the peri-operative setting we
can noninvasively detect internal bleeding, fluid responsiveness, oxygen
saturation, pulse rate, and perfusion—all in a matter of seconds. Having this
level of physiological detail immediately available at our fingertips is a
tremendous benefit that helps to speed patient assessment, treatment, care, and
the safe return to optimal health."
Children's Hospital & Research Center Oakland is a regional and global
resource for advanced pediatric care, research and medical education. With more
than 200,000 patient visits per year, Children's has Northern California's most
active pediatric trauma center, the region's busiest pediatric intensive care
unit, and one of the largest sickle cell treatment and research centers in the
world.
About Children's Hospital & Research Center
Oakland
Children's Hospital & Research Center Oakland is
Northern California's only freestanding and independent children's hospital.
Children's is a leader in many pediatric specialties including neonatology,
cardiology, neurosurgery and intensive care. The hospital is a designated Level
1 pediatric trauma center and has the largest pediatric critical care facility
in the region. Children's Hospital has 190 licensed beds, 201 hospital-based
physicians in 30 specialties, more than 2,600 employees and an annual operating
budget of $312 million. Children's research arm, Children's Hospital Oakland
Research Institute (CHORI), is internationally renowned for taking
state-of-the-art basic and clinical research to the bedside with interventions
for treating and preventing human disease. CHORI has 300 staffers, a budget of
about $50 million, and is ranked among the nation's top 10 research centers in
National Institutes of Health funding to children's hospitals. CHORI is a leader
in translational research, developing new vaccines for infectious diseases, and
discovering new treatment protocols for previously fatal or debilitating
conditions including cancer, sickle cell anemia, thalassemia, diabetes, asthma,
HIV/AIDS, pediatric obesity, nutritional deficiencies, birth defects, hemophilia
and cystic fibrosis. For more information, go to www.childrenshospitaloakland.org.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the repeatability of
clinical results, risks related to our belief that Masimo Rainbow SET will
provide sufficient sensitivity and specificity to detect physiological
abnormalities in real-time, enabling clinicians to detect and identify
potentially life-threatening conditions earlier and make better clinical and
treatment decisions for their patients, as well as other factors discussed in
the "Risk Factors" section of our most recent reports filed with the Securities
and Exchange Commission ("SEC"), which may be obtained for free
at the SEC's website at www.sec.gov. Although
we believe that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of today's date. We do not undertake any obligation to update,
amend or clarify these forward-looking statements or the "Risk Factors"
contained in our most recent reports filed with the SEC, whether as a result of
new information, future events or otherwise, except as may be required under the
applicable securities laws.
Media Contacts:
Dana Banks
Masimo Corporation
+1
(949) 297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo to Present at the Thomas Weisel Partners Healthcare Conference 2009
IRVINE, Calif., August 31, 2009 – Masimo Corporation
(NASDAQ: MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion
and Low-Perfusion pulse oximetry, today announced that its management is
scheduled to present at the Thomas Weisel Partners Healthcare Conference 2009 at
the Four Seasons Hotel in Boston, Massachusetts, on Thursday, September 10,
2009, at 10:20 a.m. EDT. A live audiocast of the presentation will be available
on the Masimo website at www.masimo.com. A
replay of the audiocast will be available following the live presentation.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care-helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET®
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at http://www.masimo.com.
Masimo
Corporation
Investor Contact:
Mark P. de
Raad
Executive Vice President and Chief Financial Officer
Masimo
Corporation
(949) 297-7080
mderaad@masimo.com
Media
Contact:
Dana Banks
Manager, Public Relations
Masimo
Corporation
(949) 297-7348
dbanks@masimo.com
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Childrens Hospital Los Angeles Completes Conversion to Masimo SET® Pulse Oximetry Technology
Irvine, California – August 25, 2009 – Masimo (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and
Low-Perfusion pulse oximetry, announced today that Childrens Hospital Los
Angeles, ranked by U.S. News & World Report as one of 'America's
Best Children's Hospitals', has completed its system-wide conversion to Masimo
SET pulse oximetry technology.
Masimo SET has been clinically proven in more than 100 independent and
objective studies to provide the most trustworthy SpO2 and
pulse rate measurements, even under the most difficult clinical conditions of
patient motion and low peripheral perfusion—conditions common to infants and
children. Its unmatched sensitivity and specificity, combined with a validated
accuracy to oxygen saturations as low as 60% on patients, including cyanotic
patients, helps clinicians keep their tiniest, most vulnerable patients safe.
Masimo SET pulse oximetry aids the detection of congenital heart disease (CHD)
and helps significantly reduce eye damage and blindness caused by retinopathy of
prematurity (ROP)—one of the most common causes of visual impairment in neonatal
patients.1-5
According to Randall Wetzel, M.D., Chair of Anesthesiology and Critical Care
Medicine at Childrens Hospital Los Angeles, "Standardizing to Masimo SET allows
us to more accurately assess oxygenation in children to detect life-threatening
conditions earlier. It also provides a unique platform for growth with the
opportunity to use Masimo Rainbow SET noninvasive measurements, such as
continuous hemoglobin measurement. The ability to measure hemoglobin
continuously during surgery will enable us to identify trends earlier and to
more quickly and effectively manage blood and fluid administration
interoperatively and in the ICUs."
Masimo Founder and CEO, Joe E. Kiani, stated, "We are happy that Childrens
Hospital Los Angeles has selected Masimo SET as their pulse oximetry technology
and Pulse CO-Oximetry platform. Given what our technology has been proven to do
for patients, it's always gratifying to convert a hospital to Masimo, but it is
especially gratifying when it is one of the world's best children's hospitals
right here in Southern California."
Childrens Hospital Los Angeles, a Level I Pediatric Trauma Center and Level
III Neonatal Intensive Care Unit, treats over 93,000 children each year who need
care that is so complex, it can only be provided by medical experts. With one of
the largest dedicated neonatal/pediatric transport programs in the nation and
the only dedicated Cardiothoracic Intensive Care Unit on the west coast,
Childrens Hospital provides innovative therapies for high-risk infants
transferred from other hospitals throughout Southern California and beyond.
In the past five years, approximately 900 hospitals in the U.S. have
converted completely to Masimo. In addition, more than half of the top hospitals
listed on the U.S. News & World Report 'Best Hospitals Honor
Roll'—including four of the top five—rely on Masimo SET pulse oximetry to
provide the best care to their patients.
1 de Wahl Granelli A, et al. "Screening for
Duct-Dependent Congenital Heart Disease with Pulse Oximetry: A Critical
Evaluation of Strategies to Maximize Sensitivity." Acta Paediatrica
2005; 94: 1590-1596.
2 Granelli AW, et al. "Noninvasive
Peripheral Perfusion Index as a Possible Tool for Screening for Critical Left
Heart Obstruction." Acta Paediatrica 2007; 96:
1455-1459.
3 Anne de-Wahl Granelli, et al., "Impact of Pulse
Oximetry Screening on the Detection of Duct Dependent Congenital Heart Disease:
a Swedish Prospective Screening Study in 39,821 newborns." BMJ. 2009;
338;a3037.
4 Armando R. Castillo, Richard Deulofeut, Augosto
Sola. "Clinical Practice and SpO2 Technology in the Prevention of ROP in ELBW
Infants." Publication 8440.7; 2007 Pediatric Academic Societies.
5
Tsutum T, et al. "Clinical Evaluation of Accuracy of Masimo LNOP Blue Sensor in
Cyanotic Infants." Critical Care Medicine 2006; 34(12): A56.
About Childrens Hospital Los Angeles
Founded in 1901,
Childrens Hospital Los Angeles has been treating the most seriously ill and
injured children in Los Angeles for more than a century, and it is acknowledged
throughout the United States and around the world for its leadership in
pediatric and adolescent health. Childrens Hospital is one of America's premier
teaching hospitals, affiliated with the Keck School of Medicine of the
University of Southern California since 1932. The Saban Research Institute of
Childrens Hospital Los Angeles is among the largest and most productive
pediatric research facilities in the United States. Since 1990, U.S. News
& World Report and its panel of board-certified pediatricians have
named Childrens Hospital Los Angeles one of the top pediatric facilities in the
nation. Childrens Hospital Los Angeles is one of only 10 children's hospitals in
the nation – and the only children's hospital on the West Coast – ranked in all
10 pediatric specialties in the U.S. News & World Report rankings
and named to the magazine's "Honor Roll" of children's hospitals.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the repeatability of
results obtained by Childrens Hospital Los Angeles, risks related to our belief
that Masimo SET will deliver sufficient sensitivity and specificity to improve
patient monitoring and will achieve accuracy in oxygen saturation as low as 60%
on patients, including cyanotic patients, and risks related to enabling
detection of CHD and ROP, as well as other factors discussed in the "Risk
Factors" section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at
the SEC's website at www.sec.gov. Although we
believe that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of today's date. We do not undertake any obligation to update,
amend or clarify these forward-looking statements or the "Risk Factors"
contained in our most recent reports filed with the SEC, whether as a result of
new information, future events or otherwise, except as may be required under the
applicable securities laws.
Media Contacts:
Dana Banks
Masimo Corporation
+1
(949) 297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
GS GmbH Signs Technology License Agreement to Integrate Masimo Rainbow SET® Pulse CO-Oximetry™ into Defibrillators and Patient Monitoring Systems
EMS Market Leader from Germany Standardizes on Masimo's Revolutionary
Rainbow SET Pulse CO-Oximetry Technology Platform
Irvine, California and Kaufering, Germany – August 20, 2009
– Masimo (NASDAQ: MASI), the inventor of Pulse CO-Oximetry™ and
Measure-Through Motion and Low-Perfusion pulse oximetry, and GS
Elektromedizinische Geräte G. Stemple GmbH, a German developer and manufacturer
of innovative medical equipment for the Emergency Medical Services (EMS), today
jointly announced a worldwide technology licensing agreement to integrate Masimo
Rainbow SET Pulse CO-Oximetry into corpuls® patient monitoring modules. The
agreement enables GS GmbH to expand the vital signs and noninvasive measurement
capabilities of its defibrillators and patient monitoring systems to help EMS
professionals detect and treat life-threatening conditions earlier.
The breakthrough noninvasive blood constituent monitoring capabilities of
Masimo Rainbow SET Pulse CO-Oximetry allow for continuous monitoring of
hemoglobin, carbon monoxide, methemoglobin, PVI for fluid responsiveness,
perfusion index, and measure-through motion pulse oximetry. With Masimo Rainbow
SET, the ability to detect internal bleeding, carbon monoxide poisoning,
methemoglobinemia, fluid responsiveness, perfusion, saturation, and pulse rate
quickly, easily and continuously can help save lives and improve patient
outcomes.
According to Klaus Stemple, General Manager of GS GmbH, the key to
"developing better lifesaving support solutions and techniques is to stay ahead
of the mainstream. Our corpuls products are innovative leaders in the
defibrillator market and the integration of Masimo Rainbow SET Pulse CO-Oximetry
measurements is another consistent step in the design and manufacture
state-of-the-art defibrillator/monitoring-systems that spearhead the industry in
patient monitoring performance. The combination of corpuls and Masimo Rainbow
SET creates a unique defibrillator solution for EMS professionals looking to
leverage additional vital parameters to more thoroughly assess a patient's
physiological status and make better clinical and treatment decisions."
The corpuls3—a unique 3-in-1 modular
defibrillator system combining three components including: a compact patient
box, a large monitoring unit, and a defibrillator/pacer unit — will be one of
the first products to feature Masimo Rainbow SET Pulse CO-Oximetry capabilities.
The Masimo Rainbow SET measurement option will be available in mid-2010.
Masimo Founder and CEO, Joe E. Kiani, stated, "GS GmbH was one of the first
European equipment manufacturers to license Masimo SET pulse oximetry technology
over 10 years ago. Today, they are still a market leader in providing innovative
EMS solutions throughout Europe and, with this technology license agreement,
will further expand the availability of Masimo Rainbow SET Pulse CO-Oximetry to
the benefit of patients and EMS professionals alike."
About GS GmbH
GS Elektromedizinische Geräte G. Stemple
GmbH is a German company and internationally-operated business specializing in
the development and manufacture of innovative high-end medical devices for
emergency medical services and intensive care for over 25 years. The corpuls®
defibrillators and patient monitoring systems are robust, reliable and durable
devices designed for use in the first aid treatment of people suffering from
sudden cardiac arrest. Additional information about corpuls and its products may
be found at www.corpuls.com.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the timing and
commercial availability of corpuls3 featuring Masimo Rainbow SET Pulse
CO-Oximetry technology, risks related to our belief that Masimo Rainbow SET will
provide sufficient sensitivity and specificity to detect physiological
abnormalities in real-time, enabling EMS professionals to detect and identify
potentially life-threatening conditions earlier and make better clinical and
treatment decisions for their patients, as well as other factors discussed in
the "Risk Factors" section of our most recent reports filed with the Securities
and Exchange Commission ("SEC"), which may be obtained for free
at the SEC's website at www.sec.gov. Although
we believe that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of today's date. We do not undertake any obligation to update,
amend or clarify these forward-looking statements or the "Risk Factors"
contained in our most recent reports filed with the SEC, whether as a result of
new information, future events or otherwise, except as may be required under the
applicable securities laws.
Media Contacts:
Dana Banks
Masimo Corporation
+1
(949) 297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation. Corpuls and Corpuls3
are trademarks or registered trademarks of GS Elektromedizinische Geräte G.
Stemple GmbH.
|
|
|
|
|
|
Masimo and the International Association of Fire Chiefs Launch Nationwide Health
& Safety Program to Reduce Firefighter Death and Injury
Program Translates New Industry Standards into Functional Procedures and
Operational Processes to Combat Carbon Monoxide (CO) Health Risks and Other
Duty-Related Hazards
Irvine, California – August 18, 2009 – Masimo (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and
Low-Perfusion pulse oximetry, and the International Association of Fire Chiefs
(IAFC) jointly announce a new health and safety program designed to help fire
departments across the nation implement new rehabilitation and medical
monitoring standards to reduce the duty-related health hazards that claim the
lives of hundreds of the nation's firefighters each year. The IAFC Firefighter
Rehabilitation and Medical Monitoring Program provides the tools, training and
resources fire departments need to put new national standards into practice.
Numerous published studies have shown that heart damage resulting from CO
poisoning is a frequent and significant predictor of mortality, requiring
appropriate screening for the detection of such injuries.1-4 Last year, the National Fire Protection Association
(NFPA) revised its national codes and standards for Section 1584, "Standard on
the Rehabilitation Process for Members During Emergency Operations and Training
Exercises," to include the routine use of CO screening.
"Evidence shows that mortality and morbidity increase following CO exposure,
which is the most commonly encountered contaminant found in environmental
studies of firefighters," stated Mike McEvoy, EMS Director for the New York
State Association of Fire Chiefs. "However, a significant number of these
injuries and deaths are preventable, simply through the implementation of
careful medical monitoring and thorough rehabilitation efforts."
The new IAFC Firefighter Rehabilitation and Medical Monitoring Program,
jointly developed and sponsored by Masimo and the IAFC, addresses vital
occupational health and safety hazards for firefighters to meet a previously
unmet need without draining department resources. The program offers free onsite
and online training, educational resources and materials, development tools for
standard operating procedures, guidance, and support to help fire departments
implement and comply with NFPA 1584 required standards.
"This program provides fire departments with the materials they need to
properly implement the national codes and standards, and train their members,"
said IAFC President Chief Larry J. Grorud, CFO, MIFireE. "Any delay or failure
to implement these critical health and safety measures could increase injury and
death rates for firefighters and reduce work capacities, manpower and efficiency
for their departments."
NFPA 1584 mandates that "Any firefighter exposed to CO or presenting with
headache, nausea, shortness of breath, or gastrointestinal symptoms at an
incident where CO is present should be assessed for carbon monoxide
poisoning."
The program identifies eight key elements for effective firefighter
rehabilitation at incident scenes and training exercises, including: relief from
environmental conditions, rest and recovery, temperature regulation, hydration,
calorie and electrolyte replacement, medical monitoring, member accountability
and tracking systems, and release for return to duty.
Masimo Founder and CEO, Joe E. Kiani, stated, "We are proud to work with the
IAFC on this Firefighter Rehabilitation and Medical Monitoring Program. Our goal
is to make it easier for fire departments to put the procedures and resources in
place to meet the rehabilitation needs of their firefighters at every incident
scene. The more successful we are, the safer firefighters will be."
1 Hampson NB, Rudd RA, Hauff NM. "Increased Long-term
Mortality Among Survivors of Acute Carbon Monoxide Poisoning." Crit Care Med.
June 2009; 37(6):2116-8.
2 Williams J, Lewis II RW, Kealey GP.,
"Carbon Monoxide Poisoning in Myocardial Ischemia in Patients with Burns." J
Burn Care Rehabilitation. 1999; 12:210-213.
3 Hedblad B, Engstrom,
Janzon E, Berglunf G, Janzon L. "COHb% as a marker of cardiovascular risk in
never smokers: Results from a population-based cohort study." Scand J Pub
Health. 2006;34:609-615.
4 DueLaita A., Per麭Castrill. L.,
Ruiz-Mambrilla M., Raymond L. W., Barringer T. A., Konen J. C., Kales S. N.,
Soteriades E. S., Christiani D. C. "Heart Disease Deaths among Firefighters." N
Engl J Med 2007; 356:2535-2537, Jun 14, 2007.
About the International Association of Fire Chiefs
(IAFC)
IAFC represents the leadership of over 1.2 million
firefighters and emergency responders. IAFC members are the world's leading
experts in firefighting, emergency medical services, terrorism response,
hazardous materials spills, natural disasters, search and rescue, and public
safety legislation. Since 1873, the IAFC has provided a forum for its members to
exchange ideas and uncover the latest products and services available to first
responders. www.iafc.org
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumption that Pulse CO-Oximetry will
become the preferred method of noninvasive CO assessment for the IAFC and NFPA,
risks related to our belief that SpCO will improve the clinical assessment of CO
poisoning in firefighters and offer a measureable improvement over existing
medical monitoring capabilities to enhance firefighter rehabilitation efforts,
as well as other factors discussed in the "Risk Factors" section of our most
recent reports, filed with the Securities and Exchange Commission
("SEC"), which may be obtained for free at the SEC's website at
www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our most
recent reports, whether as a result of new information, future events or
otherwise, except as may be required under the applicable securities laws.
Media Contact:
Dana Banks,
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo and Oridion Sign Connectivity Agreement to Integrate Capnostream™20 Portable
Bedside Monitors into the Masimo Patient SafetyNet™ System
Joint Development of a Two-way Interface Enabling Wired and Wireless
Communication Now Underway
Irvine, California/Jerusalem, Israel – August 11, 2009 –
Masimo (NASDAQ: MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through
Motion and Low-Perfusion pulse oximetry, and Oridion (SIX Swiss Exchange:
ORIDN), a global innovator of capnography monitoring solutions, today jointly
announced an agreement to establish compatibility and connectivity between
Oridion Capnostream™20 portable bedside monitors and the Masimo Patient
SafetyNet™ remote monitoring and clinician notification system. The agreement
provides for joint development of a two-way interface allowing Patient SafetyNet
to retrieve, analyze, and display physiological data from Capnostream monitors,
while managing bi-directional communication and alarm features to facilitate
earlier recognition of and clinical response to adverse respiratory events that
require immediate clinical intervention.
According to a recently released HealthGrades study on patient safety in
American hospitals, failure to rescue—which is defined as death occurring when
an adverse clinical event is not recognized in time to save a patient with
serious treatable complications—is the most common and most serious medical
error at U.S. hospitals. Masimo Patient SafetyNet was specifically developed to
provide a new level of safety to patients on general care floors, where
nurse-to-patient ratios can often preclude the level of direct surveillance
required and recommended to preempt adverse events.
The key to a successful patient rescue is getting the right information to
the right clinician at the right time. This means that accurate, reliable, and
actionable patient data is necessary for rapid response or patient safety
solutions to be effective. Oridion Capnostream monitors feature two
industry-leading technologies—Oridion's patented Microstream® sidestream Smart
Capnography™, and Masimo SET® Measure-Through Motion and Low-Perfusion pulse
oximetry—that together provide clinicians with an early warning of a possible
life-threatening deterioration in their patients' physiological status.
Oridion Microstream technology enables the most accurate and reliable
assessment of breathing quality for patients requiring continuous ventilation
monitoring, providing clinicians with timely recognition of changes that may
lead to a decline in respiratory status or airway compromise. Masimo SET is the
most accurate and reliable pulse oximetry technology, clinically proven in more
than 100 independent and objective studies to provide the most trustworthy
SpO2 and pulse rate measurements even under the most
difficult clinical conditions, including patient motion and low peripheral
perfusion. Masimo Patient SafetyNet will be the first remote monitoring and
clinician notification system to feature Oridion's newest Smart Capnography™
algorithm—Integrated Pulmonary Index™ (IPI)—enabling real-time tracking and
trending of EtCO2, respiration rate, pulse rate, and
SpO2 for an inclusive assessment of the patient's
ventilatory status with a single index parameter.
According to Gerry Feldman, President of Oridion Systems Ltd., a partnership
between the gold standards technologies in capnography and pulse oximetry
"represents a winning combination for patients, clinicians and hospitals alike
because a change in breathing quality and oxygenation can be important early
indications that a patient may be heading for big trouble. The ability to
quickly route this vital information to a qualified caregiver or rapid response
team for appropriate clinical intervention can mean the difference between a
timely rescue and failure to rescue. Oridion Microstream and Masimo SET
technologies, together with the Masimo Patient SafetyNet system, will arm
hospitals with the accurate, real-time information they need to make the most of
their patient safety efforts."
Masimo Founder and CEO, Joe E. Kiani, stated, "We are happy to partner with
Oridion to expand the variety of vital sign parameters and third-party
multi-parameter patient monitoring devices that offer real-time wireless
connectivity to the Masimo Patient SafteyNet remote monitoring and clinician
notification system. The Oridion Capnostream 20 monitor combines proven
best-in-class measurements for oxygenation and ventilation in a portable and
easy-to-use device for clinicians and patients in both hospital and outpatient
settings. Enabling full connectivity and two-way wireless communication between
Oridion Capnostream monitors and Masimo's Patient SafetyNet system will provide
additional flexibility and monitoring options for healthcare facilities looking
to advance patient safety and improve clinical outcomes."
Development of the two-way interface enabling full connectivity between
Oridion monitors and Patient SafetyNet is now underway, with completion expected
in Q4 of this year. Furthermore, existing Oridion Capnostream 20 monitors and
Masimo Patient SafteyNet systems can be easily upgraded via software to add this
functionality following full commercial release of the bi-directional interface.
About Oridion
Oridion Systems Ltd. (www.oridion.com) is a global medical device
company specializing in patient safety monitoring. The Company operates through
wholly owned subsidiaries in the United States, Europe, and Israel. Oridion
develops proprietary medical devices and patient interfaces, based on its
patented Microstream® technologies, for the enhancement of patient safety
through the monitoring of the carbon dioxide (CO2) in a
patient's breath. These products provide effective, proven airway management and
are used in various clinical environments, including procedural sedation, pain
management, operating rooms, critical care units, post-anesthesia care units,
emergency medical services, transport, alternate care and other settings where
patients' ventilation may be compromised and at risk. Additional information
about Oridion and its products may be found at www.oridion.com.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the timing and
availability of connectivity and a two-way interface between Oridion Capnostream
and Masimo Patient SafetyNet, risks related to our belief that Patient SafetyNet
will provide an effective early warning system to enable timely rescue, risks
related to our belief that Masimo SET will provide sufficient sensitivity and
specificity to detect physiological abnormalities and potentially
life-threatening conditions in real-time for all patients, as well as other
factors discussed in the "Risk Factors" section of our most recent reports filed
with the Securities and Exchange Commission ("SEC"), which may
be obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the applicable
securities laws.
Media Contacts:
Dana Banks
Masimo Corporation
+1
(949) 297-7348
Walter Tabachnik
Oridion Systems Ltd.
+972 (2) 589-9159
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation. Capnostream and
Microstream are trademarks or registered trademarks of Oridion.
|
|
|
|
|
|
Masimo Reports Second Quarter 2009 Financial Results
Q2 2009 Highlights:
- Earnings per share increased by 22% to $0.22 per share from $0.18 in prior
year
- Product revenues increased 13% to $70.0 million from $62.1 million in prior
year
- Rainbow revenues increased 56% to $4.5 million from $2.9 million in prior
year
Irvine, California, August 4, 2009 – Masimo Corporation
(NASDAQ: MASI), the inventor of Pulse CO-Oximetry and Measure-Through Motion and
Low-Perfusion pulse oximetry, today announced its financial results for the
second quarter of 2009.
For the second quarter of 2009, Masimo reported product revenues of $70.0
million representing a 13% increase over $62.1 million for the second quarter of
2008. Including royalty revenues, Masimo reported total 2009 second quarter
revenues of $83.6 million compared to $74.8 million for the second quarter of
2008. For the second quarter of 2009, Masimo reported earnings per share of
$0.22 compared to $0.18 per share for the second quarter of 2008.
Masimo reported that it shipped 27,100 Masimo SET and Masimo Rainbow SET
oximetry units, excluding handheld units, during the second quarter of 2009,
resulting in an estimated 605,000 of Masimo SET and Masimo Rainbow SET pulse
oximeters in use worldwide. In the second quarter of 2009, revenues from Masimo
Rainbow SET products increased to $4.5 million from $2.9 million in the same
prior year quarter.
For the first six months of 2009, Masimo reported product revenues of $144.5
million representing a 19% increase over $121.8 million for the first six months
of 2008. Including royalty revenues, Masimo reported total 2009 year to date
revenues of $169.1 million, representing a 16% increase compared to $145.9
million for the prior year period. For the first half of 2009, Masimo reported
earnings per share of $0.43, up 34% from $0.32 per share for the first half of
2008.
Joe E. Kiani, Chairman and Chief Executive Officer of Masimo, said, "We had a
good quarter given the recession—while revenues were down quarter over quarter,
they grew 13% year over year, thanks to continued strong Masimo SET growth and
even stronger Masimo Rainbow SET growth. These results underline both the
resilience of our business model and the power of our innovation in noninvasive
monitoring, which is helping our customers improve and automate patient
care."
Masimo also reported that as of July 4, 2009, cash and cash equivalents
totaled $156.6 million, up from $146.9 million at January 3, 2009.
Financial Guidance
While providing financial guidance in
this economic environment continues to be more difficult than in prior periods,
Masimo is reaffirming its 2009 earnings guidance of $0.83 to $0.87 per share;
however, Masimo is adjusting its total 2009 product revenue guidance to between
$295 million and $300 million, down from its prior guidance of $310 million to
$315 million. Masimo also expects its 2009 royalty revenues to be in the range
of $44 million to $46 million, compared to prior guidance of $42 million to $46
million. For the full year 2009, Masimo now expects its total revenues to be
between $339 million and $346 million, down from $352 million to $361 million.
The projections and guidance set forth above are estimates only and actual
results could differ.
Conference Call
Masimo will hold a conference call today
at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. The dial-in numbers are
(888) 520-7182 for domestic callers and +1 (706) 679-9937 for international
callers. The reservation number for both dial-in numbers is 21245431. A live web
cast of the conference call will be available online from the "Investor
Relations" page of the Company's corporate web site at www.masimo.com. After the live web cast, the
call will remain available on Masimo's website through September 4, 2009. In
addition, a telephonic replay of the call will be available until August 18,
2009. The replay dial-in numbers are (800) 642-1687 for domestic callers and +1
(706) 645-9291 for international callers. Please use reservation code 21245431.
About Masimo
Masimo (NASDAQ: MASI) develops,
manufactures and markets innovative monitoring technologies that significantly
improve patient care—helping solve "unsolvable" problems. In 1995, the Company
debuted Measure-Through Motion and Low-Perfusion pulse oximetry, known as Masimo
SET, which virtually eliminated false alarms and increased pulse oximetry's
ability to detect life-threatening events. More than 100 independent clinical
and laboratory studies demonstrate Masimo SET provides the most reliable
SpO2 and pulse rate measurements even under the most
challenging clinical conditions, including patient motion and low peripheral
perfusion. In 2005, Masimo introduced Masimo Rainbow SET, a breakthrough
noninvasive blood constituent monitoring platform that can measure many blood
constituents that previously required invasive procedures. Rainbow SET
continuously and noninvasively measures total hemoglobin (SpHb®), oxygen content
(SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®) and plethysmograph
variability index (PVI®), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com. Any information contained in,
or that can be accessed through, our website is not incorporated by reference
into, nor is it in any way a part of, this release.
Forward-Looking Statements
All statements other than
statements of historical facts included in this press release that address
activities, events or developments that we expect, believe or anticipate will or
may occur in the future are forward-looking statements including, in particular,
the statements about: our financial condition, results of operations, prospects
and business generally; expectations regarding our ability to design and deliver
innovative new noninvasive technologies; and estimates for total revenues,
including royalty and product revenues, and earnings per share for the full
fiscal year 2009. These forward-looking statements are based on management's
current expectations and beliefs and are subject to uncertainties and factors,
all of which are difficult to predict and many of which are beyond our control
and could cause actual results to differ materially and adversely from those
described in the forward-looking statements. These risks include, but are not
limited to, those related to: our dependence on Masimo SET and Masimo Rainbow
SET products and technologies for substantially all of our revenue; any failure
in protecting our intellectual property exposure to competitors' assertions of
intellectual property claims; the highly competitive nature of the markets in
which we sell our products and technologies; any failure to continue developing
innovative products and technologies; the lack of acceptance of any new products
and technologies of ours; obtaining regulatory approval of our current and
future products and technologies, including the recently announced total
hemoglobin measurement; the risk that the implementation of our international
realignment, even if timely implemented, will not produce the anticipated
operational and financial benefits, including a lower effective tax rate; the
loss of our customers the failure to retain and recruit senior management;
product liability claims exposure; a failure to obtain expected returns from the
amount of intangible assets we have recorded; the maintenance of our brand; the
impact of the decline in the worldwide credit markets on us and our customers;
the amount and type of equity awards that we may grant to employees and service
providers in the future; and other factors discussed in the "Risk Factors"
section of our most recent periodic reports filed with the Securities and
Exchange Commission ("SEC"), which you may obtain for free on the SEC's website,
at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. You are cautioned not to
place undue reliance on these forward-looking statements, which speak only as of
the date hereof, even if subsequently made available by us on our website or
otherwise. We do not undertake any obligation to update, amend or clarify these
forward-looking statements, whether as a result of new information, future
events or otherwise, except as may be required under applicable securities laws.
Masimo Corporation
Investor Contact:
Mark
P. de Raad
Executive Vice President and Chief Financial Officer
Masimo
Corporation
(949) 297-7080
mderaad@masimo.com
Media Contact:
Dana Banks
Manager, Public Relations
Masimo Corporation
(949) 297-7348
dbanks@masimo.com
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpCO, SpMet, PVI, Pulse CO-Oximetry and Pulse
CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
The International Association of Fire Fighters and Masimo Team Up on a New
Global Campaign to Raise Awareness of Carbon Monoxide-Related Death and
Injury Risks for Firefighters
New Carbon Monoxide (CO) Safety Campaign Featuring Actor Randolph
Mantooth from the Hit TV Show EMERGENCY! Urges Education, Protection and
Safety
Irvine, California – July 23, 2009 – The International
Association of Fire Fighters (IAFF) and Masimo jointly announced the launch of a
new international health and safety initiative aimed at educating fire fighters
about the duty-related dangers of carbon monoxide (CO) and reducing known risk
factors that unnecessarily kill and injure hundreds of fire fighters each year.
The campaign, kicked off at the biennial IAFF EMS Conference in Miami Beach,
Florida, will feature actor Randolph Mantooth — widely recognized as Los Angeles
County firefighter/paramedic "Johnny Gage" in the popular 1970s television
series EMERGENCY! — speaking out about his own near-death CO experience
while highlighting the immediate and long-term health risks and prevention
strategies of CO exposure at IAFF district meetings and conferences throughout
the year.
CO poisoning is a danger at every fire, but its symptoms — headache,
dizziness, fatigue — are often absent or non-specific, making on-scene awareness
and detection difficult. This puts fire fighters at significant risk on the
scene of a fire because even mild CO poisoning can rob the brain of oxygen,1 which can lead to poor decision making.2 It can also rob the heart of oxygen, causing
immediate life-threatening complications — with half of on-duty fire fighter
deaths being attributed to heart attacks or stroke.3 And, just one severe CO poisoning almost doubles
their long-term risk of death.4 CO poisoning is
often present without symptoms and is not easy to detect,5 — making fire fighter education and awareness a
critical necessity. The new educational campaign builds on last year's efforts
to increase CO awareness and safety among fire fighters by distributing
education materials to more than 3,200 local union presidents in the United
States and Canada.
"We are pleased to team with Masimo and with Randolph Mantooth in this
important effort," said IAFF General President Harold Schaitberger. "This is a
critical educational endeavor that we hope will help contribute to the
protection of our members."
Mantooth's involvement is personal: "Since my own near-death CO experience
and subsequent rescue by two fire fighter/paramedics, I've become an advocate of
fire fighters, paramedics, EMTs, and other emergency responders as a first step
toward repaying my debt to these brave men and women. I want to encourage them
to protect their own lives, so they can be there to protect others."
Randy's new IAFF presentation encourages fire fighters to get their CO levels
tested on the fire scene and, if elevated, seek prompt treatment. He also urges
fire fighters to take personal responsibility for their safety by recognizing
the dangers of CO and preventing unnecessary exposures.
"The trade-offs for ignoring the serious dangers of CO exposure are heart
attack, stroke, loss of motor skills, lifelong disability, or death," Mantooth
explained. "Our fire fighters need to know and understand these significant
occupational hazards, how to properly protect themselves and prevent unnecessary
health risks to improve the odds that they will be around tomorrow to do what
they were born to do."
As part of the campaign, Randy has created a new web site — www.COsafetynet.org — to provide
immediate and free access to valuable information and educational resources
designed to increase awareness of the immediate personal safety, long-term
health, and departmental risks associated with CO exposure for fire fighters.
The web site will provide fast facts and other important information about
specific occupational exposures to CO and associated risks to fire fighter
health and safety, as well as links to resources designed to help keep fire
fighters safe from the dangers of CO poisoning.
Joe E. Kiani, Chairman and CEO of Masimo, stated, "Fire fighters, within
their normal course of work, are routinely exposed to dangerous levels of CO and
bear the largest risks to their own health and safety. We are happy to partner
with the IAFF and Mr. Mantooth to introduce this special CO education and
outreach campaign to save the lives and preserve the health of all fire fighters
from the potentially life-threatening effects of CO."
1 Bledsoe, BE: "The Perils of CO" FireRescue
Magazine. September 2005.
2 Jakubowski, G. The Invisible
Incidents: How to respond to CO alarms. FireRescue Magazine.
22(11):52–55, 2004.
3 Bledsoe, BE. "The Dangers of CO:
Understanding Cardiovascular Risks to Responders from CO Exposure." Journal
of Emergency Medical Service. 32:54-59, 2007.
4 Hampson, NB
et al. "Increased long term mortality among survivors of acute carbon monoxide
poisoning." Crit Care Med. 2009; 37(6): 1941-47.
5
Hampson, NB, et al: "Carboxyhemoglobin levels in carbon monoxide poisoning: do
they correlate with the clinical picture?" American Journal of Emergency
Medicine. 26:665-669, 2008.
About IAFF
The International Association of Fire Fighters
is a member driven union — for fire fighters, by fire fighters — representing
more than 295,000 full-time professional fire fighters and paramedics who
protect 85 percent of the nation's population. With one of the most active
lobbying organizations in Washington, IAFF serves as the primary advocate for
providing fire fighters and paramedics with the tools they need to perform their
jobs and is the driving force behind nearly every advance within the fire and
emergency services for the past 90 years. With more than 3,200 affiliates
protecting communities in every state of the United States and in Canada, the
IAFF has established professional standards for the North American fire service
and provides a strong voice in the development and implementation of new
training programs and equipment. The IAFF in no way endorses, sponsors, or is
otherwise involved in the design, manufacture, sale or distribution of goods and
services by the Masimo Corporation. No representation, warranty or condition,
express or implied, statutory or otherwise is given or assumed by the IAFF in
respect to goods and services designed, manufactured, sold and/or distributed by
the Masimo corporation.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions that the superior sensitivity
and specificity of Masimo Rainbow SET Pulse CO-Oximetry technology will improve
the detection of elevated CO blood levels over alternative methods and
facilitate rapid detection of CO poisoning during fire fighter rehabilitation,
as well as other factors discussed in the "Risk Factors" section of our
Quarterly Report on Form 10-Q for the fiscal quarter year ended April 4, 2009,
filed with the Securities and Exchange Commission ("SEC") on
May 6, 2009, which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our
Quarterly Report on Form 10-Q for the fiscal quarter ended April 4, 2009,
whether as a result of new information, future events or otherwise, except as
may be required under the applicable securities laws.
Media Contact:
Dana Banks,
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo to Report Second Quarter 2009 Financial Results on August 4, 2009
Conference call and webcast to begin after markets close at 1:30 p.m. PT
(4:30 p.m. ET)
IRVINE, Calif., July 22, 2009—Masimo Corporation (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry and Measure-Through Motion and
Low-Perfusion pulse oximetry, today announced it will release second quarter
2009 financial results for the period ended July 4, 2009 after the market closes
on Tuesday, August 4, 2009.
A conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m.
ET) and will be hosted by Joe E. Kiani, Chairman and Chief Executive Officer,
and Mark P. de Raad, Executive Vice President and Chief Financial Officer.
A live webcast of the conference call will be available online from the
investor relations page of the Company's corporate web site at www.masimo.com. The dial-in numbers are (888)
520-7182 for domestic callers and +1 (706) 679-9937 for international callers.
The reservation number for both dial-in numbers is 21245431. After the live
webcast, the call will remain available on Masimo's website through September 4,
2009. In addition, a telephonic replay of the call will be available through
August 18, 2009. The replay dial-in numbers are (800) 642-1687 for domestic
callers and +1 (706) 645-9291 for international callers. Please use reservation
code 21245431.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care-helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET
Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Rainbow SET continuously and noninvasively measures total
hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at http://www.masimo.com.
Masimo Corporation
Investor Contact:
Mark P.
de Raad
Executive Vice President and Chief Financial Officer
Masimo
Corporation
(949) 297-7080
mderaad@masimo.com
Media Contact:
Dana Banks
Manager, Public
Relations
Masimo Corporation
(949) 297-7348
dbanks@masimo.com
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo Receives FDA Clearance for New Rainbow® Resposable™ Sensor System
Innovative Combination Reusable-Disposable Sensor System Provides
Cost-Effective & Environmentally Green Pulse CO-Oximetry Monitoring
Irvine, California – July 21, 2009 – Masimo (NASDAQ: MASI),
the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low-Perfusion
pulse oximetry, today announced the FDA 510(k) clearance of its new Masimo
Rainbow Resposable™ Sensor System, a revolutionary new sensor system that offers
the performance and comfort of a single-use adhesive disposable sensor with the
cost-effectiveness and environmentally-green advantages of a reusable sensor.
The new sensor system provides continuous and noninvasive measurements of
hemoglobin (SpHb™), oxygen content (SpOC™), PVI™ for fluid responsiveness, and
methemoglobin (SpMet®), in addition to oxygen saturation (SpO2), perfusion index, and pulse rate—at savings of about 50%
compared to the existing single patient use adhesive Rainbow sensor.
The Rainbow Resposable Sensor System combines the best features of Masimo
LNOP®, LNCS®, and Rainbow® sensors into an innovative two-piece design that
includes a reusable sensor—enabling the portion that connects to the patient
cable to be used on multiple patients - while the adhesive disposable sensor
that attaches directly to the patient's finger is used on only one patient. This
dramatically minimizes waste, enabling hospitals to reduce their costs safely,
and effectively fulfill their 'green' initiatives.
The reusable portion of the two-piece system provides multi-patient use for
cost-effectiveness, while the flexible cable design maximizes patient comfort,
and enables easy, one-step cleaning. The snap-in-place connector design allows
easy connection and reconnection to the same patient—and reuse on the next
patient. The single-use disposable portion of system features an adhesive that
keeps emitter and detector positions stable against the skin to assure the best
in Masimo SET and Rainbow SET measurement performance. The design maximizes fit
and comfort for the patient, while the protective covering minimizes contact
with patient to reduce cross contamination risk.
"We have tried the Masimo Rainbow Resposable System and found that these
sensors provided us with all of the benefits and superior performance of
Masimo's continuous and noninvasive Rainbow measurements, including noninvasive
hemoglobin monitoring, along with the cleanliness and patient comforts of the
standard single patient use sensor at a fraction of the cost and waste," stated
Bertrand Debaene, M.D., Department of Anesthesia at the University Hospital
Center in Poitiers, France.
"The Masimo Rainbow Resposable Sensor System is based on more than ten years
of research and development stemming from the feedback of hundreds of clinicians
who told us what they wanted most in a sensor—less waste and more value with
superior performance," stated Masimo Founder and CEO, Joe E. Kiani. "We are
happy that by combining the performance and patient comfort of a single-use
adhesive sensor with the cost effectiveness of a reusable sensor, the Masimo
Rainbow Resposable Sensor System also minimizes medical waste and its impact on
the environment."
A Capgemini study released earlier this year showed that a typical 500-bed
hospital incorporating Masimo Rainbow SET Pulse CO-Oximetry into its clinical
standards and care pathways could generate nearly $500,000 in net annual cost
savings and financial gains. With the Masimo Rainbow Resposable Sensor System,
the potential savings to hospitals could increase to nearly $700,000
annually.
 |
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted
Measure-Through-Motion-and-Low-Perfusion pulse oximetry, known as Masimo SET,
which virtually eliminated false alarms and increased pulse oximetry's ability
to detect life-threatening events. More than 100 independent and objective
studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion. In
2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a breakthrough
noninvasive blood constituent monitoring platform that can measure many blood
constituents that previously required invasive procedures. Masimo Rainbow SET
continuously and noninvasively measures total hemoglobin (SpHb™), oxygen content
(SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI™, in
addition to oxyhemoglobin (SpO2), pulse rate (PR), and
perfusion index (PI), allowing early detection and treatment of potentially
life-threatening conditions. Founded in 1989, Masimo has the mission of
"Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive
Monitoring to New Sites and Applications." Additional information about Masimo
and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our belief that the features, function and
design of the Masimo Rainbow Resposable Sensor System will enable hospitals to
reduce associated waste and costs, as well as other factors discussed in the
"Risk Factors" section of our Quarterly Report on Form 10-Q for the fiscal
quarter year ended April 4, 2009, filed with the Securities and Exchange
Commission ("SEC") on May 6, 2009, which may be obtained for
free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our forward-looking
statements are reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press release are
expressly qualified in their entirety by the foregoing cautionary statements.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of today's date. We do not undertake any
obligation to update, amend or clarify these forward-looking statements or the
"Risk Factors" contained in our Quarterly Report on Form 10-Q for the fiscal
quarter year ended April 4, 2009, filed with the Securities and Exchange
Commission ("SEC") on May 6, 2009, whether as a result of new
information, future events or otherwise, except as may be required under the
applicable securities laws.
Contact:
Dana Banks
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo Announces Settlement of Lawsuit
Irvine, California – July 17, 2009 – Masimo Corporation
(NASDAQ: MASI), today announced that it has reached a settlement with
Respironics, Inc. of pending litigation under which Masimo and Respironics will
dismiss all claims and counterclaims currently pending in the litigation between
them in California Superior Court. As part of the settlement, Respironics and
Masimo have agreed upon a schedule for the phase-out of the MARS oximetry
technology.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted
Measure-Through-Motion-and-Low-Perfusion pulse oximetry, known as Masimo SET,
which virtually eliminated false alarms and increased pulse oximetry's ability
to detect life-threatening events. More than 100 independent and objective
studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion. In
2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a breakthrough
noninvasive blood constituent monitoring platform that can measure many blood
constituents that previously required invasive procedures. Masimo Rainbow SET
continuously and noninvasively measures total hemoglobin (SpHb™), oxygen content
(SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI™, in
addition to oxyhemoglobin (SpO2), pulse rate (PR), and
perfusion index (PI), allowing early detection and treatment of potentially
life-threatening conditions. Founded in 1989, Masimo has the mission of
"Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive
Monitoring to New Sites and Applications." Additional information about Masimo
and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors. Important
factors that may cause such a difference for Masimo in connection with our
settled litigation with Respironics, include, but are not limited to realizing
the expected increased placement of Masimo pulse oximeters as a result of the
settlement, and the expected expansion of our business relationship with
Respironics; the impact of our lawsuit against Philips, given that Philips owns
Respironics; and, the risks associated with the litigation being dismissed
without prejudice. Additional factors that may cause Masimo's actual results to
differ materially and adversely from those expressed in forward-looking
statements include, but are not limited to: those factors discussed in the "Risk
Factors" section of our Quarterly Report on Form 10-Q for the fiscal quarter
ended April 4, 2009, filed with the Securities and Exchange Commission
("SEC") on May 6, 2009, which may be obtained for free at the
SEC's website at www.sec.gov. Although we
believe that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of today's date. We do not undertake any obligation to update,
amend or clarify these forward-looking statements or the "Risk Factors"
contained in our Quarterly Report on Form 10-Q for the fiscal quarter ended
April 4, 2009, whether as a result of new information, future events or
otherwise, except as may be required under the applicable securities laws.
Contact:
Mark P. de Raad
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo Rad-87® Pulse CO-Oximeter™ Garners Silver 2009 Medical Design Excellence
Award
Award Honors Product Innovation, Design and Engineering Achievement,
End-user Benefit, and Cost-effectiveness in Manufacturing and Healthcare
Delivery
Irvine, California – July 14, 2009 – Masimo (NASDAQ: MASI),
the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low-Perfusion
pulse oximetry, has received the 2009 Silver Medical Design Excellence Award in
the general hospital devices and therapeutic products category for the Masimo
Rad-87 Pulse CO-Oximeter. The award recognizes Rad-87's excellence in medical
technology engineering and design as an intuitive bedside patient monitor that
helps improve clinical efficiency and keep patients safe when a clinician can't
be at the bedside.
The
Masimo Rad-87 features the breakthrough noninvasive blood constituent monitoring
capabilities of Masimo Rainbow SET® Pulse CO-Oximetry for continuous monitoring
of hemoglobin, carbon monoxide, methemoglobin, PVI (fluid responsiveness),
perfusion index, and measure through motion pulse oximetry with upgradability to
acoustic respiration rate monitoring. Its built-in 802.11a/b/g radio allows
wireless communication with the Masimo Patient SafetyNet™ remote monitoring and
clinician notification system to provide patients with an enhanced level of
safety on general care floors. Designed for ease-of-use, the Rad-87 allows the
features clinicians need most often to be accessed with a single touch. And, as
the first Masimo Rainbow SET device with a bright white LED-based display, its
high contrast visual display allows measurements to be clearly seen from across
the room, while an innovative new device profile feature lets clinical settings
be customized and color-coded for a particular care area.
Masimo Founder and CEO, Joe E. Kiani, stated, "It is an honor to receive our
third Medical Design Excellence Award for product design and engineering
innovations that improve healthcare delivery and advance medical practices. We
received the Gold Medical Design Excellence Award in 2006 for the Masimo Rad-57
Pulse CO-Oximeter and in 2001 for the Masimo Radical Signal Extraction pulse
oximeter."
The Medical Design Excellence Awards (MDEA) competition is the only awards
program that exclusively recognizes advances in the design of medical products
and the achievements of medical device manufacturers responsible for the
groundbreaking innovations that are changing the face of healthcare. 2009 MDEA
winners were announced and honored at the June 10th ceremony during the Medical
Design & Manufacturing (MD&M) East Conference and Exposition in New
York. For more information about the Medical Design Excellence Awards—including
details about the winning products—visit www.MDEAwards.com.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted
Measure-Through-Motion-and-Low-Perfusion pulse oximetry, known as Masimo SET,
which virtually eliminated false alarms and increased pulse oximetry's ability
to detect life-threatening events. More than 100 independent and objective
studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion. In
2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a breakthrough
noninvasive blood constituent monitoring platform that can measure many blood
constituents that previously required invasive procedures. Masimo Rainbow SET
continuously and noninvasively measures total hemoglobin (SpHb™), oxygen content
(SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI™, in
addition to oxyhemoglobin (SpO2), pulse rate (PR), and
perfusion index (PI), allowing early detection and treatment of potentially
life-threatening conditions. Founded in 1989, Masimo has the mission of
"Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive
Monitoring to New Sites and Applications." Additional information about Masimo
and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our belief that the features, function and
design of the Masimo Rad-87 Pulse CO-Oximeter will enable clinicians to detect
and treat life-threatening conditions earlier, improve patient outcomes,
increase clinical efficiency gains, and reduce the cost of care for patients,
risks related to our belief that Masimo Rainbow SET Pulse CO-Oximetry technology
will provide a sufficient level of sensitivity and specificity to facilitate the
noninvasive, continuous measurement of multiple blood constituents, fluid
assessment and physiological parameters, risks related to our assumption that
the combination of Masimo Rad-87 and Masimo Patient SafetyNet will help
clinicians keep patients safe on general care floors, as well as other factors
discussed in the "Risk Factors" section of our Quarterly Report on Form 10-Q for
the fiscal quarter year ended April 4, 2009, filed with the Securities and
Exchange Commission ("SEC") on May 6, 2009, which may be
obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our
Quarterly Report on Form 10-Q for the fiscal quarter year ended April 4, 2009,
filed with the Securities and Exchange Commission ("SEC") on
May 6, 2009, whether as a result of new information, future events or otherwise,
except as may be required under the applicable securities laws.
Contact:
Dana Banks
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
New Studies Presented at European Society of Anaesthesia Further Validate
Masimo PVI™ for Noninvasive and Continuous Fluid Monitoring
Irvine, California – June 12, 2009 – Masimo (NASDAQ: MASI),
the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low-Perfusion
pulse oximetry, announced today that three new independent studies demonstrating
the clinical accuracy and utility of Masimo PVI as a noninvasive and continuous
measure of patient fluid status and responsiveness were presented this week at
the European Society of Anaesthesiology (ESA) Annual Congress in Milan, Italy.
Although fluid administration is critical to optimizing patient status and
enabling end organ preservation, unnecessary fluid administration is associated
with increased morbidity and mortality. Traditional invasive measurements such
as central venous pressure are not reliable to predict whether a patient will
benefit from fluid administration, and newer more reliable methods to predict
fluid responsiveness are also invasive and costly. Multiple recent studies
have shown that Masimo PVI provides a simple and cost-effective method for
accurate, noninvasive, and continuous monitoring of fluid responsiveness. The
three studies presented at the ESA reinforce the accuracy of PVI compared to
invasive measures and highlight its value for before, during, and after
anesthesia.
Does the Pleth Variability Index correlate with stroke volume
variation?
Researchers in the Department of Anesthesiology at the
Hamamatsu University School of Medicine in Hamamatsu-City, Japan, compared the
accuracy of Masimo PVI measurements with Stroke Volume Variation (SVV) obtained
via an invasive catheter (Flo Trac™) in 13 patients. After analyzing data
recorded at five points—in the supine position, lateral position, start and end
of one-lung ventilation, and in the supine position again—researchers found a
significant correlation between PVI and SVV (r = 0.75; p = 0.02). The study
concluded that "Our results suggest that an accurate prediction of fluid
responsiveness can be obtained non-invasively using the PVI." 1
The Change of Upper Limbs PVI in Spinal Block (Comparison in High
Spinal Block and Non-High Spinal Block)
At the Tokai University
School of Medicine in Tokyo, Japan, researchers examined how PVI in the upper
limbs of patients undergoing caesarean procedures for hernia surgery changed in
response to the level of spinal block reached. PVI was recorded in all patients
before and every two minutes after spinal block was performed. In patients
reaching the anesthetic level C-area—identified as the high spinal block
group—PVI decreased. In patients who did not reach the C-area—identified as the
non-high spinal block group—PVI of the upper limbs did not change
significantly. Researchers summarized that high spinal block dilates vessels
and increases blood flow in the upper limbs, which in turn, is shown by
decreased PVI.2
Perfusion Index and Pleth Variability Index After Administration of
General Anesthetic Agents
In this study, anesthesiologists at the
Teikyo University School of Medicine in Tokyo, Japan, analyzed changes in PVI
and Masimo perfusion index (PI) in 21 surgical patients before and after
administration of general anesthetic agents. After administration of general
anesthetic agents and 10ml/kg/hr of fluid during induction, PVI significantly
decreased from 22.9±8.1 to 17.1±7.2 (p<0.05) and PI significantly increased
from 2.1±1.7 to 3.8±2.3 (p<0.001), leading researchers to conclude that "an
increase in peripheral perfusion and improvement of fluid status and preload"
occurred "after administration of general anesthetic agents and intravenous
fluid administration during anesthesia induction."3
Michael O'Reilly, MD, EVP of Medical Affairs at Masimo, stated; "These
studies confirm what previous results have shown—that PVI's accuracy at
predicting fluid responsiveness is better than traditional measurements and
similar to the newer invasive monitoring techniques at fraction of the cost and
complexity. Because PVI is noninvasive and is available from the same sensor
used with Masimo Rainbow SET® Pulse CO-Oximeters, it has the strong potential to
expand and improve fluid monitoring and management in patients who would
otherwise not be monitored with the newer invasive techniques."
PVI is available as part of Masimo Rainbow SET Pulse CO-Oximetry™—the
first-and-only technology platform to noninvasively measure blood constituents
and fluid responsiveness that previously required invasive procedures,
including: noninvasive and continuous total hemoglobin (SpHb™), oxygen content
(SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI, in addition
to the 'gold standard' Measure-Through Motion and Low-Perfusion performance of
Masimo SET® oxyhemoglobin (SpO2), pulse rate (PR), and
perfusion index (PI).
1 Y. Kawashima, Y. Shiraishi, S. Sato. Does the Pleth
Variability Index correlate with stroke volume variation?. Eur J
Anaesthesiol 2009; 26 (Suppl 45): 3AP5-9
2 K. Takeyama, M.
Yoshikawa. The change of upper limbs PVI in spinal block (The comparison in high
spinal block and non-high spinal block). Eur J Anaesthesiol 2009; 26
(Suppl 45): 3AP5-1
3 J. Mizuno, Y. Morita, A. Kakinuma, S. Morita.
Perfusion Index and Pleth Variability Index after administration of general
anesthetic agents. Eur J Anaesthesiol 2009; 26 (Suppl 45):
4AP8-3
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted
Measure-Through-Motion-and-Low-Perfusion pulse oximetry, known as Masimo SET,
which virtually eliminated false alarms and increased pulse oximetry's ability
to detect life-threatening events. More than 100 independent and objective
studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion. In
2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a breakthrough
noninvasive blood constituent monitoring platform that can measure many blood
constituents that previously required invasive procedures. Masimo Rainbow SET
continuously and noninvasively measures total hemoglobin (SpHb™), oxygen content
(SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and PVI™, in
addition to oxyhemoglobin (SpO2), pulse rate (PR), and
perfusion index (PI), allowing early detection and treatment of potentially
life-threatening conditions. Founded in 1989, Masimo has the mission of
"Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive
Monitoring to New Sites and Applications." Additional information about Masimo
and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the repeatability of
clinical results, risks related to our belief that Masimo SpHb and PVI will
provide a sufficient level of sensitivity and specificity to facilitate
continuous measurement capabilities and deliver clinical improvement over
alternative hemoglobin and fluid assessment measurement capabilities to allow
for further adoption of the technology, as well as other factors discussed in
the "Risk Factors" section of our Quarterly Report on Form 10-Q for the fiscal
quarter year ended April 4, 2009, filed with the Securities and Exchange
Commission ("SEC") on May 6, 2009, which may be obtained for
free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our forward-looking
statements are reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press release are
expressly qualified in their entirety by the foregoing cautionary statements.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of today's date. We do not undertake any
obligation to update, amend or clarify these forward-looking statements or the
"Risk Factors" contained in our Quarterly Report on Form 10-Q for the fiscal
quarter year ended April 4, 2009, filed with the Securities and Exchange
Commission ("SEC") on May 6, 2009, whether as a result of new
information, future events or otherwise, except as may be required under the
applicable securities laws.
Contact:
Dana Banks
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation. Flo Trac is a
registered trademark of Edwards Lifesciences.
|
|
|
|
|
|
Masimo Debuts New Rad-8® Pulse Oximeter to Largest Gathering of Sleep Specialists from Around the World at SLEEP 2009
New Features and Design Optimize Care and Process Efficiencies for
Clinicians in both the Sleep Center and Homecare Environments
Irvine, California – June 9, 2009 – Masimo (NASDAQ: MASI),
the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low-Perfusion
pulse oximetry, announced today the debut of its new compact, lightweight Rad-8
pulse oximeter at SLEEP 2009, the 23rd Annual Meeting of the Associated
Professional Sleep Societies (APSS), June 6-11, 2009 in Seattle, Washington.
Newly redesigned with greater clinical efficiency in mind, the new Masimo Rad-8
has a streamlined look and a host of easy-to-use special features that enable
sleep clinicians to more effectively and efficiently monitor, diagnose, and care
for patients with sleep disorders.
According to the National Institutes
of Health (NIH), more than 70 million Americans are affected by chronic sleep
disorders. Sleep apnea is a very common yet serious sleep disorder where a
person's breathing is uncontrollably and repeatedly interrupted during sleep,
resulting in very brief or prolonged periods of oxygen deprivation. Serious
problems can result from the oxygen deprivation of sleep apnea—including: heart
disease, high blood pressure and learning/memory problems—and, if left
untreated, sleep apnea can be life-threatening.1
Pulse oximetry is the standard method for assessing oxygenation in sleep
testing and, as such, plays a critical role in treatment decisions, including
whether to administer Continuous Positive Airway Pressure (CPAP) therapy or
perform surgery. Inaccurate pulse oximetry data can have serious implications
because false pulse oximetry desaturations can lead to misdiagnosis and
inappropriate treatment or surgery, while missed true desaturations can prevent
correct diagnosis and potentially lifesaving treatment. The new Rad-8 combines
the unmatched sensitivity and specificity of Masimo SET® Measure-Through Motion
and Low-Perfusion pulse oximetry—clinically-proven to reduce false alarms by
over 90% and increase capture of true desaturation events by 98%—with enhanced
functionality to help clinicians better capture, analyze, and report vital
oxygen saturation, pulse rate, and perfusion data for improved sleep disorder
detection.
The superior fidelity of Masimo SET has been clinically-shown to outperform
other pulse oximeters in the accurate identification and quantification of brief
dips in oxygen saturation due to apneas and hypopneas—an important marker and
measure of severity for Obstructive Sleep Apnea (OSA) diagnosis and treatment.
In fact, previous research conducted at Montreal Children's Hospital in Quebec
found that using a Masimo pulse oximeter with very short averaging time was not
only more accurate in detecting true desaturation events, including brief dips
in oxygen saturation as well as larger ones, but could also "significantly
reduce workload and improve reliability of desaturation detection" over other
pulse oximeters. Study findings confirmed that Masimo detected 98.6% of true
desaturations, while the N-395 detected only 45.3%, leading researchers to
conclude that "the sensitivity and motion artifact rejection characteristics of
the Nellcor N-395 oximeter are not adequate for a pediatric sleep laboratory
setting."2
And, based on clinician input,
Rad-8 now features an intuitive user-interface and easy menu navigation to save
time and enable faster, easier set-up, and operation, while one-touch quick
access buttons allow clinicians to engage special features in an instant. New
user-selectable alarm settings make it quick and easy for clinicians to set and
save configurations for specific patient monitoring needs and unique clinical
applications. In addition, 72-hour trending, configurable Sleep and Home modes,
and enhanced data collection/reporting compatibility make the new Rad-8 the
ideal patient monitoring solution for sleep center, home, sub-acute, and
transport applications.
1 National Institutes of Health "Frontiers of
Knowledge in Sleep and Sleep Disorders: Opportunities for Improving Health and
Quality of Life." March 2004. http://www.nhlbi.nih.gov/about/ncsdr/research/research-a.htm
2 Robert Brouillette, MD, Jacinthe Lavergne, RRT, Andra
Leimanis, BSc, Gillian Nixon, MB ChB, FRACP, Sylvia Ladan, RRT, Christine
McGregor, RRT. "Differences in Pulse Oximetry Technology can Affect Detection of
Sleep-Disordered Breathing in Children." Anesth Analg 2002; 94: S47-S53.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our belief that the commercial availability of
the new Rad-8 will serve to increase adoption, market share and/or revenues for
the company, risks that Masimo SET sensitivity and specificity performance will
be duplicated in other studies and applications, risks related to our assumption
that the new Rad-8 will enable clinicians to more effectively and efficiently
monitor, diagnose, and care for patients with sleep disorders, as well as other
factors discussed in the "Risk Factors" section of our Quarterly Report on Form
10-Q for the fiscal quarter year ended April 4, 2009, filed with the Securities
and Exchange Commission ("SEC") on May 6, 2009, which may be
obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our
Quarterly Report on Form 10-Q for the fiscal quarter ended April 4, 2009,
whether as a result of new information, future events or otherwise, except as
may be required under the applicable securities laws.
Contact:
Dana Banks
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation. Other trademarks used
herein are the property of their respective owners.
|
|
|
|
|
|
Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly
Increases Morbidity and Mortality After Surgery
Studies Advocate Blood Conservation and Appropriate Indicators for
Transfusion
Irvine, California – June 8, 2009 – Masimo (NASDAQ: MASI),
the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low-Perfusion
pulse oximetry, announced today that two new studies - one conducted in patients
undergoing general surgery and published in the Journal of American College
of Surgeons and another conducted in patients undergoing cardiac surgery
and published in the Anesthesia & Analgesia- provide additional new
evidence that transfusion of just one or two units of blood significantly
increases infection, pneumonia, sepsis, and mortality after surgery.1,2 These studies suggest that transfusions and their
associated risks could be "largely avoided" through implementation of better
blood management techniques and "more appropriate indicators" for transfusions.
Blood transfusions may be necessary to ensure survival when a patient is
bleeding heavily or has severe symptomatic anemia. However, transfusions are
also given in the presence of stable anemia or when significant blood loss is
expected but does not occur. These two new studies add to the growing evidence
that transfusions carry life-threatening risks and urge that in the absence of
benefit from transfusion, avoidance of transfusions through the use of more
restrictive transfusion practices could improve patient outcomes.
In the general surgery study, researchers evaluated 125,177 patients from 121
hospitals and showed that after adjusting for all risk variables, transfusion of
a single unit of blood increased 30-day mortality by 32% and morbidity
(pneumonia, sepsis, or surgical site infection) by 23%. Transfusion of two units
of blood increased the mortality risk by 38% and morbidity risk by 40%. In the
cardiac surgery study, researchers evaluated long-term survival of 9,079
patients at eight hospitals and showed that transfusion of one or two units of
blood increased six-month mortality 67% and five-year mortality 16% .
"These two new studies demonstrate that the risk of blood transfusion is
significant and thus we should avoid transfusions when ever possible," stated
Dr. Aryeh Shander, Clinical Professor of Anesthesiology, Medicine and Surgery at
Mt. Sinai School of Medicine in New York, NY. "The current practice of using
intermittent, invasive measurements of hemoglobin to help guide transfusion
decisions may contribute to unnecessary blood transfusions. Blood transfusion
should not simply be based on any particular level of hemoglobin but rather a
thorough evaluation of the patient, including whether hemoglobin levels are
stable or changing. The ability to continuously and noninvasively trend a
patient's hemoglobin level offers a breakthrough in blood management. Continuous
and noninvasive SpHb™ monitoring has the potential to greatly improve clinical
decision-making and reduce patient exposure to allogeneic transfusion, reduce
complications, and preserve a precious resource and costs."
Masimo continuous and noninvasive hemoglobin monitoring (SpHb) technology is
available as part of the upgradeable Masimo Rainbow SET® Pulse CO-Oximetry
platform.
1 Bernard AC et al. Intraoperative transfusion of 1U
to 2U of packed red blood cells is associated with increased 30-day mortality,
surgical site infection, pneumonia, and sepsis in general surgery patients.
Journal of the American College of Surgeons. 2009;208:931-937.
2
Surgenor SD et al, for the Northern New England Cardiovascular Disease Study
Group. The Association of Perioperative Red Blood Cell Transfusions and
Decreased Long-Term Survival After Cardiac Surgery. Anesthesia & Analgesia
2009; 108:1741-1746.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the accuracy and
repeatability of the Capgemini results; risks related to our assumption that
Masimo SpHb technology and products will provide faster, easier and safer means
for measuring total hemoglobin and will deliver a sufficient level of clinical
improvement over alternative measurement capabilities to enable more restrictive
transfusion practices, as well as other factors discussed in the "Risk Factors"
section of our Quarterly Report on Form 10-Q for the fiscal quarter year ended
April 4, 2009, filed with the Securities and Exchange Commission
("SEC") on May 6, 2009, which may be obtained for free at the
SEC's website at www.sec.gov. Although we
believe that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of today's date. We do not undertake any obligation to update,
amend or clarify these forward-looking statements or the "Risk Factors"
contained in our Quarterly Report on Form 10-Q for the fiscal quarter ended
April 4, 2009, whether as a result of new information, future events or
otherwise, except as may be required under the applicable securities laws.
Media Contact:
Dana Banks,
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Leading University Hospital Completes System-wide Conversion to Masimo SET® Pulse
Oximetry
Standardizing on Masimo SET Allows Clinicians to Overcome the Limitations
of Conventional Pulse Oximetry, Offering Significant Clinical Advancements
Irvine, California—June 3, 2009 – Masimo, the inventor of
Pulse CO-Oximetry™ and Measure-Through Motion and Low-Perfusion Pulse Oximetry,
today announced it has completed the conversion of Duke University Hospital to
Masimo SET pulse oximetry technology.
"Ultimately, the decision to convert to Masimo SET came down to what was best
for patients," said Tony Caruso, Senior Director of Clinical Engineering, Duke
University Health System in Durham, North Carolina. "It is critically important
for us to access technologies that result in improvements in patient care. In
this case, we believe we have improved our ability to increase detection of true
clinical events earlier."
"In the emergency department, there are many times when we don't have time to
second-guess our pulse oximeter performance, wonder whether the measurements we
are getting are accurate, or take excessive time to obtain a reading," said
Frank DeMarco, RN, emergency department clinical operations director, Duke
University Hospital. "This technology offers us improvements over the system we
had used previously and, hopefully, will contribute to more effective clinical
operations."
Masimo Founder and CEO, Joe E. Kiani, stated, "We are happy to be the pulse
oximetry standard-of-care solution chosen by the Duke University Hospital system
to noninvasively and continuously monitor their patients. With the unprecedented
accuracy and performance of Masimo SET, clinicians at Duke are afforded the
opportunity to better monitor, manage and treat patients using advanced pulse
oximetry capabilities that allow them to detect life-threatening events
earlier."
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumption that Masimo SET and Masimo
Rainbow SET will deliver a sufficient level of clinical improvement over
alternative pulse oximetry and noninvasive patient monitoring solutions to allow
for further adoption of the technology at other hospitals, risks related to our
assumption that Duke University Hospital's system-wide conversion to Masimo
technology will serve to substantially increase revenues, as well as other
factors discussed in the "Risk Factors" section of our Quarterly Report on Form
10-Q for the fiscal quarter year ended April 4, 2009, filed with the Securities
and Exchange Commission ("SEC") on May 6, 2009, which may be
obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our
Quarterly Report on Form 10-Q for the fiscal quarter year ended April 4, 2009,
filed with the Securities and Exchange Commission ("SEC") on
May 6, 2009, whether as a result of new information, future events or otherwise,
except as may be required under the applicable securities laws.
Contact:
Dana Banks
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation. Other trademarks used
herein are the property of their respective owners.
|
|
|
|
|
|
New NIH-Funded Study Shows Masimo Rainbow SET® May Help Clinicians Assess
Oxygenation in Children with Sickle Cell Disease
Study Presented at the American Thoracic Society by Researchers at The
Children's Hospital of Philadelphia Confirms Accuracy and Clinical Value of
Noninvasive SpCO® and SpMet®
Irvine, California – May 19, 2009 – Masimo (NASDAQ: MASI),
the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low-Perfusion
pulse oximetry, announced today that a new independent clinical study, funded by
the National Institutes of Health (NIH) and presented at the American Thoracic
Society in San Diego, CA, shows that the noninvasive measurement of
carboxyhemoglobin (SpCO) and methemoglobin (SpMet) with Masimo Rainbow SET Pulse
CO-Oximetry is accurate and may help clinicians better detect hypoxemia—a
potentially life-threatening lack of oxygen in the blood—in children with sickle
cell disease.
Sickle cell disease is an inherited blood disorder characterized by
abnormally-shaped red blood cells that compromise vital blood and oxygen supply
to the tissues and organs, causing life-threatening complications. The presence
of carboxyhemoglobin and methemoglobin in a sickle cell patient's blood reduces
oxygen supply further because these dyshemoglobins that take the place of normal
oxyhemoglobin lack the ability to carry any oxygen. However, conventional
two-wavelength pulse oximeters are incapable of measuring carboxyhemoglobin and
methemoglobin levels and as a result cannot provide clinicians with an accurate
picture of their patients' true oxygenation status in the presence of
dyshemoglobins.
Masimo Rainbow SET—the first-and-only technology that noninvasively and
continuously measures SpCO and SpMet, in addition to total hemoglobin (SpHb™),
oxygen content (SpOC™), PVI, oxyhemoglobin (SpO2), pulse
rate, and PI—allows for faster and more accurate assessment of the patient's
true oxygenation, which may help to advance the care and management of patients
with sickle cell disease.
In the study presented, Dr. Caboot and colleagues at Children's Hospital of
Philadelphia simultaneously compared SpCO and SpMet measurements obtained
noninvasively using the Masimo Radical-7 Pulse CO-Oximeter with invasive blood
draws and laboratory analysis of carboxyhemoglobin and methemoglobin in 38
asymptomatic children (2-18 years of age) with sickle cell disease. The
researchers found SpCO (with a bias of 0.1% and precision of ? 2.2%) and SpMet
(with a bias of -0.19% and precision of ? 0.39%) to be closely comparable to
invasive laboratory measurements. Researchers concluded that the Masimo
Radical-7 Pulse CO-Oximeter "is useful in measuring carboxyhemoglobin and
methemoglobin levels in pediatric patients with sickle cell disease."
Masimo Executive Vice President of Medical Affairs, Dr. Michael O'Reilly,
stated, "This research not only reinforces the clinical accuracy of SpCO and
SpMet in assessing the true oxygenation of patients, but also highlights the
importance of measuring these dyshemoglobins while managing and treating
pediatric patients with sickle cell disease."
Caboot, J.B., Jawad, A.F., McDonough, J.M., Bowdre, C.Y.,
Ohene-Frempong, K., Smith-Whitley, K., Allen, J.L. "Non-Invasive Measurements of
Carboxyhemoglobin and Methemoglobin in Pediatric Patients with Sickle Cell
Disease." Am. J. Respir. Crit. Care Med., Apr 2009; 179: A4788.
Presented at the American Thoracic Society (ATS) Annual Meeting, May 19, 2009,
San Diego, California. http://www.abstracts2view.com/ats09/view.php?nu=ATS09L_2057
Editor's Note: The study abstract available online depicts study
data and results at the time of the "call for abstracts" submission deadline,
although the study was on-going and continued beyond the submission date. The
data and results captured in this press release represent the updated, final
study data and results presented at the ATS International Conference on May 19,
2009.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the repeatability of
clinical results and our belief that SpCO and SpMet will improve clinical
assessments and the identification of hypoxemia in patients with sickle cell
disease, as well as other factors discussed in the "Risk Factors" section of our
Quarterly Report on Form 10-Q for the fiscal quarter year ended April 4, 2009,
filed with the Securities and Exchange Commission ("SEC") on
May 6, 2009, which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our
Quarterly Report on Form 10-Q for the fiscal quarter ended April 4, 2009,
whether as a result of new information, future events or otherwise, except as
may be required under the applicable securities laws.
Media Contact:
Dana Banks,
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
New Study Funded by the National Institutes of Health (NIH) Finds Masimo SpCO® May Provide a Noninvasive Measure of Acute Asthma Severity in Children
Study Presented at the Pediatric Academic Societies Annual Meeting by
Vanderbilt University Researchers Shows a Statistically-Significant Association
between SpCO and Measures of Lung Function
Irvine, California – May 13, 2009 – Masimo (NASDAQ: MASI),
the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low-Perfusion
pulse oximetry, announced today that a new clinical study conducted in the
Emergency Department at Vanderbilt Children's Hospital shows that the
noninvasive measurement of carbon monoxide in the blood with Masimo Rainbow SET®
Pulse CO-Oximetry (SpCO) may help clinicians better assess acute asthma severity
during and after treatment. The study was funded by the National Institutes of
Health (NIH) and presented at the Pediatric Academic Societies (PAS) Annual
Meeting on May 5, 2009.1
Asthma is a life-threatening inflammatory disease of the airways that affects
more than 6 million children in the U.S., leading to more pediatric
hospitalizations than any other cause.2 However,
a common challenge for children with asthma is the requirement of a forced
expiratory test called spirometry. In contrast to spirometry, SpCO—a noninvasive
measurement easily obtained from Masimo Rainbow SET Pulse CO-Oximeters and
sensors already used in many hospitals—does not require patient instruction or
breathing effort. As a result, SpCO may help to improve the assessment of asthma
severity and response to treatment in young children and patients who are
unconscious, heavily sedated, unable to understand and follow instructions, or
have limitations that would interfere with vigorous respiratory efforts.
"We have limited measures to assess severity of acute asthma exacerbations
and the finding of an association between carboxyhemoglobin (SpCO) by
multi-wavelength Pulse CO-Oximeter may have clinical importance," stated Donald
H. Arnold, MD, MPH, Associate Professor of Emergency Medicine and Pediatrics,
Vanderbilt University School of Medicine, Nashville, Tennessee. "Our preliminary
results suggest that SpCO is a measure of oxidative stress and inflammation in
pediatric patients with acute asthma exacerbations."
Dr. Arnold and colleagues at Vanderbilt used the Masimo Radical-7 Pulse
CO-Oximeter to measure SpCO in 139 children (5-10 years of age) during acute
asthma exacerbations and 2-hours after initiation of corticosteroid and
bronchodilator treatment. Comparing SpCO measurements to conventional measures
of airway obstruction and inflammation, researchers found a significant
association between SpCO and percent predicted Forced Expiratory Volume in 1
Second (%FEV1, p = 0.001) and airway resistance (p = 0.04),
as well as a trend with exhaled nitric oxide (eNO, p = 0.1). Study findings
showed that for every 6% increase in SpCO, there was an associated 79%
proportionate decrease in lung function (%FEV1, p=0.015) and
a trend indicating SpCO may predict lung function after 2-hours of treatment, as
measured by the change in %FEV1 (p = 0.06). Researchers
concluded that SpCO may "represent a noninvasive, effort-independent measure of
acute asthma disease severity as assessed by physiologic measures."
Masimo Executive Vice President of Medical Affairs, Dr. Michael O'Reilly,
stated, "This study adds new evidence that expands the value of Masimo's Pulse
CO-Oximetry SpCO measurement. The researchers at Vanderbilt Children's Hospital
have shown that the ability to easily and quickly perform SpCO measurements on
almost any patient without cooperation or risk has the potential to enable more
immediate, accurate, and reliable asthma severity assessment."
1 D. H. Arnold, T. Gebretsadik, D. Resha, T. V.
Hartert. "Association of Carboxyhemoglobin Levels with Clinical Measures of
Acute Asthma Severity." Presented at the Pediatric Academic Societies (PAS)
Annual Meeting, May 5, 2009, Baltimore, Maryland. http://www.abstracts2view.com/pas/view.php?nu=PAS09L1_3201
2 Centers for Disease Control and Prevention. "Current Asthma
Prevalence" 2005. http://www.cdc.gov/nchs/products/pubs/pubd/hestats/ashtma03-05/asthma03-05.htm
Editor's Note: The study abstract available online via the PAS
website depicts study data and results at the time of the "call for abstracts"
and submission deadline (late 2008), although the study was on-going and
continued beyond the submission deadline. The data and results captured in this
press release represent the actual study data and results presented at the PAS
Annual Meeting on May 5, 2009.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the repeatability of
clinical results, and our belief that noninvasive SpCO measurements will prove
to be an effective clinical indicator of lung function and acute asthma severity
in children or other patients such that SpCO measurement can effectively
substitute for spirometry, as well as other factors discussed in the "Risk
Factors" section of our Annual Quarterly Report on Form 10-Q for the fiscal
quarter year ended April 4, 2009, filed with the Securities and Exchange
Commission ("SEC") on May 6, 2009, which may be obtained for
free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our forward-looking
statements are reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press release are
expressly qualified in their entirety by the foregoing cautionary statements.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of today's date. We do not undertake any
obligation to update, amend or clarify these forward-looking statements or the
"Risk Factors" contained in our Quarterly Report on Form 10-Q for the fiscal
quarter ended April 4, 2009, whether as a result of new information, future
events or otherwise, except as may be required under the applicable securities
laws.
Media Contact:
Dana Banks,
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo to Present at the Deutsche Bank 34th Annual Health Care Conference
IRVINE, Calif., May 12, 2009 – Masimo Corporation (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and
Low-Perfusion pulse oximetry, today announced that its management is scheduled
to present at the Deutsche Bank 34th Annual Health Care Conference in Boston,
Massachusetts, on Tuesday, May 19, 2009, at 2:35 p.m. EDT. A live audiocast of
the presentation will be available on the Masimo website at www.masimo.com. A replay of the audiocast will
be available following the live presentation.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care-helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET
Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Rainbow SET continuously and noninvasively measures total
hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at http://www.masimo.com.
Masimo
Corporation
Investor Contact:
Mark P. de
Raad
Executive Vice President and Chief Financial Officer
Masimo
Corporation
(949) 297-7080
mderaad@masimo.com
Media Contact:
Dana Banks
Manager, Public
Relations
Masimo Corporation
(949) 297-7348
dbanks@masimo.com
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo Reports First Quarter 2009 Financial Results
Q1 2009 Highlights:
- Earnings per share increased by 47% to $0.22 per share from $0.15 in prior
year
- Product revenues increased approximately 25% to $74.5 million from $59.7
million in prior year
Irvine, California, May 5, 2009 – Masimo Corporation
(NASDAQ: MASI), the inventor of Pulse CO-Oximetry and Measure-Through Motion and
Low Perfusion pulse oximetry, today announced its financial results for the
first quarter of 2009.
For the first quarter of 2009, Masimo reported product revenues of $74.5
million representing a 24.7% increase over $59.7 million for the first quarter
of 2008. Including royalty revenues, Masimo reported total 2009 first quarter
revenues of $85.5 million compared to $71.1 million for the first quarter of
2008. For the first quarter of 2009, Masimo reported earnings per share of $0.22
compared to $0.15 per common share for the first quarter of 2008.
Masimo reported that it shipped 27,700 Masimo SET and Masimo Rainbow SET
oximetry units, excluding handheld units, during the first quarter of 2009,
resulting in at least 587,000 of Masimo SET and Masimo Rainbow SET pulse
oximeters in use worldwide. In the first quarter of 2009, revenues from Masimo
Rainbow SET products increased to $3.1 million from $2.7 million in the same
prior year quarter.
Joe E. Kiani, Chairman and Chief Executive Officer of Masimo, said, "Despite
the continuing difficult economic environment, we are happy that our revenues
and earning were better than we had expected in Q1. We believe that this
performance is largely due to our gold standard Masimo SET pulse oximetry
technology and our expanding Masimo Rainbow SET Pulse CO-Oximetry platform,
including the March 23, 2009 commercial release of total hemoglobin, the world's
first continuous non-invasive total hemoglobin monitor."
Masimo also reported that as of April 4, 2009, cash and cash equivalents
totaled $152.2 million, up from $146.9 million at January 3, 2009.
Conference Call
Masimo will hold a conference call today
at 2:00 p.m. PT (5:00 p.m. ET) to discuss the results. The dial-in numbers are
(888) 520-7182 for domestic callers and +1 (706) 679-9937 for international
callers. The reservation number for both dial-in numbers is 95073118. A live web
cast of the conference call will be available online from the "Investor
Relations" page of the Company's corporate web site at www.masimo.com. After the live web cast, the
call will remain available on Masimo's website through June 5, 2009. In
addition, a telephonic replay of the call will be available until May 19, 2009.
The replay dial-in numbers are (800) 642-1687 for domestic callers and +1 (706)
645-9291 for international callers. Please use reservation code 95073118.
About Masimo
Masimo (NASDAQ: MASI) develops,
manufactures and markets innovative monitoring technologies that significantly
improve patient care—helping solve "unsolvable" problems. In 1995, the Company
debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo
SET, which virtually eliminated false alarms and increased pulse oximetry's
ability to detect life-threatening events. More than 100 independent clinical
and laboratory studies demonstrate Masimo SET provides the most reliable
SpO2 and pulse rate measurements even under the most
challenging clinical conditions, including patient motion and low peripheral
perfusion. In 2005, Masimo introduced Masimo Rainbow SET, a breakthrough
noninvasive blood constituent monitoring platform that can measure many blood
constituents that previously required invasive procedures. Rainbow SET
continuously and noninvasively measures total hemoglobin (SpHb®), oxygen content
(SpOC™), carboxyhemoglobin (SpCO® ), methemoglobin (SpMet®) and plethysmograph
variability index (PVI®), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com. Any information contained in,
or that can be accessed through, our website is not incorporated by reference
into, nor is it in any way a part of, this release.
Forward-Looking Statements
All statements other than
statements of historical facts included in this press release that address
activities, events or developments that we expect, believe or anticipate will or
may occur in the future are forward-looking statements including, in particular,
the statements about: our financial condition, results of operations, prospects
and business generally; and expectations regarding our ability to design and
deliver innovative new noninvasive technologies. These forward-looking
statements are based on management's current expectations and beliefs and are
subject to uncertainties and factors, all of which are difficult to predict and
many of which are beyond our control and could cause actual results to differ
materially and adversely from those described in the forward-looking statements.
These risks include, but are not limited to, those related to: our dependence on
Masimo SET and Masimo Rainbow SET products and technologies for substantially
all of our revenue; any failure in protecting our intellectual property exposure
to competitors' assertions of intellectual property claims; the highly
competitive nature of the markets in which we sell our products and
technologies; any failure to continue developing innovative products and
technologies; the lack of acceptance of any new products and technologies of
ours; obtaining regulatory approval of our current and future products and
technologies, including the recently announced total hemoglobin measurement; the
risk that the implementation of our international realignment, even if timely
implemented, will not produce the anticipated operational and financial
benefits, including a lower effective tax rate; the loss of our customers the
failure to retain and recruit senior management; product liability claims
exposure; a failure to obtain expected returns from the amount of intangible
assets we have recorded; the maintenance of our brand; the impact of the decline
in the worldwide credit markets on us and our customers; the amount and type of
equity awards that we may grant to employees and service providers in the
future; and other factors discussed in the "Risk Factors" section of our most
recent reports filed with the Securities and Exchange Commission ("SEC"), which
you may obtain for free on the SEC's website, at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. You are cautioned not to
place undue reliance on these forward-looking statements, which speak only as of
the date hereof, even if subsequently made available by us on our website or
otherwise. We do not undertake any obligation to update, amend or clarify these
forward-looking statements, whether as a result of new information, future
events or otherwise, except as may be required under applicable securities laws.
Masimo Corporation
Investor Contact:
Mark P. de Raad
Executive Vice President and Chief Financial
Officer
Masimo Corporation
(949) 297-7080
mderaad@masimo.com
Media Contact:
Dana Banks
Manager, Public Relations
Masimo Corporation
(949) 297-7348
dbanks@masimo.com
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpCO, SpMet, PVI, Pulse CO-Oximetry and Pulse
CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
FEMA Adds Masimo Rad-57® Pulse CO-Oximeter™ to Required Medical Equipment List
Citing Need for Early and Accurate Carbon Monoxide Exposure Detection
Following Disasters, Agency Unanimously Approves and Authorizes Funds to
Purchase Rad-57's
Irvine, California – April 28, 2009 – Masimo (NASDAQ: MASI),
the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low-Perfusion
pulse oximetry, announced today that the Masimo Rad-57 Pulse CO-Oximeter has
been added to the Federal Emergency Management Agency's (FEMA) list of required
health and safety equipment for all Urban Search & Rescue (US&R) task
forces throughout the United States. FEMA authorizes funding for each of its
US&R task forces to purchase multiple Rad-57's, enabling them to quickly,
accurately and noninvasively detect carbon monoxide (CO) poisoning on the scene
of disaster recovery operations.
FEMA has 28 national US&R task forces staffed and equipped to conduct
round-the-clock search and rescue operations following earthquakes, tornadoes,
floods, hurricanes, aircraft accidents, hazardous materials spills, and
catastrophic structure collapses. Search and rescue operations often function in
confined or poorly ventilated spaces with gas-powered equipment producing
elevated levels of CO, which until now had been an overlooked hazard. Adding the
Rad-57 to its mandatory medical equipment cache now allows FEMA's US&R task
forces to quickly, noninvasively evaluate and address the significant health and
safety risks associated with CO poisoning for both civilians and rescue
personnel in the urban search and rescue environment—helping to save and sustain
lives, minimize suffering and enhance safety.
"Early and accurate CO exposure detection is important for successful
mitigation and treatment of carbon monoxide poisoning," stated Neil Hampson, MD,
Medical Director, Center for Hyperbaric Medicine at the Virginia Mason Medical
Center in Seattle, Washington. "The Rad-57 will allow FEMA's US&R teams to
swiftly, thoroughly and easily assess and diagnose CO poisoning to increase
their public safety efforts in the urban search and response environment."
According to the Centers for Disease Control and Prevention (CDC), carbon
monoxide—a common, yet lethal poison produced whenever any carbon-based fuel,
such as gas, oil, kerosene, wood, or charcoal is burned—presents a significant
two-fold risk during a disaster when "chemicals are most commonly released from
businesses and industries, storage tanks, agricultural facilities and homes,"
and "when power outages occur, the use of alternative sources of fuel or
electricity cause CO to build up." The most common symptoms of CO poisoning are
headache, dizziness, weakness, nausea, vomiting, chest pain, and confusion,
while high levels of CO inhalation can cause loss of consciousness and death.
Unless suspected, CO poisoning can be difficult to diagnose because the symptoms
mimic other illnesses.
Joe Kiani, Founder and CEO of Masimo, stated, "When elevated CO levels are
present, disaster often strikes a second time, placing victims and their brave,
unsuspecting rescuers in grave jeopardy. This is now a preventable disaster for
rescuers and victims alike with Masimo Rad-57 in action on the front lines of
U.S. disaster search and rescue efforts."
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumption that the Rad-57 will deliver a
sufficient level of sensitivity and specificity for improved CO detection over
alternative methods to facilitate rapid diagnosis and treatment in the urban
search and rescue environment, risks related to our belief that prior positive
results and clinical outcomes achieved by the Rad-57 will be repeated in future
incidents, and as well as other factors discussed in the "Risk Factors" section
of our Annual Report on Form 10-K for the fiscal year ended January 3, 2009,
filed with the Securities and Exchange Commission ("SEC") on
March 4, 2009, which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our Annual
Report on Form 10-K for the fiscal year ended January 3, 2009, whether as a
result of new information, future events or otherwise, except as may be required
under the applicable securities laws.
Contact:
Dana Banks
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation. Other trademarks used
herein are the property of their respective owners.
NOTE TO REPORTERS AND EDITORS:
The CDC case report,
titled: "Carbon Monoxide Kills Three Volunteer Firefighters Inside Well in
Pennsylvania," available online at: http://www.cdc.gov/niosh/face/In-house/full9030.html,
illustrates the significant tragedy and inherent risks associated with rescue
attempts in confined or poorly ventilated area where dangerously elevated CO
levels are present.
|
|
|
|
|
|
Capgemini Releases New Study on Financial Impact of Masimo Noninvasive and Continuous Hemoglobin (SpHb™)
Hospital-wide Implementation of Masimo Rainbow SET® Pulse CO-Oximetry™
Could Generate Nearly $500,000 in Net Annual Cost Savings and Financial
Gains
Irvine, California – April 16, 2009 – Masimo (NASDAQ: MASI),
the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low-Perfusion
pulse oximetry, announced today that Capgemini, a leading supplier of global
consulting and technology services, has released a study showing that a typical
500 bed hospital incorporating Masimo Rainbow SET Pulse CO-Oximetry into its
clinical standards and care pathways could generate nearly $500,000 in net
annual cost savings and financial gains.
Capgemini reported that significant financial benefits could be derived from
incorporating noninvasive total hemoglobin (SpHb) by helping clinicians prevent
unnecessary blood transfusions, identify internal bleeding earlier, and increase
patient throughput. The study concluded that "whether considered on a
per-patient, department, or hospital-wide analysis, there are significant
clinical and financial benefits to implementing Pulse CO-Oximetry technology."
Masimo commissioned the Capgemini study for a third-party evaluation of the
potential financial benefits of Masimo Rainbow SET. Hospital inputs were
evaluated by Capgemini through 70 in-depth one-on-one interviews with clinicians
and other decision-makers at 15 U.S. acute care hospitals and then quantified
through a follow-on survey of 200 hospital-based physicians. The study found
that the majority of anesthesiologists and two-thirds of surgeons believed that
SpHb monitoring could prevent at least one unnecessary blood transfusion in
every ten surgical cases on which it was used, contributing to $93,600 in net
annual cost savings in a surgical department using 20 SpHb-enabled devices. The
study also found that the majority of intensivists believed that SpHb monitoring
could reduce intensive care length of stay by at least one day for every 15 or
fewer patients on which it was used, contributing to $67,350 in net annual cost
savings in an intensive care department using 10 SpHb-enabled devices.
Joe Kiani, Founder and CEO of Masimo, stated, "We believe that the Capgemini
study will significantly aid hospitals seeking to evaluate the initial and
ongoing investment in Masimo Rainbow SET by clearly identifying each of the
various mechanisms by which SpHb can improve the clinical process of care and
create net financial benefits."
The Capgemini study can be downloaded at www.masimo.com/capgemini. In
addition, a customized financial analysis based on a hospital's own inputs
incorporated into the Capgemini financial model is available upon request.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the accuracy and
repeatability of the Capgemini financial model and results; risks related to our
belief that the applications of Masimo Rainbow SET measurements described in the
foregoing statements will deliver a sufficient level of clinical improvement
over alternative measurement capabilities to create substantial financial
benefits for hospitals, allow for rapid adoption of the technology, and
materially increase market share and/or revenues for the company, as well as
other factors discussed in the "Risk Factors" section of our Annual Report on
Form 10-K for the fiscal year ended January 3, 2009, filed with the Securities
and Exchange Commission ("SEC") on March 4, 2009, which may be
obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our
Quarterly Report on Form 10-Q for the fiscal year ended January 3, 2009, whether
as a result of new information, future events or otherwise, except as may be
required under the applicable securities laws.
Contact:
Dana Banks
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation. Other trademarks used
herein are the property of their respective owners.
|
|
|
|
|
|
Masimo to Report First Quarter 2009 Financial Results on May 5, 2009
Conference call and webcast to begin after markets close at 2:00 p.m. PT
(5:00 p.m. ET)
Irvine, Calif., April 14, 2009—Masimo Corporation (NASDAQ: MASI),
the inventor of Pulse CO-Oximetry and Measure-Through Motion and
Low-Perfusion pulse oximetry, today announced it will release first quarter 2009
financial results for the period ended April 4, 2009 after the market closes on
Tuesday, May 5, 2009.
A conference call to review the results will begin at 2:00 p.m. PT (5:00 p.m.
ET) and will be hosted by Joe E. Kiani, Chairman and Chief Executive Officer,
and Mark P. de Raad, Executive Vice President and Chief Financial Officer.
A live webcast of the conference call will be available online from the
investor relations page of the Company's corporate web site at www.masimo.com. The dial-in numbers are (888)
520-7182 for domestic callers and +1 (706) 679-9937 for international callers.
The reservation number for both dial-in numbers is 95073118. After the live
webcast, the call will remain available on Masimo's website through June 5,
2009. In addition, a telephonic replay of the call will be available through May
19, 2009. The replay dial-in numbers are (800) 642-1687 for domestic callers and
+1 (706) 645-9291 for international callers. Please use reservation code
95073118.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care-helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET
Pulse CO-Oximetry, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Rainbow SET continuously and noninvasively measures total
hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at http://www.masimo.com.
Masimo Corporation
Investor Contact
Mark P.
de Raad
Executive Vice President and Chief Financial Officer
Masimo
Corporation
(949) 297-7080
mderaad@masimo.com
Media Contact:
Dana Banks
Manager, Public
Relations
Masimo Corporation
(949) 297-7348
dbanks@masimo.com
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
New Clinical Study Shows Masimo PVI™ Accurately Predicts Fluid Responsiveness
in the ICU
First Study to Expand PVI Utility Beyond the OR Presented at the 29th
International Symposium on Intensive Care and Emergency Medicine in Brussels
Irvine, California – March 31, 2009 – Masimo (NASDAQ: MASI),
the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low-Perfusion
pulse oximetry, announced today that a new independent clinical study
demonstrates Masimo PVI to be an "accurate index of fluid responsiveness" for
critical care patients in the intensive care unit (ICU).1 The study, presented at the 29th International
Symposium on Intensive Care and Emergency Medicine on March 25, 2009, in
Brussels, Belgium, is the first to show the potential value of Masimo PVI to
predict fluid responsiveness beyond the operating room (OR) into the ICU.
Critically-ill patients are at great risk for volume depletion. Fluid
administration is critical to optimizing oxygen delivery to organs and tissues,
but giving too much fluid can induce life-threatening adverse effects.
Therefore, parameters that aid clinicians in fluid management decisions may help
improve patient outcomes. The most validated predictor of fluid responsiveness
is pulse pressure variation (ΔPP). However, this parameter requires an invasive
arterial pressure catheter, which is not appropriate for all patients, or
special software, which is not available in all monitoring systems. Masimo PVI
is not only noninvasive, enabling easy application on almost any patient, but is
also easily obtained from existing or field upgradable Masimo Rainbow SET® pulse
oximeters and sensors that are already being used to monitor SpO2 and pulse rate.
In the study, Marc Feissel, MD, and colleagues at Le Centre Hospitalier
Belfort-Montbeliard (CHBM) in Belfort, France, along with a team of researchers
from Assistance Publique–H?aux de Paris (AP-HP) in Le Kremlin-Bicetre, France,
conducted a two-step analysis of 43 mechanically-ventilated patients with septic
shock to: 1) identify the optimal Masimo PVI threshold for distinguishing fluid
responders from non-responders; and 2) test the accuracy of PVI at the optimal
threshold to predict fluid responsiveness.
In the first step, researchers infused fluid (500 ml saline) in with pulse
pressure variation (ΔPP) ≥ 15% and performed passive leg raising in patients
with ΔPP <15% while simultaneously recording Masimo PVI and ΔPP. A >15%
increase in velocity-time-integral (VTI) from echocardiography was used to
determine fluid responsiveness. After comparing all data for the 25 enrolled ICU
patients in the first step, researchers found that a "threshold PVI value of 20
identified patients with ΔPP >15% with a sensitivity of 84% and specificity
of 90%."
In the second step, researchers found that a PVI value of 20 was an effective
threshold for discriminating fluid responders from non-responders among 18
additional ICU patients, with PVI >20 predicting all 8 fluid responders and
PVI <20 predicting all non-responders. The researchers concluded that a PVI
value of 20 "distinguished responders from non-responders with good sensitivity
and specificity," and appeared to represent an "accurate index of fluid
responsiveness" for critically-ill patients in the ICU.
Masimo Executive Vice President of Medical Affairs Dr. Michael O'Reilly,
stated: "We are pleased to see the value and significance of Masimo PVI in the
ICU, where clinicians are often faced with difficult decisions about whether to
administer fluid. While traditional invasive measurements offer limited accuracy
at predicting fluid responsiveness, this study showed that a PVI threshold of 20
was able to accurately predict both fluid responders and non-responders,
underscoring the strong potential for PVI to aid clinicians in optimizing fluid
management and improving patient outcomes."
1 M. Feissel, R. Kalakhy, J. Badie, G. Robles, J. Faller, JL.
Teboul. "Plethysmography Variability Index: A New Fluid Responsiveness
Parameter."
Presented at the 29th International Symposium on Intensive Care
and Emergency Medicine (ISICEM) Annual Meeting, March 25, 2009, Brussels,
Belgium. http://www.intensive.org/admin/upload/abstract/1079190502/P/P205.pdf
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the repeatability of
clinical results; risks related to our belief that PVI will prove to be an
effective clinical indicator of patient hydration and the need for fluid
loading, and will deliver a sufficient level of clinical improvement over
alternative fluid assessment methods to allow for rapid adoption of the
technology, as well as other factors discussed in the "Risk Factors" section of
our Annual Report on Form 10-K for the fiscal year ended January 3, 2009, filed
with the Securities and Exchange Commission ("SEC") on March 4,
2009, which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our Annual
Report on Form 10-K for the fiscal year ended January 3, 2009, whether as a
result of new information, future events or otherwise, except as may be required
under the applicable securities laws.
Contact:
Dana Banks
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation. Other trademarks used
herein are the property of their respective owners.
|
|
|
|
|
|
Masimo Initiates Full Market Release of First-Ever Noninvasive Continuous Hemoglobin
Monitor
Success in Limited Market Release Hospitals Highlights Early Clinical
Benefits and Patient Impact
Irvine, California – March 24, 2009 – Masimo (NASDAQ: MASI),
the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low-Perfusion
pulse oximetry, announced today that it has initiated the full market release of
its breakthrough noninvasive and continuous hemoglobin (SpHb™) monitoring
technology. As the first noninvasive and continuous hemoglobin monitoring
technology to receive FDA 510(k) clearance and be available for widespread
commercial adoption, Masimo SpHb is already transforming the way hemoglobin
testing is performed at over 40 hospitals in the U.S., Europe, Asia, and Africa,
that have participated in the technology's limited market release initiated in
September of 2008.
The availability of noninvasive, continuous, and immediate hemoglobin
measurements is expected to have wide ranging clinical impact, from surgery and
intensive care to less acute care settings, including the emergency department,
physician office, ambulatory surgery center, and long-term care facility by
facilitating prompt detection of internal bleeding and more appropriate
administration of blood transfusions. Early benefits and impact of Masimo SpHb
were evident in feedback received from clinicians at hospitals around the world
who participated in the limited market release.
Ronald Miller, MD, Chief of Anesthesia, Professor and Chairman of the Dept.
of Anesthesia and Perioperative Care at the University of California, San
Francisco, stated, "Masimo SpHb is an impressive new tool that helps us to more
safely guide patients in surgery through to recovery. With it, not only can we
spot hemoglobin changes as they occur, but we can see where they are heading.
This ability to identify an upward or downward hemoglobin trend on a
second-by-second basis as it occurs has been of tremendous value."
Randy Marcel, MD, Medical Director and Chief of Anesthesiology at The Heart
Hospital Baylor Plano in Plano, Texas, stated, "In the past, we've only received
glimpses of our patients' hemoglobin levels from lab measurements, but now we
have complete and real-time hemoglobin visibility. We initially purchased SpHb
for use during cardiac surgeries in the OR, and brought in additional units for
the ICU, where post-operative monitoring of internal bleeding is critical to
patient recovery."
Javed Akhtar, MD, FAAP, Medical Director, Pediatric Intensive Care Unit at
Creighton University Medical Center in Omaha, Nebraska, stated, "We purchased
the SpHb monitor after seeing it in a hands-on demonstration, and I'm glad we
did! SpHb has reduced the traumatic experience for pediatric patients, increased
the satisfaction of parents, and reduced the workload on our nursing staff,
phlebotomist and laboratory personnel."
Madhava Karunarathna, MD, OB/GYN at Balangoda Hospital in Sri Lanka, stated,
"With SpHb, we now have accurate hemoglobin measurements available at our
fingertips, around the clock. In cases of severe hemorrhaging during and after
childbirth, SpHb has enabled us to immediately identify and continuously assess
blood loss severity to better manage internal bleeding, prevent overloading of
fluid, and decrease maternal death."
Adi Abdussalam Adham, MD, Chief Manager at Accidents Hospital Abu Saleem in
Tripoli, Libya reinforced Dr. Karunarathna's comments, adding that: "In the
operating room, Masimo SpHb has enabled us to more effectively monitor blood
loss and better manage transfusions in surgery, while routine screening in the
ED has helped us to more rapidly identify patients with anemia or internal
bleeding."
Bertrand Debaene, MD, Anesthesiologist at the University Hospital Center of
Poitiers in Poitiers, France believes the combination of SpHb and PVI may prove
to have significant clinical benefits, saying that "SpHb, along with PVI, have
been important improvements for both the department and our patients. The
ability to track hemoglobin and fluid volume in real-time allows us to be more
precise in our clinical routine."
SpHb is part of the Masimo Rainbow SET Pulse CO-Oximetry patient monitoring
platform—the first-and-only upgradable technology platform capable of
continuously and noninvasively measuring multiple blood constituents and helping
to predict fluid responsiveness in patients previously requiring invasive
procedures. Masimo Rainbow SET noninvasive measurements—including: total
hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), PVI™, oxyhemoglobin (SpO2), pulse
rate (PR), and perfusion index (PI)—have the potential to facilitate faster,
easier and safer health decisions.
Currently available in bedside Masimo Radical-7® and Rad-87® Pulse
CO-Oximeter patient monitors, SpHb will also be offered in handheld monitors and
select multiparameter patient monitoring brands through Masimo Rainbow SET Pulse
CO-Oximetry technology license agreements.
Joe Kiani, Founder and CEO of Masimo said, "SpHb's success during the limited
market release phase at hospitals around the world illustrates its expected
significant impact on clinical practice and patient care. In addition and as we
expected, our limited market release program provided us with the opportunity to
enhance the robustness in low perfusion situations and broaden the cross section
of individuals on which the technology performs. The ability for clinicians in
hospitals, private practices, and other healthcare settings to perform immediate
and continuous noninvasive hemoglobin monitoring creates new opportunities to
save lives, optimize decision making, improve care, and reduce costs."
SpHb has received regulatory clearance in the U.S., Canada, Europe and
Australia, and is now available for sale in most of the countries in the
world.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our belief that the commercial availability of
SpHb technology and products will serve to increase adoption, market share
and/or revenues for the company, risks that limited market release clinical
results may not be duplicated in the full market launch, risks related to our
assumption that SpHb technology and products will provide faster, easier and
safer means for measuring total hemoglobin and will lead to additional device
sales, and risks related to our assumptions that Rainbow measurements will
deliver a sufficient level of clinical improvement over alternative capabilities
to allow for rapid adoption of the technology, as well as other factors
discussed in the "Risk Factors" section of our Annual Report on Form 10-K for
the fiscal year ended January 3, 2009, filed with the Securities and Exchange
Commission ("SEC") on March 4, 2009, which may be obtained for
free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our forward-looking
statements are reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press release are
expressly qualified in their entirety by the foregoing cautionary statements.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of today's date. We do not undertake any
obligation to update, amend or clarify these forward-looking statements or the
"Risk Factors" contained in our Annual Report on Form 10-K for the fiscal year
ended January 3, 2009, whether as a result of new information, future events or
otherwise, except as may be required under the applicable securities laws.
Contact:
Dana Banks
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation. Other trademarks used
herein are the property of their respective owners.
|
|
|
|
|
|
New Clinical Study Finds Masimo Rainbow SET® Pulse CO-Oximetry™ Accurate in
the Noninvasive Monitoring of Fluid Status During Surgery
UCSF Researchers Presented Study Data Demonstrating the Unique Ability of
Masimo PVI™ to Reflect Acute Changes in Intravascular Fluid Volume at the
International Anesthesia Research Society
83rd Scientific Congress
Irvine, California – March 16, 2009 – Masimo (NASDAQ: MASI),
the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low-Perfusion
pulse oximetry, today announce that a new clinical study, independently
conducted by researchers from the University of California-San Francisco (UCSF),
demonstrates that Masimo PVI accurately and reliably reflects acute changes in
intravascular fluid volume (preload).1 The study,
presented at the International Anesthesia Research Society (IARS) 83rd Scientific Congress on March 14th in San Diego,
Calif., affirms PVI as a highly predictive indicator of patient fluid status.
Assessing whether a patient needs fluid to increase their cardiac index
(amount of blood the heart pumps each minute) is one of the biggest challenges
anesthesiologists face during surgery. Although fluid administration is critical
to optimizing patient status and enabling end organ preservation, unnecessary
fluid administration is associated with increased morbidity and mortality2 and traditional invasive measurements are only 50 to
60% accurate at predicting improvement in cardiac index after volume
administration.3 PVI—a new method for noninvasive
and automatic assessment of fluid responsiveness—has been shown in multiple
studies to predict fluid responsiveness in mechanically ventilated patients,
helping clinicians to optimize fluid administration and improve patient
outcomes.4-6
In the study, Errol P. Lobo, M.D., PhD, at UCSF in San Francisco, Calif., and
colleagues used Masimo Radical-7 Pulse CO-Oximeters to noninvasively measure and
continuously track PVI, perfusion index (PI) and pulse rate (PR) data during 16
consecutive liver transplant operations. Researchers extracted and analyzed the
noninvasive data at three critical points where preload changes occur rapidly:
1) immediately before clamping, 2) during clamping, and 3) immediately after
clamping of the inferior vena cava (IVC), and found that PVI changed rapidly and
significantly in response to known acute changes in preload (clamping and
unclamping of IVC) in 100% of the cases.
The study results showed that PVI increased in response to IVC clamping (from
11.4, +/- 4.3, to 25.2, +/- 4.4; p<0.0001) and decreased after unclamping
(from 25.2, +/- 4.4, to 8.9, +/- 3.8; p<0.0001) in all 16 transplant
patients. Researchers concluded that this study data demonstrates that PVI may
have "a role in monitoring intravascular volume in mechanically ventilated
patients."
PVI is available as part of Masimo Rainbow SET Pulse CO-Oximetry—a
revolutionary noninvasive patient monitoring platform that measures multiple
blood constituents and helps to predict fluid responsiveness in patients
previously requiring invasive procedures. The first-and-only upgradable
noninvasive blood constituent monitoring technology platform capable of
continuously and noninvasively measuring total hemoglobin (SpHb™), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and pleth
variability index (PVI™), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), Masimo Rainbow SET
has the potential to facilitate faster, easier and safer health decisions.
Masimo Executive Vice President of Medical Affairs Dr. Michael O'Reilly,
stated: "This UCSF study adds to the growing evidence base demonstrating PVI to
be an accurate and reliable indicator of fluid status and responsiveness in
mechanically-ventilated patients under general anesthesia. The ability to
noninvasively and automatically assess fluid responsiveness in surgical patients
has the potential to increase patient safety, improve the quality of care, and
reduce the cost of care for hospitals and surgery centers."
1 E. Lobo, C. Niemann, P. Talke. Anesthesia and
Perioperative Medicine, University of California-San Francisco, San Francisco,
California. "Effect of Preload Changes on Pleth Variability Index During Liver
Transplants." Available online at: http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={FC027C9B-21B5-4032-AD74-280AEE162B5D}&SKey={1462FF08-CFFF-4A5F-95FC-D52A5461EC2C}&MKey={64BDB940-2A51-4B0D-91DB-FA4060CA2127}&AKey={733594F2-AA75-4C15-986B-948550CDD4D4}
2 Michard F, Teboul JL. "Predicting fluid responsiveness
in ICU patients: a critical analysis of the evidence." Chest. 2002
Jun;121(6):2000-8.
3 Joshi G. "Intraoperative Fluid Restriction
Improves Outcome After Major Elective Gastrointestinal Surgery." Anesthesia
Analgesia 2005; 101:601-5.
4 Cannesson M, Desebbe O, Rosamel
P, Delannoy B, Robin J, Bastien O, Lehot JJ. "Pleth variability Index to Monitor
the Respiratory Variations in the Pulse Oximeter Plethysmographic Waveform
Amplitude and Predict Fluid Responsiveness in the Operating Theatre."
British Journal of Anaesthesia 2008; 0:aen133v1-7.
5
Christopher Wray, M.D., Jack Buckley, M.D., Derek Kwan, B.S., Tayeba Maktabi,
Aman Mahajan, M.D., Ph.D. Anestheiology, UCLA David Geffen School of Medicine,
Los Angeles, California. "Ability of Pleth Variability Index to Detect Preload
Changes in Orthotopic Liver Transplant Patients."
6 Olivier
Desebbe, M.D., Bertrand Delannoy, R.A., Jean-Jacques Lehot, M.D., Ph.D., Olivier
Bastien, M.D., Ph.D., Maxime Cannesson, M.D. Department of Anesthesiology, Louis
Pradel Hospital, Lyon-Bron, France. "Pleth Variability Index: A Noninvasive
Device for Fluid Responsiveness Assessment during Anesthesia."
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our assumptions regarding the repeatability of
clinical results; that PVI will prove to be an effective clinical indicator of
patient hydration and the need for fluid loading, and will deliver a sufficient
level of clinical improvement over alternative fluid assessment methods to allow
for rapid adoption of the technology; and our belief that the applications of
Masimo Rainbow SET measurements described in the foregoing statements will
deliver a sufficient level of clinical improvement over alternative measurement
capabilities to materially increase market share and/or revenues, as well as
other factors discussed in the "Risk Factors" section of our Annual Report on
Form 10-K for the fiscal year ended January 3, 2009, filed with the Securities
and Exchange Commission ("SEC") on March 4, 2009, which may be
obtained for free at the SEC's website at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or clarify
these forward-looking statements or the "Risk Factors" contained in our
Quarterly Report on Form 10-Q for the fiscal quarter ended September 27, 2008,
whether as a result of new information, future events or otherwise, except as
may be required under the applicable securities laws.
Contact:
Dana Banks
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation. Other trademarks used
herein are the property of their respective owners.
|
|
|
|
|
|
Masimo Reports Fourth Quarter and Full Year 2008 Financial Results
Record results mark 22nd consecutive quarter and 14th year of consecutive
product revenue growth. Company also announces international realignment to
better support growing non-US business.
Q4 2008 Highlights:
- Product revenues increased 29.4% to $71.4 million
- Rainbow revenues increased 161% to $4.7 million
- Over 31,700 Masimo SET and Masimo Rainbow SET pulse oximeter units were
shipped in Q4 2008
- International realignment results in a Q4 2008 tax charge of $0.25 per share
and a Q4 2008 net loss of $0.01 per share; Q4 2008 earnings per share, excluding
the tax charge, was $0.24 per share
Full Year 2008 Highlights:
- Product revenues increased 29.7% to $258.9 million
- Rainbow revenues increased 91% to $13.4 million
- Over 120,000 Masimo SET and Masimo Rainbow SET pulse oximeter units were
shipped in 2008
- International realignment results in a Q4 2008 tax charge of $0.25 per share
and full year 2008 earnings per share of $0.53; full year 2008 earnings per
share, excluding the Q4 tax charge, was $0.78 per share
Irvine, California, March 3, 2009 – Masimo Corporation
(NASDAQ: MASI), the inventor of Pulse CO-Oximetry and Measure-Through Motion and
Low-Perfusion pulse oximetry, today announced its financial results for both the
quarter and year ended January 3, 2009.
For the fiscal fourth quarter, Masimo reported product revenues of $71.4
million representing a 29.4% increase over $55.2 million for the fourth quarter
of 2007. Including royalty revenues, Masimo reported total 2008 fourth quarter
revenues of $83.1 million compared to $69.3 million for the fourth quarter of
2007. For the fourth quarter, Masimo reported a loss of $0.01 per share,
resulting from a $14.9 million, or $0.25 per share, tax charge related to the
implementation of its new international business organization and structure.
Excluding this tax charge, fourth quarter net income would have been $14.4
million, or $0.24 per diluted share, compared to $0.20 per common share for the
fourth quarter of 2007. In addition, higher research and development tax credits
added $0.03 per share in the fourth quarter of 2008 and $0.02 in the fourth
quarter of 2007. Masimo also reported that it shipped 31,700 Masimo SET and
Masimo Rainbow SET oximetry units, excluding handheld units, during the fourth
quarter of 2008, up from 29,400 in the comparable prior year period, resulting
in a new estimated worldwide installed base of 567,000 Masimo SET and Masimo
Rainbow SET pulse oximeters.
During the fourth quarter of 2008, Masimo implemented a new international
business organization and structure designed to better serve and support
Masimo's growing international business. By centralizing its international
operations, including sales management, marketing, customer support, planning,
logistics and administrative functions, Masimo believes it will be able to
develop a more efficient and scalable international organization – capable of
being even more responsive to the business needs of its international customers
- all under one centralized management structure. As result of this realignment,
in Q4 2008, Masimo incurred a one-time tax charge related to expenses for
sharing in the costs of our ongoing research and development efforts as well as
the prepayment of licensing commercial rights to utilize pre-existing
intangibles. As a result of this new international business structure, Masimo
believes that its future income tax rates will decline although future income
tax rates will depend on various factors, including profits (losses) before
taxes, changes to tax law and the geographic composition of pre-tax income.
For the fiscal year ended January 3, 2009, Masimo reported product revenues
of $258.9 million, up 29.7% from $199.7 million in 2007. Including royalty
revenues, Masimo's total revenues were $307.1 million for the year ended January
3, 2009, up from $256.3 million in 2007. For the year ended January 3, 2009,
Masimo reported earnings of $31.9 million or $0.53 per share, including the
$14.9 million tax charge related to the implementation of its new international
business organization and structure. Excluding the Q4 2008 tax charge, net
income would have been $46.8 million, or $0.78 per share compared to $0.60 per
share in 2007. In the year ended January 3, 2009, Masimo shipped 120,100 Masimo
SET and Masimo Rainbow SET pulse oximeter units, excluding handheld pulse
oximeters, compared to 116,300 in 2007.
In the fourth quarter of 2008, revenues from Masimo Rainbow SET products
increased to $4.7 million or 161% from $1.8 million in the same prior year
quarter. For the year ended January 3, 2009, revenues from Masimo Rainbow SET
products were $13.4 million, an increase of 91% compared to 2007. As a result,
2008 Masimo Rainbow SET revenues accounted for 5.2% of total product revenues up
from 3.7% in 2007.
Joe E. Kiani, Chairman and Chief Executive Officer of Masimo, said, "We have
been fortunate that, despite the very challenging economic environment,
hospitals and physicians continue to focus on the quality and efficiency of
their patients' care and, as a result, continue to migrate to Masimo's gold
standard SET pulse oximetry and Rainbow SET Pulse CO-Oximetry platforms. Our
on-going business model, which is based on both new product innovation and a
recurring revenue stream, is continuing to show resilience in this difficult
worldwide economic climate."
As of January 3, 2009, cash and cash equivalents totaled $146.9 million, up
from $96.7 million at December 29, 2007, including the previously announced
first quarter 2008 repayment in full of a $26.7 million debt obligation which
had been established in early fiscal 2007.
Financial Guidance
While providing financial guidance in
this economic environment is more difficult than in prior periods, Masimo
expects 2009 product revenues will be between $310 million and $315 million.
Masimo also expects 2009 royalty revenues to be between $42 million to $46
million. As a result of these ranges, Masimo expects total 2009 revenues to be
between $352 million and $361 million. For the full year 2009, Masimo expects
its GAAP earnings per share to be between $0.83 and $0.87 per common share.
Included in these 2009 earnings per share ranges are an expected reduction in
year over year royalty payments, an expected increase in 2009 non-cash stock
based compensation expenses of $11.9 million, up from $7.7 million in 2008 and
the expected benefits from our new international business structure. The
projections and guidance set forth above are estimates only and actual
performance could differ.
Conference Call
Masimo will hold a conference call today
at 2:00 p.m. PT (5:00 p.m. ET) to discuss the results. The dial-in numbers are
(888) 520-7182 for domestic callers and +1 (706) 679-9937 for international
callers. The reservation number for both dial-in numbers is 84029998. A live web
cast of the conference call will be available online from the "Investor
Relations" page of the Company's corporate web site at www.masimo.com. After the live web cast, the
call will remain available on Masimo's website through April 3, 2009. In
addition, a telephonic replay of the call will be available until March 17,
2009. The replay dial-in numbers are (800) 642-1687 for domestic callers and +1
(706) 645-9291 for international callers. Please use reservation code 84029998.
Non-GAAP Measures
Masimo prepares its consolidated
financial statements in conformity with accounting principles generally accepted
in the United States of America, or U.S. GAAP. In an effort to provide investors
with additional information regarding the Company's results and to provide a
meaningful period-over-period comparison of the Company's financial performance,
the Company uses non-GAAP financial measures as defined by the Securities and
Exchange Commission. The differences between the U.S. GAAP and non-GAAP
financial measures are reconciled below. In presenting comparable results, the
Company discloses non-GAAP financial measures when it believes such measures
will be useful to investors, analysts and other interested parties in evaluating
the Company's underlying business performance on a comparable basis with past
and future reported earnings per share and with the financial guidance provided
in this release. Management uses the non-GAAP financial measures to evaluate the
Company's financial performance against internal budgets and targets.
Importantly, management believes non-GAAP financial measures should be
considered in addition to, and not in lieu of, U.S. GAAP financial measures.
These non-GAAP financial measures are not based on a comprehensive set of
accounting rules or principles and may be different from non-GAAP financial
measures used by other companies.
About Masimo
Masimo (NASDAQ: MASI) develops,
manufactures and markets innovative monitoring technologies that significantly
improve patient care—helping solve "unsolvable" problems. In 1995, the Company
debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo
SET, which virtually eliminated false alarms and increased pulse oximetry's
ability to detect life-threatening events. More than 100 independent clinical
and laboratory studies demonstrate Masimo SET provides the most reliable
SpO2 and pulse rate measurements even under the most
challenging clinical conditions, including patient motion and low peripheral
perfusion. In 2005, Masimo introduced Masimo Rainbow SET, a breakthrough
noninvasive blood constituent monitoring platform that can measure many blood
constituents that previously required invasive procedures. Rainbow SET
continuously and noninvasively measures total hemoglobin (SpHb®), oxygen content
(SpOC™), carboxyhemoglobin (SpCO® ), methemoglobin (SpMet®) and plethysmograph
variability index (PVI®), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com. Any information contained in,
or that can be accessed through, our website is not incorporated by reference
into, nor is it in any way a part of, this release.
Forward-Looking Statements
All statements other than
statements of historical facts included in this press release that address
activities, events or developments that we expect, believe or anticipate will or
may occur in the future are forward-looking statements including, in particular,
the statements about: our financial condition, results of operations, prospects
and business generally; expectations regarding our ability to design and deliver
innovative new noninvasive technologies; and expectations for total revenues,
including royalty revenues, product revenues and Rainbow revenues, non-cash
stock based compensation charges, GAAP earnings per share and non-GAAP pro forma
earnings per share for the full fiscal year 2009. These forward-looking
statements are based on management's current expectations and beliefs and are
subject to uncertainties and factors, all of which are difficult to predict and
many of which are beyond our control and could cause actual results to differ
materially and adversely from those described in the forward-looking statements.
These risks include, but are not limited to, those related to: our dependence on
Masimo SET and Masimo Rainbow SET products and technologies for substantially
all of our revenue; any failure in protecting our intellectual property exposure
to competitors' assertions of intellectual property claims; the highly
competitive nature of the markets in which we sell our products and
technologies; any failure to continue developing innovative products and
technologies; the lack of acceptance of any new products and technologies of
ours; obtaining regulatory approval of our current and future products and
technologies, including the recently announced total hemoglobin measurement; the
risk that the implementation of our international realignment, even if timely
implemented, will not produce the anticipated operational and financial
benefits, including a lower effective tax rate; the loss of our customers, the
failure to retain and recruit senior management; product liability claims
exposure; a failure to obtain expected returns from the amount of intangible
assets we have recorded; the maintenance of our brand; the impact of the decline
in the worldwide credit markets on us and our customers; the amount and type of
equity awards that we may grant to employees and service providers in the
future; and other factors discussed in the "Risk Factors" section of our
Quarterly Report on Form 10-Q for the fiscal quarter ended September 27, 2008
filed with the Securities and Exchange Commission ("SEC") on October 29, 2008,
which you may obtain for free on the SEC's website, at www.sec.gov. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do
not know whether our expectations will prove correct. You are cautioned not to
place undue reliance on these forward-looking statements, which speak only as of
the date hereof, even if subsequently made available by us on our website or
otherwise. We do not undertake any obligation to update, amend or clarify these
forward-looking statements or the risk factors contained in our Quarterly Report
on Form 10-Q for the fiscal quarter ended September 27, 2008, whether as a
result of new information, future events or otherwise, except as may be required
under applicable securities laws.
Investor Contact:
Mark P. de Raad
Executive Vice
President, Finance and Chief Financial Officer
Masimo Corporation
(949)
297-7080
mderaad@masimo.com
Media Contact:
Dana Banks
Manager, Public Relations
Masimo Corporation
(949) 297-7348
dbanks@masimo.com
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpCO, SpMet, PVI, Pulse CO-Oximetry and Pulse
CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Three Healthcare GPOs to Offer Masimo Rainbow SET® Pulse CO-Oximetry™ to Their
Members
Novation, MedAssets Supply Chain Systems, and Amerinet Also Extend
Existing Multi-Year Supplier Agreements
Irvine, California – March 2, 2009 – Masimo (NASDAQ: MASI),
the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low-Perfusion
pulse oximetry, announced today that three of the nation's top hospital Group
Purchasing Organizations (GPOs) have established a new Pulse CO-Oximetry™
category and extended multi-year supplier agreements for Masimo SET® pulse
oximetry and Masimo Rainbow SET® Pulse CO-Oximetry products. Masimo licenses
the technology and supplies Pulse CO-Oximetry products that noninvasively
measure multiple blood constituents, which previously required invasive blood
drawing procedures.
Establishing a new Pulse CO-Oximetry product category on national contract
portfolios allows Novation, MedAssets Supply Chain Systems, and Amerinet to
offer an innovative new selection of patient monitoring devices clinically
proven to help clinicians provide earlier detection of potentially
life-threatening conditions. This enables customer hospitals and healthcare
facilities to purchase breakthrough noninvasive blood monitoring products that
may increase patient safety, improve the quality of care, and reduce the cost of
care at a great value.
Mark Miriani, President,MedAssets Supply Chain Systems, stated: "MedAssets
remains focused on the important trends and issues facing the healthcare
community and we recognize the importance of providing advanced technology
solutions and innovative new product offerings to our customers. Pulse
CO-Oximetry has the potential to improve patient safety and clinical
performance, thereby delivering greater value to both hospitals and patients.
We are proud to be among the first to offer Masimo Rainbow SET Pulse CO-Oximetry
products on contract to our customers, creating the opportunity for measurable
performance improvement as well as cost savings."
Brad Morgan, Director of Material Management, The Heart Hospital Baylor
Plano, stated: "We are pleased that our GPO is making medical technologies like
Masimo Rainbow SET available."
Masimo Rainbow SET Pulse CO-Oximetry is a noninvasive monitoring platform
that measures multiple blood constituents and helps to predict fluid
responsiveness in patients previously requiring invasive procedures. The
first-and-only upgradable technology platform capable of continuously and
noninvasively measuring total hemoglobin (SpHb™), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and pleth variability index
(PVI™), in addition to oxyhemoglobin (SpO2), pulse rate
(PR), and perfusion index (PI), Masimo Rainbow SET has the potential to
facilitate faster, easier and safer health decisions.
Martin Allard, M.B.Ch.B, FRC, Anesthesiologist, Loma Linda University Medical
Center, stated: "Pulse CO-Oximetry has enormous potential. We chose the Masimo
Rainbow SET Pulse CO-Oximetry platform because it provides us with the unique
ability to noninvasively, continuously and immediately measure a variety of
blood constituents, in addition to standard pulse oximetry measurements. Having
this amount of vital physiologic data available at our fingertips has allowed us
to make more rapid diagnoses, initiate intervention and treatment earlier, and
make better care decisions for patients."
Rick Fishel, Masimo President of Americas and Worldwide OEM Business, stated:
"Novation, MedAssets, and Amerinet are leading the way toward a new paradigm of
potentially more effective and efficient patient care enabled by
state-of-the-art noninvasive medical devices. These new GPO agreements reinforce
the clinical and operational adoption of Masimo Rainbow SET Pulse CO-Oximetry as
an emerging standard of care."
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our belief that creation of a new GPO product
category for Pulse CO-Oximetry will serve to broaden the use of Masimo Rainbow
SET Pulse CO-Oximetry products or provide substantially increased revenues, and
risks related to our assumptions that Rainbow measurements will deliver a
sufficient level of clinical improvement over alternative capabilities to allow
for rapid adoption of the technology, as well as other factors discussed in the
"Risk Factors" section of our Quarterly Report on Form 10-Q for the fiscal
quarter ended September 27, 2008, filed with the Securities and Exchange
Commission ("SEC") on October 29, 2008, which may be obtained
for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our forward-looking
statements are reasonable, we do not know whether our expectations will prove
correct. All forward-looking statements included in this press release are
expressly qualified in their entirety by the foregoing cautionary statements.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of today's date. We do not undertake any
obligation to update, amend or clarify these forward-looking statements or the
"Risk Factors" contained in our Quarterly Report on Form 10-Q for the fiscal
quarter ended September 27, 2008, whether as a result of new information, future
events or otherwise, except as may be required under the applicable securities
laws.
Contact:
Dana Banks
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation. Other trademarks used
herein are the property of their respective owners.
|
|
|
|
|
|
United Kingdom House of Commons Safety Group Recommends Carbon Monoxide Screening
by Pulse CO-Oximetry™ to Reduce Misdiagnosis and Prevent Deaths
New Evidence from London Ambulance Service Study Shows Five Masimo Rad-57
Pulse CO-Oximeters™ Detected 83 Unsuspected CO Poisonings in One Year—Over a
Third of the UK Reported Annual CO Poisonings
Irvine, California – February 18, 2009 – Masimo
(NASDAQ: MASI), the inventor of Pulse CO-Oximetry and Measure-Through Motion and
Low-Perfusion pulse oximetry, today announced that in a newly published report,
the UK House of Commons All Party Parliamentary Gas Safety Group (APPGSG)
recommends handheld, noninvasive Pulse CO-Oximeters for Emergency Departments,
primary care providers, and medical professionals who visit patients' homes as a
way to improve the country's rate of detection and diagnosis of carbon monoxide
(CO) poisoning.1 In addition, new evidence from a
London Ambulance Service pre-hospital CO screening study shows that using the
Masimo Rainbow SET Rad-57 Pulse CO-Oximeter significantly improved detection of
CO poisoning at an earlier stage, while reducing unnecessary hospital transports
and patients entering the Accidents & Emergency system.2
The UK House of Commons APPGSG report, 'Raising Medical Professionals'
Awareness of Carbon Monoxide Poisoning,' cites "increasing concern that little
is being done to ensure that medical professionals are able to correctly
diagnose the symptoms of carbon monoxide and treat victims effectively," as the
catalyst that ultimately resulted in the group's January 2009 report and
recommendations for action. The UK National Health Service (NHS) reports that
hundreds of people are seriously injured or killed by CO poisoning in the UK
each year.3 However, the APPGSG suggests that
because of the lack of adequate testing, the actual number may be much higher.
In addition, because the vast majority of cases simply go to their GP
complaining of symptoms similar to the flu, the incidents of misdiagnosis by
medical professionals are grossly under-reported.
"From the collated data, information gained during and prior to the
feasibility study and correspondence with other interested agencies it is clear
that there are gaping holes in the way that CO poisoning is recognised,
monitored, treated, recorded and publicised in the United Kingdom," stated
Andrew Humber, Team Leader, London Ambulance Service.
While authors of the APPGSG report advise that "targeting improved diagnosis
of CO poisoning is doubly important not just in containing the immediate effects
of the illness, but also in reducing the need to direct resources toward
tackling subsequent chronic or acute medical problems," a year-long feasibility
study also released in January 2009 by the London Ambulance Service demonstrates
Masimo Rad-57's ability to deliver these benefits.
In their report, 'A Feasibility Study into Pre-Hospital Carbon Monoxide
Monitoring of Patients,' the London Ambulance Service equipped three First
Response Units (FRU) and two Hazardous Area Response Team (HART) vehicles with
Rad-57s to determine the benefits of pre-hospital CO monitoring and found that
the ability to noninvasively screen patients on the scene made an important
difference in six key ways:
- Earlier detection & treatment of CO poisoning
- Prevention of further harm, possible higher level intoxications &
long-term effects of untreated exposure
- Reduced clinical risk to the ambulance service & increased safety for
the attending crew
- Improved on-scene triage ensures the fastest & most appropriate care
(A&E or Hyperbaric)
- Reduction in unnecessary hospital transports & patients entering the
A&E system
- Increased efficiency gains as ambulances/crews returned to core duties
earlier
Prior to this study, London Ambulance crews had no way to accurately diagnose
CO poisoned patients. With just five Rad-57s, the London Ambulance Service was
able to diagnose and treat 83 patients with unsuspected CO poisoning in a year,
which is over a third of the reported annual number of CO poisonings in the UK.
"On site monitoring of carbon monoxide blood levels mean that the paramedics are
now able to triage patients at scene and receive expert advice at the scene, so
that they take patients to the most appropriate A&E department and those
with severe CO poisoning can now be referred directly to appropriate hyperbaric
units," stated Andrew Humber. "It is due to this that there has been a marked
improvement in the time to treatment."
Masimo Founder and CEO, Joe E. Kiani, stated: "The UK recommendations and
London Ambulance Service study are a call to action for all medical and
emergency professionals who see patients with potential carbon monoxide
poisoning. We are proud that the technology we have invented and produced is
helping these professionals improve and save lives."
1 United Kingdom, House of Commons, All Party
Parliamentary Gas Safety Group. "Raising Medical Professionals' Awareness of
Carbon Monoxide Poisoning." January 2009. http://www.gassafetygroup.org.uk
2
London Ambulance Service, NHS Trust. "A Feasibility Study into Pre-Hospital
Carbon Monoxide Monitoring of Patients." January 2009.
3 NHS
Choices, "Carbon Monoxide Poisoning" http://www.nhs.uk/conditions/carbon-monoxide-poisoning/Pages/Introduction.aspx?url=Pages/what-is-it.aspx
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our belief that the positive results and
clinical outcomes achieved in the London Ambulance Service study will be
repeated in other studies, and risks related to our assumption that the Masimo
Rad-57 will deliver a sufficient level of sensitivity and specificity for
improved carbon monoxide detection over alternative methods to allow for rapid
adoption of the technology, as well as other factors discussed in the "Risk
Factors" section of our Quarterly Report on Form 10-Q for the fiscal quarter
ended September 27, 2008, filed with the Securities and Exchange Commission
("SEC") on October 29, 2008, which may be obtained for free at
the SEC's website at www.sec.gov. Although we
believe that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of today's date. We do not undertake any obligation to update,
amend or clarify these forward-looking statements or the "Risk Factors"
contained in our Quarterly Report on Form 10-Q for the fiscal quarter ended
September 27, 2008, whether as a result of new information, future events or
otherwise, except as may be required under the applicable securities laws.
Contact:
Dana Banks
Masimo
Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
Masimo to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
Irvine, California – February 6, 2009 – Masimo Corporation
(NASDAQ: MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion
and Low-Perfusion pulse oximetry, today announced that its management is
scheduled to present at the Roth Capital Partners 21st Annual OC Growth Stock
Conference at The Ritz-Carlton, Laguna Niguel in Dana Point, California, on
Wednesday, February 18, 2009, at 11:00 a.m. PT. A live audiocast of the
presentation will be available on the Masimo website at www.masimo.com. A replay of the audiocast will
be available following the live presentation.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care-helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low-Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Masimo Corporation
Investor Contact:
Mark P. de Raad
Executive Vice
President and Chief Financial Officer
Masimo Corporation
(949) 297-7080
mderaad@masimo.com
Media Contact:
Dana Banks
Manager, Public
Relations
Masimo Corporation
(949) 297-7348
dbanks@masimo.com
Masimo, SET, Signal Extraction Technology, Improving
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87,
Rad-57,Rad-9, Rad-8, Rad-5, Pulse CO-Oximetry and Pulse CO-Oximeter are
trademarks or registered trademarks of Masimo Corporation.
|
|
|
|
|
|
New Clinical Study Presented at the Society for Critical Care Medicine Shows
Value of Pulse CO-Oximetry™ to Identify Acquired Methemoglobinemia
1 out of 7 HIV+ Patients Receiving Dapsone Therapy at Significant Health
Risk Due to Dangerously High Levels of Methemoglobin
Irvine, California – February 6, 2009 – Masimo (NASDAQ:
MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and
Low-Perfusion pulse oximetry, today announced that a new study presented at the
Society for Critical Care Medicine 38th Critical Care Congress suggests
providers should consider routine screening with Masimo Rainbow SET Pulse
CO-Oximetry for the immediate and noninvasive detection of potentially
life-threatening acquired methemoglobinemia in patients receiving Dapsone
therapy. Results showed that "Dapsone therapy is associated with a clinically
significant elevation of methemoglobin levels" in 1 out of 7 HIV+ patients.
In the study, Hollis R. O'Neal, M.D., and colleagues at the Vanderbilt
University School of Medicine in Nashville, TN, found that 32% of HIV positive
patients receiving chronic Dapsone therapy, a commonly used antimicrobial agent
for the treatment of prophylaxis of pneumocystis jirovecii pneumonia (PCP), had
elevated methemoglobin blood levels (>2%) and 15% had dangerously high
methemoglobin blood levels (>3%) when compared to a control group of
HIV positive patients not receiving Dapsone.1
Dapsone has been shown to cause potentially deadly levels of methemoglobin—a
damaged form of hemoglobin that cannot bind to oxygen—to accumulate in the
blood. Elevated methemoglobin concentration reduces oxygen delivery to vital
organs and tissues, which can lead to brain and organ damage, or even
death.2 The researchers concluded: "As
noninvasive Pulse CO-Oximetry is now available, providers should consider the
routine screening of persons receiving Dapsone for methemoglobinemia."
Masimo Executive Vice President of Medical Affairs, Dr. Michael O'Reilly,
stated: "Previous studies have shown that methemoglobinemia can occur in any
patient type in any care area of the hospital. This study reinforces the need
for clinicians to quickly, easily and conveniently screen all patients receiving
Dapsone therapy using Masimo Rainbow SET Pulse CO-Oximetry as the first line of
defense and prevention against acquired methemoglobinemia."
1 Hollis R. O'Neal, John H. Newman, Catherine McGowan, Stephen
P. Raffanti, Timothy Sterling, Vanderbilt University School of Medicine,
Nashville, TN. "The Prevalence of Methemoglobinemia in HIV-Infected Patients on
Chronic Dapsone Therapy for Prophylaxis of Pneumocystis Jirovecci Infection."
Society of Critical Care Medicine, February 2, 2009.
2 Ash-Bernal, R., Wise,
R., Wright, SM. "The Johns Hopkins Study: Acquired Methemoglobinemia."
Medicine (Baltimore). 2004 Sep;83(5):265-73.
About Masimo
Masimo (NASDAQ: MASI) develops innovative
monitoring technologies that significantly improve patient care—helping solve
"unsolvable" problems. In 1995, the company debuted Measure-Through Motion and
Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated
false alarms and increased pulse oximetry's ability to detect life-threatening
events. More than 100 independent and objective studies demonstrate Masimo SET
provides the most reliable SpO2 and pulse rate measurements
even under the most challenging clinical conditions, including patient motion
and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET®
Pulse CO-Oximetry™, a breakthrough noninvasive blood constituent monitoring
platform that can measure many blood constituents that previously required
invasive procedures. Masimo Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb™), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and PVI™, in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early
detection and treatment of potentially life-threatening conditions. Founded in
1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of
Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, in connection with
the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our actual
results to differ materially and adversely from those expressed in our
forward-looking statements as a result of various risk factors, including, but
not limited to: risks related to our belief that the positive results and
clinical outcomes achieved in this study will be repeated in other studies, and
risks related to our assumption that Masimo Rainbow SET Pulse CO-Oximetry
technology and devices will deliver a sufficient level of sensitivity for
improved methemoglobinemia detection over alternative methods to allow for rapid
adoption of the technology, as well as other factors discussed in the "Risk
Factors" section of our Quarterly Report on Form 10-Q for the fiscal quarter
ended September 27, 2008, filed with the Securities and Exchange Commission
("SEC") on October 29, 2008, which may be obtained for free at
the SEC's website at www.sec.gov. Although we
believe that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements, which
speak only as of today's date. We do not undertake any obligation to update,
amend or clarify these forward-looking statements or the "Risk Factors"
contained in our Quarterly Report on Form 10-Q for the fiscal quarter ended
September 27, 2008, whether as a result of new information, future events or
otherwise, except as may be required under the applicable securities laws.
Contact:
Dana Banks
Masimo
Corporation
949-297-7348
| |
